<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by EDGARfilings PROfile 4.3.3.1 Broadridge-->
<xbrl xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2018-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2018-01-31" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2017-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2018-01-31" xmlns:srt="http://fasb.org/srt/2018-01-31" xmlns:ebs="http://emergentbiosolutions.com/20180930" xmlns="http://www.xbrl.org/2003/instance">
  <link:schemaRef xlink:type="simple" xlink:href="ebs-20180930.xsd" />
  <xbrli:context id="c20180101to20180930">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20181026">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-10-26</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20180930">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20171231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20180101to20180930_ProductOrServiceAxis_ProductMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20180701to20180930">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-07-01</xbrli:startDate>
      <xbrli:endDate>2018-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20180701to20180930_ProductOrServiceAxis_ContractsAndGrantsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractsAndGrantsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-07-01</xbrli:startDate>
      <xbrli:endDate>2018-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20180101to20180930_ProductOrServiceAxis_ContractManufacturingMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractManufacturingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20170101to20170930_ProductOrServiceAxis_ProductMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20170701to20170930_ProductOrServiceAxis_ContractManufacturingMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractManufacturingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-07-01</xbrli:startDate>
      <xbrli:endDate>2017-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20180101to20180930_ProductOrServiceAxis_ContractsAndGrantsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractsAndGrantsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20170701to20170930">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-07-01</xbrli:startDate>
      <xbrli:endDate>2017-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20170101to20170930">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20180701to20180930_ProductOrServiceAxis_ContractManufacturingMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractManufacturingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-07-01</xbrli:startDate>
      <xbrli:endDate>2018-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20180701to20180930_ProductOrServiceAxis_ProductMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-07-01</xbrli:startDate>
      <xbrli:endDate>2018-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20170701to20170930_ProductOrServiceAxis_ProductMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-07-01</xbrli:startDate>
      <xbrli:endDate>2017-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20170701to20170930_ProductOrServiceAxis_ContractsAndGrantsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractsAndGrantsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-07-01</xbrli:startDate>
      <xbrli:endDate>2017-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20170101to20170930_ProductOrServiceAxis_ContractManufacturingMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractManufacturingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20170101to20170930_ProductOrServiceAxis_ContractsAndGrantsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractsAndGrantsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20161231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20170930">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20171231_StatementEquityComponentsAxis_RetainedEarningsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20171231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20171231_AdjustmentsForNewAccountingPronouncementsAxis_AccountingStandardsUpdate201409Member_StatementEquityComponentsAxis_TreasuryStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20171231_AdjustmentsForNewAccountingPronouncementsAxis_AccountingStandardsUpdate201409Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20171231_AdjustmentsForNewAccountingPronouncementsAxis_AccountingStandardsUpdate201409Member_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20171231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20171231_StatementEquityComponentsAxis_CommonStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20171231_AdjustmentsForNewAccountingPronouncementsAxis_AccountingStandardsUpdate201409Member_StatementEquityComponentsAxis_RetainedEarningsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20171231_StatementEquityComponentsAxis_TreasuryStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20171231_AdjustmentsForNewAccountingPronouncementsAxis_AccountingStandardsUpdate201409Member_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20171231_AdjustmentsForNewAccountingPronouncementsAxis_AccountingStandardsUpdate201409Member_StatementEquityComponentsAxis_CommonStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20180101to20180930_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20180101to20180930_StatementEquityComponentsAxis_CommonStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20180101to20180930_StatementEquityComponentsAxis_TreasuryStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20180101to20180930_StatementEquityComponentsAxis_RetainedEarningsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20180101to20180930_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20180930_StatementEquityComponentsAxis_CommonStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20180930_StatementEquityComponentsAxis_RetainedEarningsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20180930_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20180930_StatementEquityComponentsAxis_TreasuryStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20180930_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20171231_AdjustmentsForNewAccountingPronouncementsAxis_AccountingStandardsUpdate201409Member_InitialApplicationPeriodCumulativeEffectTransitionAxis_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_CIADMMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:InitialApplicationPeriodCumulativeEffectTransitionAxis">us-gaap:DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">ebs:CIADMMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20170101to20171231_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_CIADMMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">ebs:CIADMMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20170101to20171231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20171231_AdjustmentsForNewAccountingPronouncementsAxis_AccountingStandardsUpdate201409Member_InitialApplicationPeriodCumulativeEffectTransitionAxis_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:InitialApplicationPeriodCumulativeEffectTransitionAxis">us-gaap:DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20171231_InitialApplicationPeriodCumulativeEffectTransitionAxis_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:InitialApplicationPeriodCumulativeEffectTransitionAxis">us-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20180101to20180930_ProductOrServiceAxis_ContractsAndGrantsMember_StatementGeographicalAxis_NonUsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractsAndGrantsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20180101to20180930_StatementGeographicalAxis_NonUsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20180101to20180930_ProductOrServiceAxis_ProductMember_StatementGeographicalAxis_US">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20180101to20180930_StatementGeographicalAxis_US">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20180701to20180930_ProductOrServiceAxis_ContractManufacturingMember_StatementGeographicalAxis_NonUsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractManufacturingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-07-01</xbrli:startDate>
      <xbrli:endDate>2018-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20180101to20180930_ProductOrServiceAxis_ContractsAndGrantsMember_StatementGeographicalAxis_US">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractsAndGrantsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20180101to20180930_ProductOrServiceAxis_ProductMember_StatementGeographicalAxis_NonUsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20180101to20180930_ProductOrServiceAxis_ContractManufacturingMember_StatementGeographicalAxis_NonUsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractManufacturingMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20180701to20180930_StatementGeographicalAxis_US">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-07-01</xbrli:startDate>
      <xbrli:endDate>2018-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20180701to20180930_ProductOrServiceAxis_ContractManufacturingMember_StatementGeographicalAxis_US">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractManufacturingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-07-01</xbrli:startDate>
      <xbrli:endDate>2018-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20180101to20180930_ProductOrServiceAxis_ContractManufacturingMember_StatementGeographicalAxis_US">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractManufacturingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20180701to20180930_ProductOrServiceAxis_ProductMember_StatementGeographicalAxis_US">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-07-01</xbrli:startDate>
      <xbrli:endDate>2018-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20180701to20180930_StatementGeographicalAxis_NonUsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-07-01</xbrli:startDate>
      <xbrli:endDate>2018-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20180701to20180930_ProductOrServiceAxis_ContractsAndGrantsMember_StatementGeographicalAxis_NonUsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractsAndGrantsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-07-01</xbrli:startDate>
      <xbrli:endDate>2018-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20180701to20180930_ProductOrServiceAxis_ContractsAndGrantsMember_StatementGeographicalAxis_US">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractsAndGrantsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-07-01</xbrli:startDate>
      <xbrli:endDate>2018-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20180701to20180930_ProductOrServiceAxis_ProductMember_StatementGeographicalAxis_NonUsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-07-01</xbrli:startDate>
      <xbrli:endDate>2018-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20180930_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_Two0180401Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
          <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2018-04-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
        </xbrldi:typedMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20171006to20171006_BusinessAcquisitionAxis_ACAM2000Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ebs:ACAM2000Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-10-06</xbrli:startDate>
      <xbrli:endDate>2017-10-06</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20171006_BusinessAcquisitionAxis_ACAM2000Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ebs:ACAM2000Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-10-06</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20171231_BusinessAcquisitionAxis_ACAM2000Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ebs:ACAM2000Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20171006to20171006_BusinessAcquisitionAxis_SanofiMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ebs:SanofiMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-10-06</xbrli:startDate>
      <xbrli:endDate>2017-10-06</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20171006_BusinessAcquisitionAxis_SanofiMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ebs:SanofiMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-10-06</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20171006to20171006_BusinessAcquisitionAxis_ACAM2000Member_MeasurementInputTypeAxis_MeasurementInputDiscountRateMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ebs:ACAM2000Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-10-06</xbrli:startDate>
      <xbrli:endDate>2017-10-06</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20180101to20180930_SubsegmentsAxis_RsdlMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">ebs:RsdlMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20170701to20170930_SubsegmentsAxis_RsdlMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">ebs:RsdlMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-07-01</xbrli:startDate>
      <xbrli:endDate>2017-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20180701to20180930_SubsegmentsAxis_RsdlMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">ebs:RsdlMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-07-01</xbrli:startDate>
      <xbrli:endDate>2018-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20170101to20170930_SubsegmentsAxis_RsdlMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">ebs:RsdlMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20180930_PropertyPlantAndEquipmentByTypeAxis_BuildingAndBuildingImprovementsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20180930_PropertyPlantAndEquipmentByTypeAxis_ConstructionInProgressMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20171231_PropertyPlantAndEquipmentByTypeAxis_ConstructionInProgressMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20180930_PropertyPlantAndEquipmentByTypeAxis_FurnitureAndFixturesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20171231_PropertyPlantAndEquipmentByTypeAxis_ComputerSoftwareIntangibleAssetMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20171231_PropertyPlantAndEquipmentByTypeAxis_BuildingAndBuildingImprovementsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20171231_PropertyPlantAndEquipmentByTypeAxis_FurnitureAndFixturesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20180930_PropertyPlantAndEquipmentByTypeAxis_LandAndLandImprovementsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandAndLandImprovementsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20171231_PropertyPlantAndEquipmentByTypeAxis_LandAndLandImprovementsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandAndLandImprovementsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20180930_PropertyPlantAndEquipmentByTypeAxis_ComputerSoftwareIntangibleAssetMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20180101to20180930_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EmergentBiosolutionsInc2006StockIncentivePlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ebs:EmergentBiosolutionsInc2006StockIncentivePlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20180101to20180930_AwardTypeAxis_RestrictedStockUnitsRSUMember_PlanNameAxis_EmergentBiosolutionsInc2006StockIncentivePlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ebs:EmergentBiosolutionsInc2006StockIncentivePlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20180930_PlanNameAxis_EmergentBiosolutionsInc2006StockIncentivePlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ebs:EmergentBiosolutionsInc2006StockIncentivePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20180524to20180524_PlanNameAxis_EmergentBiosolutionsInc2006StockIncentivePlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ebs:EmergentBiosolutionsInc2006StockIncentivePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-05-24</xbrli:startDate>
      <xbrli:endDate>2018-05-24</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20180524_PlanNameAxis_EmergentBiosolutionsInc2006StockIncentivePlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ebs:EmergentBiosolutionsInc2006StockIncentivePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-05-24</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20170930_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EmployeeStockOptionMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20181004to20181004_BusinessAcquisitionAxis_PaxVaxMember_SubsequentEventTypeAxis_SubsequentEventMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ebs:PaxVaxMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-10-04</xbrli:startDate>
      <xbrli:endDate>2018-10-04</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20181015to20181015_BusinessAcquisitionAxis_AdaptPharmaMember_SubsequentEventTypeAxis_SubsequentEventMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ebs:AdaptPharmaMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-10-15</xbrli:startDate>
      <xbrli:endDate>2018-10-15</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20181015_BusinessAcquisitionAxis_AdaptPharmaMember_SubsequentEventTypeAxis_SubsequentEventMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ebs:AdaptPharmaMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-10-15</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20181015_BusinessAcquisitionAxis_AdaptPharmaMember_RangeAxis_MaximumMember_SubsequentEventTypeAxis_SubsequentEventMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ebs:AdaptPharmaMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-10-15</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20170929to20170929_DebtInstrumentAxis_CreditAgreementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:CreditAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-09-29</xbrli:startDate>
      <xbrli:endDate>2017-09-29</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20170929_DebtInstrumentAxis_CreditAgreementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:CreditAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-09-29</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20181015_CreditFacilityAxis_TermLoanFacilityMember_DebtInstrumentAxis_AmendedCreditAgreementMember_SubsequentEventTypeAxis_SubsequentEventMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">ebs:TermLoanFacilityMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:AmendedCreditAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-10-15</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20181015_CreditFacilityAxis_RevolvingCreditFacilityMember_DebtInstrumentAxis_AmendedCreditAgreementMember_SubsequentEventTypeAxis_SubsequentEventMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:AmendedCreditAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-10-15</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20181015to20181015_CreditFacilityAxis_RevolvingCreditFacilityMember_DebtInstrumentAxis_AmendedCreditAgreementMember_SubsequentEventTypeAxis_SubsequentEventMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:AmendedCreditAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-10-15</xbrli:startDate>
      <xbrli:endDate>2018-10-15</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20181004_DebtInstrumentAxis_CreditAgreementMember_SubsequentEventTypeAxis_SubsequentEventMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:CreditAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-10-04</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20181004_CreditFacilityAxis_RevolvingCreditFacilityMember_DebtInstrumentAxis_AmendedCreditAgreementMember_SubsequentEventTypeAxis_SubsequentEventMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:AmendedCreditAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-10-04</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20181015to20181015_DebtInstrumentAxis_AmendedCreditAgreementMember_RangeAxis_MinimumMember_SubsequentEventTypeAxis_SubsequentEventMember_VariableRateAxis_BaseRateMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:AmendedCreditAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-10-15</xbrli:startDate>
      <xbrli:endDate>2018-10-15</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20181015to20181015_DebtInstrumentAxis_AmendedCreditAgreementMember_RangeAxis_MaximumMember_SubsequentEventTypeAxis_SubsequentEventMember_VariableRateAxis_BaseRateMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:AmendedCreditAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-10-15</xbrli:startDate>
      <xbrli:endDate>2018-10-15</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20181015to20181015_DebtInstrumentAxis_AmendedCreditAgreementMember_SubsequentEventTypeAxis_SubsequentEventMember_VariableRateAxis_EurodollarMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:AmendedCreditAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-10-15</xbrli:startDate>
      <xbrli:endDate>2018-10-15</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20181015to20181015_DebtInstrumentAxis_AmendedCreditAgreementMember_RangeAxis_MinimumMember_SubsequentEventTypeAxis_SubsequentEventMember_VariableRateAxis_EurodollarMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:AmendedCreditAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-10-15</xbrli:startDate>
      <xbrli:endDate>2018-10-15</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20181015to20181015_DebtInstrumentAxis_AmendedCreditAgreementMember_RangeAxis_MaximumMember_SubsequentEventTypeAxis_SubsequentEventMember_VariableRateAxis_EurodollarMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:AmendedCreditAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-10-15</xbrli:startDate>
      <xbrli:endDate>2018-10-15</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20181015to20181015_DebtInstrumentAxis_AmendedCreditAgreementMember_SubsequentEventTypeAxis_SubsequentEventMember_VariableRateAxis_FederalFundsEffectiveSwapRateMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:FederalFundsEffectiveSwapRateMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:AmendedCreditAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-10-15</xbrli:startDate>
      <xbrli:endDate>2018-10-15</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20181015to20181015_DebtInstrumentAxis_AmendedCreditAgreementMember_RangeAxis_MaximumMember_SubsequentEventTypeAxis_SubsequentEventMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:AmendedCreditAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-10-15</xbrli:startDate>
      <xbrli:endDate>2018-10-15</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20181015to20181015_DebtInstrumentAxis_AmendedCreditAgreementMember_RangeAxis_MinimumMember_SubsequentEventTypeAxis_SubsequentEventMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:AmendedCreditAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-10-15</xbrli:startDate>
      <xbrli:endDate>2018-10-15</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20181015to20181015_CreditFacilityAxis_TermLoanFacilityMember_DebtInstrumentAxis_AmendedCreditAgreementMember_SubsequentEventTypeAxis_SubsequentEventMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">ebs:TermLoanFacilityMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:AmendedCreditAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-10-15</xbrli:startDate>
      <xbrli:endDate>2018-10-15</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20181015to20181015_CreditFacilityAxis_RevolvingCreditFacilityMember_DebtInstrumentAxis_AmendedCreditAgreementMember_RangeAxis_MinimumMember_SubsequentEventTypeAxis_SubsequentEventMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:AmendedCreditAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-10-15</xbrli:startDate>
      <xbrli:endDate>2018-10-15</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20181015to20181015_CreditFacilityAxis_RevolvingCreditFacilityMember_DebtInstrumentAxis_AmendedCreditAgreementMember_RangeAxis_MaximumMember_SubsequentEventTypeAxis_SubsequentEventMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:AmendedCreditAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-10-15</xbrli:startDate>
      <xbrli:endDate>2018-10-15</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:unit id="U001">
    <xbrli:measure>xbrli:shares</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="U002">
    <xbrli:measure>iso4217:USD</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="U003">
    <xbrli:divide>
      <xbrli:unitNumerator>
        <xbrli:measure>iso4217:USD</xbrli:measure>
      </xbrli:unitNumerator>
      <xbrli:unitDenominator>
        <xbrli:measure>xbrli:shares</xbrli:measure>
      </xbrli:unitDenominator>
    </xbrli:divide>
  </xbrli:unit>
  <xbrli:unit id="U004">
    <xbrli:measure>ebs:Period</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="U005">
    <xbrli:measure>ebs:Segment</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="U006">
    <xbrli:measure>xbrli:pure</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="U007">
    <xbrli:measure>ebs:Installment</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="U008">
    <xbrli:measure>ebs:Employee</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="U009">
    <xbrli:measure>ebs:Institution</xbrli:measure>
  </xbrli:unit>
  <!--Amendment Flag-->
  <dei:AmendmentFlag contextRef="c20180101to20180930">false</dei:AmendmentFlag>
  <!--Current Fiscal Year End Date-->
  <dei:CurrentFiscalYearEndDate contextRef="c20180101to20180930">--12-31</dei:CurrentFiscalYearEndDate>
  <!--Document Period End Date-->
  <dei:DocumentPeriodEndDate contextRef="c20180101to20180930">2018-09-30</dei:DocumentPeriodEndDate>
  <!--Entity Filer Category-->
  <dei:EntityFilerCategory contextRef="c20180101to20180930">Large Accelerated Filer</dei:EntityFilerCategory>
  <!--Entity Registrant Name-->
  <dei:EntityRegistrantName contextRef="c20180101to20180930">Emergent BioSolutions Inc.</dei:EntityRegistrantName>
  <!--Entity Central Index Key-->
  <dei:EntityCentralIndexKey contextRef="c20180101to20180930">0001367644</dei:EntityCentralIndexKey>
  <!--Entity Common Stock, Shares Outstanding-->
  <dei:EntityCommonStockSharesOutstanding contextRef="c20181026" unitRef="U001" decimals="INF">50945056</dei:EntityCommonStockSharesOutstanding>
  <!--Document Fiscal Year Focus-->
  <dei:DocumentFiscalYearFocus contextRef="c20180101to20180930">2018</dei:DocumentFiscalYearFocus>
  <!--Document Fiscal Period Focus-->
  <dei:DocumentFiscalPeriodFocus contextRef="c20180101to20180930">Q3</dei:DocumentFiscalPeriodFocus>
  <!--Document Type-->
  <dei:DocumentType contextRef="c20180101to20180930">10-Q</dei:DocumentType>
  <!--Entity Emerging Growth Company-->
  <dei:EntityEmergingGrowthCompany contextRef="c20180101to20180930">false</dei:EntityEmergingGrowthCompany>
  <!--Entity Ex Transition Period-->
  <dei:EntityExTransitionPeriod contextRef="c20180101to20180930">false</dei:EntityExTransitionPeriod>
  <!--Entity Small Business-->
  <dei:EntitySmallBusiness contextRef="c20180101to20180930">false</dei:EntitySmallBusiness>
  <!--Accounts Payable, Current-->
  <us-gaap:AccountsPayableCurrent contextRef="c20180930" unitRef="U002" decimals="-3">38874000</us-gaap:AccountsPayableCurrent>
  <!--Accounts Payable, Current-->
  <us-gaap:AccountsPayableCurrent contextRef="c20171231" unitRef="U002" decimals="-3">41751000</us-gaap:AccountsPayableCurrent>
  <!--Accounts Receivable, Net, Current-->
  <us-gaap:AccountsReceivableNetCurrent contextRef="c20180930" unitRef="U002" decimals="-3">76955000</us-gaap:AccountsReceivableNetCurrent>
  <!--Accounts Receivable, Net, Current-->
  <us-gaap:AccountsReceivableNetCurrent contextRef="c20171231" unitRef="U002" decimals="-3">143653000</us-gaap:AccountsReceivableNetCurrent>
  <!--Accrued expenses and other current liabilities-->
  <us-gaap:AccruedLiabilitiesCurrent contextRef="c20171231" unitRef="U002" decimals="-3">4831000</us-gaap:AccruedLiabilitiesCurrent>
  <!--Accrued expenses and other current liabilities-->
  <us-gaap:AccruedLiabilitiesCurrent contextRef="c20180930" unitRef="U002" decimals="-3">7425000</us-gaap:AccruedLiabilitiesCurrent>
  <!--Accrued Income Taxes, Noncurrent-->
  <us-gaap:AccruedIncomeTaxesNoncurrent contextRef="c20180930" unitRef="U002" decimals="-3">12500000</us-gaap:AccruedIncomeTaxesNoncurrent>
  <!--Accrued Income Taxes, Noncurrent-->
  <us-gaap:AccruedIncomeTaxesNoncurrent contextRef="c20171231" unitRef="U002" decimals="-3">12500000</us-gaap:AccruedIncomeTaxesNoncurrent>
  <!--Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment-->
  <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c20180930" unitRef="U002" decimals="-3">160384000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
  <!--Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment-->
  <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c20171231" unitRef="U002" decimals="-3">132374000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
  <!--Accumulated other comprehensive loss-->
  <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c20171231" unitRef="U002" decimals="-3">-3698000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
  <!--Accumulated other comprehensive loss-->
  <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c20180930" unitRef="U002" decimals="-3">-4666000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
  <!--Weighted average amortization period-->
  <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife contextRef="c20180101to20180930">P8Y2M12D</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
  <!--Additional paid-in capital-->
  <us-gaap:AdditionalPaidInCapital contextRef="c20180930" unitRef="U002" decimals="-3">640178000</us-gaap:AdditionalPaidInCapital>
  <!--Additional paid-in capital-->
  <us-gaap:AdditionalPaidInCapital contextRef="c20171231" unitRef="U002" decimals="-3">618416000</us-gaap:AdditionalPaidInCapital>
  <!--Amortization of Intangible Assets-->
  <us-gaap:AmortizationOfIntangibleAssets contextRef="c20180101to20180930" unitRef="U002" decimals="-5">11700000</us-gaap:AmortizationOfIntangibleAssets>
  <!--Amortization of Intangible Assets-->
  <us-gaap:AmortizationOfIntangibleAssets contextRef="c20170101to20170930" unitRef="U002" decimals="-5">4700000</us-gaap:AmortizationOfIntangibleAssets>
  <!--Amortization of Intangible Assets-->
  <us-gaap:AmortizationOfIntangibleAssets contextRef="c20170701to20170930" unitRef="U002" decimals="-5">1600000</us-gaap:AmortizationOfIntangibleAssets>
  <!--Amortization of Intangible Assets-->
  <us-gaap:AmortizationOfIntangibleAssets contextRef="c20180701to20180930" unitRef="U002" decimals="-5">3900000</us-gaap:AmortizationOfIntangibleAssets>
  <!--Assets-->
  <us-gaap:Assets contextRef="c20180930" unitRef="U002" decimals="-3">1173623000</us-gaap:Assets>
  <!--Assets-->
  <us-gaap:Assets contextRef="c20171231" unitRef="U002" decimals="-3">1070206000</us-gaap:Assets>
  <!--Assets, Current-->
  <us-gaap:AssetsCurrent contextRef="c20180930" unitRef="U002" decimals="-3">563148000</us-gaap:AssetsCurrent>
  <!--Assets, Current-->
  <us-gaap:AssetsCurrent contextRef="c20171231" unitRef="U002" decimals="-3">485389000</us-gaap:AssetsCurrent>
  <!--Acquired intangible asset-Sanofi [Member]-->
  <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill contextRef="c20171006_BusinessAcquisitionAxis_SanofiMember" unitRef="U002" decimals="-3">16700000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
  <!--Business Combination, Contingent Consideration, Liability, Noncurrent-Adapt Pharma [Member]-Maximum [Member]-Subsequent Event [Member]-->
  <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent contextRef="c20181015_BusinessAcquisitionAxis_AdaptPharmaMember_RangeAxis_MaximumMember_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="U002" decimals="-6">100000000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
  <!--Share price (in dollars per share)-Adapt Pharma [Member]-Subsequent Event [Member]-->
  <us-gaap:BusinessAcquisitionSharePrice contextRef="c20181015_BusinessAcquisitionAxis_AdaptPharmaMember_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="U003" decimals="2">65.28</us-gaap:BusinessAcquisitionSharePrice>
  <!--Total purchase price-Sanofi [Member]-->
  <us-gaap:BusinessCombinationConsiderationTransferred1 contextRef="c20171006to20171006_BusinessAcquisitionAxis_SanofiMember" unitRef="U002" decimals="-3">119700000</us-gaap:BusinessCombinationConsiderationTransferred1>
  <!--Fair value of contingent purchase consideration-Sanofi [Member]-->
  <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c20171006_BusinessAcquisitionAxis_SanofiMember" unitRef="U002" decimals="-3">2200000</us-gaap:BusinessCombinationContingentConsiderationLiability>
  <!--Amount of common stock issued for acquisition including adjustments-Adapt Pharma [Member]-Subsequent Event [Member]-->
  <us-gaap:BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned contextRef="c20181015_BusinessAcquisitionAxis_AdaptPharmaMember_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="U002" decimals="0">47870412</us-gaap:BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned>
  <!--Common stock issued for acquisition (in shares)-Adapt Pharma [Member]-Subsequent Event [Member]-->
  <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued contextRef="c20181015to20181015_BusinessAcquisitionAxis_AdaptPharmaMember_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="U001" decimals="INF">733309</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
  <!--Acquisitions-->
  <us-gaap:BusinessCombinationDisclosureTextBlock contextRef="c20180101to20180930">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; line-height: 10.25pt;"&gt;&lt;font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"&gt;3.&lt;/font&gt;&amp;#160;&lt;font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"&gt;Acquisitions&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height: 11.4pt;"&gt;&lt;br style="line-height: 11.4pt;" /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; font-style: italic; text-align: left; line-height: 10.25pt; text-indent: 18pt;"&gt;Acquisition of ACAM2000 business&lt;/div&gt;&lt;div style="line-height: 10.25pt;"&gt;&lt;br style="line-height: 10.25pt;" /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; line-height: 10.25pt; text-indent: 36pt;"&gt;On October 6, 2017, the Company completed the acquisition of the ACAM2000&amp;#174; (Smallpox (Vaccinia) Vaccine, Live) business of Sanofi Pasteur Biologics, LLC ("Sanofi"). This acquisition included ACAM2000, the only smallpox vaccine licensed by the FDA, a current good manufacturing practices ("cGMP") live viral manufacturing facility and office and warehouse space, both in Canton, Massachusetts, and a cGMP viral fill/finish facility in Rockville, Maryland. With this acquisition, the Company also acquired an existing 10-year contract with the Centers for Disease Control and Prevention ("CDC"), which under the terms expired in March 2018. This contract had a stated value of up to $425 million, with a remaining contract value of up to approximately $160 million as of the acquisition date, for the delivery of ACAM2000 to the &lt;font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;U.S. Strategic National Stockpile ("SNS")&lt;/font&gt; and the establishment of U.S.-based manufacturing of ACAM2000. &lt;font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;This acquisition added to the Company's product portfolio and expanded the Company's manufacturing capabilities.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height: 10.25pt;"&gt;&lt;br style="line-height: 10.25pt;" /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; line-height: 10.25pt; text-indent: 36pt;"&gt;At the closing, the Company paid $97.5 million in an upfront payment and $20 million in milestone payments earned as of the closing date tied to the achievement of certain regulatory and manufacturing-related milestones, for a total payment in cash of $117.5 million. The agreement included an additional milestone payment of up to $7.5 million upon achievement of a regulatory milestone, which was achieved in November 2017. The $7.5 million milestone payment was made during the fourth quarter of 2017. This transaction was accounted for by the Company under the acquisition method of accounting, with the Company as the acquirer. Under the acquisition method of accounting, the assets and liabilities of the ACAM2000 business were preliminarily recorded as of October 6, 2017, the acquisition date, at their respective fair values, and combined with those of the Company.&lt;/div&gt;&lt;div style="line-height: 10.25pt;"&gt;&lt;br style="line-height: 10.25pt;" /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; line-height: 10.25pt; text-indent: 36pt;"&gt;The contingent purchase consideration obligation is based on a regulatory milestone. At October 6, 2017, the contingent purchase consideration obligation related to the regulatory milestone was recorded at a fair value of $2.2 million. The fair value of this obligation is based on a present value model of management's assessment of the probability of achievement of the regulatory milestone as of the acquisition date. This assessment is based on inputs that have no observable market (Level 3).&lt;/div&gt;&lt;div style="line-height: 11.4pt;"&gt;&lt;br style="line-height: 11.4pt;" /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; line-height: 10.25pt; text-indent: 36pt;"&gt;The total purchase price is summarized below:&lt;/div&gt;&lt;div style="line-height: 11.4pt;"&gt;&lt;br style="line-height: 11.4pt;" /&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; line-height: 9.1pt;"&gt;&lt;font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"&gt;(in thousands)&lt;/font&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: middle; border-bottom: #000000 2px solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 88%; vertical-align: middle; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; line-height: 9.1pt;"&gt;Amount of cash paid to Sanofi&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;117,500&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 88%; vertical-align: middle; padding-bottom: 2px; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; line-height: 9.1pt;"&gt;Fair value of contingent purchase consideration&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;2,200&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 88%; vertical-align: middle; padding-bottom: 4px; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; line-height: 9.1pt;"&gt;Total purchase price&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;119,700&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height: 11.4pt;"&gt;&lt;br style="line-height: 11.4pt;" /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; line-height: 10.25pt; text-indent: 36pt;"&gt;The table below summarizes the allocation of the purchase price based upon the estimated fair values of assets acquired at October 6, 2017. The Company did not assume any liabilities in the acquisition. The Company has finalized the purchase price allocation related to this acquisition.&lt;/div&gt;&lt;div style="line-height: 10.25pt;"&gt;&lt;br style="line-height: 10.25pt;" /&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: left; line-height: 9.1pt;"&gt;(in thousands)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; line-height: 9.1pt;"&gt;Fair value of tangible assets acquired:&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 88%; vertical-align: bottom; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; line-height: 9.1pt;"&gt;Inventory&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;74,876&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 88%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; line-height: 9.1pt;"&gt;Property, plant and equipment&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;19,995&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 88%; vertical-align: bottom; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; line-height: 9.1pt;"&gt;Total fair value of tangible assets acquired&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;94,871&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 88%; vertical-align: bottom; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; line-height: 9.1pt;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 88%; vertical-align: bottom; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; line-height: 9.1pt;"&gt;Acquired intangible asset&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;16,700&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 88%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; line-height: 9.1pt;"&gt;Goodwill&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;8,129&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 88%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; line-height: 9.1pt;"&gt;Total purchase price&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;119,700&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height: 11.4pt;"&gt;&lt;br style="line-height: 11.4pt;" /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; line-height: 10.25pt; text-indent: 36pt;"&gt;The Company determined the fair value of the intangible asset using the income approach, which is based on the present value of future cash flows. The fair value measurements are based on significant unobservable inputs that are developed by the Company using estimates and assumptions of the respective market and market penetration of the Company's products. The Company determined the fair value of the ACAM2000 intangible asset using the income approach with a present value discount rate of 15.5%; this discount rate is derived from the estimated weighted-average cost of capital for substantially similar companies and assets. This is comparable to the estimated internal rate of return for the acquisition and represents the rate that market participants would use to value these intangible assets. The projected cash flows from the ACAM2000 intangible asset were based on key assumptions, including: estimates of revenues and operating profits, the life of the potential commercialized product and associated risks, and risks related to the viability of and potential alternative treatments in any future target markets. The Company has determined the ACAM2000 intangible asset will be amortized over 10 years.&lt;/div&gt;&lt;div style="line-height: 10.25pt;"&gt;&lt;br style="line-height: 10.25pt;" /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; line-height: 10.25pt; text-indent: 36pt;"&gt;The Company determined the fair value of the inventory using the probability adjusted comparative sales method, which estimates the expected sales price reduced for all costs expected to be incurred to complete and dispose of the inventory with a profit on those costs.&lt;/div&gt;&lt;div style="line-height: 10.25pt;"&gt;&lt;br style="line-height: 10.25pt;" /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; line-height: 10.25pt; text-indent: 36pt;"&gt;The Company determined the fair value of the property, plant and equipment utilizing either the cost approach or the sales comparison approach. The cost approach is derived by determining replacement cost of the asset and then subtracting any value that has been lost due to economic obsolescence, functional obsolescence, or physical deterioration. The sales comparison approach is derived by the determination that an asset is equal to the market price of an asset of comparable features such as design, location, size, construction, materials, use, capacity, specification, operational characteristics and other features or descriptions.&lt;/div&gt;&lt;div style="line-height: 10.25pt;"&gt;&lt;br style="line-height: 10.25pt;" /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; line-height: 10.25pt; text-indent: 36pt;"&gt;The Company recorded approximately $8.1 million in goodwill related to the ACAM2000 acquisition, representing the amount of the purchase price paid in the acquisition in excess of the fair value of the tangible and intangible assets acquired. There is no goodwill for tax purposes.&lt;/div&gt;&lt;div style="line-height: 11.4pt;"&gt;&lt;br style="line-height: 11.4pt;" /&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:BusinessCombinationDisclosureTextBlock>
  <!--Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net-Sanofi [Member]-->
  <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet contextRef="c20171006_BusinessAcquisitionAxis_SanofiMember" unitRef="U002" decimals="-3">94871000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
  <!--Inventory-Sanofi [Member]-->
  <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory contextRef="c20171006_BusinessAcquisitionAxis_SanofiMember" unitRef="U002" decimals="-3">74876000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory>
  <!--Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment-Sanofi [Member]-->
  <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment contextRef="c20171006_BusinessAcquisitionAxis_SanofiMember" unitRef="U002" decimals="-3">19995000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment>
  <!--Cash and Cash Equivalents, Period Increase (Decrease)-->
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="c20180101to20180930" unitRef="U002" decimals="-3">161066000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <!--Cash and Cash Equivalents, Period Increase (Decrease)-->
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="c20170101to20170930" unitRef="U002" decimals="-3">69478000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <!--Cash and Cash Equivalents, at Carrying Value-->
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c20180930" unitRef="U002" decimals="-3">339358000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <!--Cash and Cash Equivalents, at Carrying Value-->
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c20171231" unitRef="U002" decimals="-3">178292000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <!--Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents-->
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c20161231" unitRef="U002" decimals="-3">271513000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
  <!--Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents-->
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c20171231" unitRef="U002" decimals="-3" id="Item-1">179335000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
  <!--Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents-->
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c20170930" unitRef="U002" decimals="-3">340991000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
  <!--Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents-->
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c20180930" unitRef="U002" decimals="-3" id="Item-2">340401000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
  <!--Common stock, shares authorized (in shares)-->
  <us-gaap:CommonStockSharesAuthorized contextRef="c20180930" unitRef="U001" decimals="0">200000000</us-gaap:CommonStockSharesAuthorized>
  <!--Common stock, shares authorized (in shares)-->
  <us-gaap:CommonStockSharesAuthorized contextRef="c20171231" unitRef="U001" decimals="0">200000000</us-gaap:CommonStockSharesAuthorized>
  <!--Common stock, par value (in dollars per share)-->
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="c20171231" unitRef="U003" decimals="INF">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
  <!--Common stock, par value (in dollars per share)-->
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="c20180930" unitRef="U003" decimals="INF">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
  <!--Common stock, shares issued (in shares)-->
  <us-gaap:CommonStockSharesIssued contextRef="c20180930" unitRef="U001" decimals="0">51403585</us-gaap:CommonStockSharesIssued>
  <!--Common stock, shares issued (in shares)-->
  <us-gaap:CommonStockSharesIssued contextRef="c20171231" unitRef="U001" decimals="0">50619808</us-gaap:CommonStockSharesIssued>
  <!--Common stock, shares outstanding (in shares)-->
  <us-gaap:CommonStockSharesOutstanding contextRef="c20171231" unitRef="U001" decimals="0">49405365</us-gaap:CommonStockSharesOutstanding>
  <!--Common stock, shares outstanding (in shares)-->
  <us-gaap:CommonStockSharesOutstanding contextRef="c20180930" unitRef="U001" decimals="0">50186299</us-gaap:CommonStockSharesOutstanding>
  <!--Common stock, shares outstanding (in shares)-Common Stock [Member]-->
  <us-gaap:CommonStockSharesOutstanding contextRef="c20171231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="0">50619808</us-gaap:CommonStockSharesOutstanding>
  <!--Common stock, shares outstanding (in shares)-Treasury Stock [Member]-->
  <us-gaap:CommonStockSharesOutstanding contextRef="c20171231_StatementEquityComponentsAxis_TreasuryStockMember" unitRef="U001" decimals="0">-1214443</us-gaap:CommonStockSharesOutstanding>
  <!--Common stock, shares outstanding (in shares)-ASC 606 [Member]-Common Stock [Member]-->
  <us-gaap:CommonStockSharesOutstanding contextRef="c20171231_AdjustmentsForNewAccountingPronouncementsAxis_AccountingStandardsUpdate201409Member_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="0">50619808</us-gaap:CommonStockSharesOutstanding>
  <!--Common stock, shares outstanding (in shares)-ASC 606 [Member]-Treasury Stock [Member]-->
  <us-gaap:CommonStockSharesOutstanding contextRef="c20171231_AdjustmentsForNewAccountingPronouncementsAxis_AccountingStandardsUpdate201409Member_StatementEquityComponentsAxis_TreasuryStockMember" unitRef="U001" decimals="0">-1214443</us-gaap:CommonStockSharesOutstanding>
  <!--Common stock, shares outstanding (in shares)-Treasury Stock [Member]-->
  <us-gaap:CommonStockSharesOutstanding contextRef="c20180930_StatementEquityComponentsAxis_TreasuryStockMember" unitRef="U001" decimals="0">-1217286</us-gaap:CommonStockSharesOutstanding>
  <!--Common stock, shares outstanding (in shares)-Common Stock [Member]-->
  <us-gaap:CommonStockSharesOutstanding contextRef="c20180930_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="0">51403585</us-gaap:CommonStockSharesOutstanding>
  <!--Common stock, $0.001 par value; 200,000,000 shares authorized, 51,403,585 shares issued and 50,186,299 shares outstanding at September 30, 2018; 50,619,808 shares issued and 49,405,365 shares outstanding at December 31, 2017-->
  <us-gaap:CommonStockValue contextRef="c20180930" unitRef="U002" decimals="-3">51000</us-gaap:CommonStockValue>
  <!--Common stock, $0.001 par value; 200,000,000 shares authorized, 51,403,585 shares issued and 50,186,299 shares outstanding at September 30, 2018; 50,619,808 shares issued and 49,405,365 shares outstanding at December 31, 2017-->
  <us-gaap:CommonStockValue contextRef="c20171231" unitRef="U002" decimals="-3">50000</us-gaap:CommonStockValue>
  <!--Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest-->
  <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest contextRef="c20180101to20180930" unitRef="U002" decimals="-3">65213000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
  <!--Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest-->
  <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest contextRef="c20170701to20170930" unitRef="U002" decimals="-3">33255000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
  <!--Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest-->
  <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest contextRef="c20180701to20180930" unitRef="U002" decimals="-3">20695000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
  <!--Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest-->
  <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest contextRef="c20170101to20170930" unitRef="U002" decimals="-3">49168000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
  <!--Basis of presentation and consolidation-->
  <us-gaap:ConsolidationPolicyTextBlock contextRef="c20180101to20180930">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: justify; line-height: 10.25pt; text-indent: 36pt;"&gt;Basis of presentation and consolidation&lt;/div&gt;&lt;div style="line-height: 10.25pt;"&gt;&lt;br style="line-height: 10.25pt;" /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; line-height: 10.25pt; text-indent: 36pt;"&gt;The accompanying unaudited condensed consolidated financial statements include the accounts of Emergent BioSolutions Inc. ("Emergent" or the "Company") and its wholly owned and majority owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation. The unaudited consolidated financial statements included herein have been prepared in accordance with U.S. generally accepted accounting principles for interim financial information and in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X issued by the Securities and Exchange Commission ("SEC"). Certain information and footnote disclosures normally included in consolidated financial statements prepared in accordance with U.S. generally accepted accounting principles have been condensed or omitted pursuant to such rules and regulations. These consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto contained in the Company's Annual Report on Form 10-K for the year ended December 31, 2017, as filed with the SEC.&lt;/div&gt;&lt;div style="line-height: 10.25pt;"&gt;&lt;br style="line-height: 10.25pt;" /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; line-height: 10.25pt; text-indent: 36pt;"&gt;In the opinion of the Company's management, any adjustments contained in the accompanying unaudited condensed consolidated financial statements are of a normal recurring nature and are necessary to present fairly the financial position of the Company as of September 30, 2018. Interim results are not necessarily indicative of results that may be expected for any other interim period or for an entire year.&lt;/div&gt;&lt;div style="line-height: 11.4pt;"&gt;&lt;br style="line-height: 11.4pt;" /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; font-style: italic; text-align: justify; line-height: 10.25pt; text-indent: 36pt;"&gt;Significant accounting policies&lt;/div&gt;&lt;div style="line-height: 11.4pt;"&gt;&lt;br style="line-height: 11.4pt;" /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; line-height: 10.25pt; text-indent: 36pt;"&gt;During the nine months ended September 30, 2018, there have been no significant changes to the Company's summary of significant accounting policies contained in the Company's Annual Report on Form 10-K for the year ended December 31, 2017, as filed with the SEC, except for the new revenue recognition standard the Company adopted effective January 1, 2018. See Note 2. "Revenue recognition" for further details.&lt;/div&gt;&lt;div style="line-height: 11.4pt;"&gt;&lt;br style="line-height: 11.4pt;" /&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
  <!--Recognition of revenue included in beginning of year contract liability-->
  <us-gaap:ContractWithCustomerLiabilityRevenueRecognized contextRef="c20180101to20180930" unitRef="U002" decimals="-3">-15121000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
  <!--Deferred revenue, net of current portion-->
  <us-gaap:ContractWithCustomerLiabilityNoncurrent contextRef="c20180930" unitRef="U002" decimals="-3">65343000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
  <!--Deferred revenue, net of current portion-->
  <us-gaap:ContractWithCustomerLiabilityNoncurrent contextRef="c20171231" unitRef="U002" decimals="-3">17259000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
  <!--Contract liability-Difference between Revenue Guidance in Effect before and after Topic 606 [Member]-ASC 606 [Member]-->
  <us-gaap:ContractWithCustomerLiability contextRef="c20171231_AdjustmentsForNewAccountingPronouncementsAxis_AccountingStandardsUpdate201409Member_InitialApplicationPeriodCumulativeEffectTransitionAxis_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member" unitRef="U002" decimals="-3">42379000</us-gaap:ContractWithCustomerLiability>
  <!--Contract liability-Calculated under Revenue Guidance in Effect before Topic 606 [Member]-->
  <us-gaap:ContractWithCustomerLiability contextRef="c20171231_InitialApplicationPeriodCumulativeEffectTransitionAxis_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member" unitRef="U002" decimals="-3">30491000</us-gaap:ContractWithCustomerLiability>
  <!--Contract liability-ASC 606 [Member]-->
  <us-gaap:ContractWithCustomerLiability contextRef="c20171231_AdjustmentsForNewAccountingPronouncementsAxis_AccountingStandardsUpdate201409Member" unitRef="U002" decimals="-3">72870000</us-gaap:ContractWithCustomerLiability>
  <!--Contract liability-ASC 606 [Member]-Difference between Revenue Guidance in Effect before and after Topic 606 [Member]-CIADM [Member]-->
  <us-gaap:ContractWithCustomerLiability contextRef="c20171231_AdjustmentsForNewAccountingPronouncementsAxis_AccountingStandardsUpdate201409Member_InitialApplicationPeriodCumulativeEffectTransitionAxis_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_CIADMMember" unitRef="U002" decimals="-5">42400000</us-gaap:ContractWithCustomerLiability>
  <!--Contract liability-->
  <us-gaap:ContractWithCustomerLiability contextRef="c20180930" unitRef="U002" decimals="-3">76133000</us-gaap:ContractWithCustomerLiability>
  <!--Deferred revenue, current portion-->
  <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="c20180930" unitRef="U002" decimals="-3">10790000</us-gaap:ContractWithCustomerLiabilityCurrent>
  <!--Deferred revenue, current portion-->
  <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="c20171231" unitRef="U002" decimals="-3">13232000</us-gaap:ContractWithCustomerLiabilityCurrent>
  <!--Rollforward of Contract Liabilities-->
  <us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock contextRef="c20180101to20180930">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; line-height: 10.25pt; text-indent: 36pt;"&gt;When performance obligations are not transferred to a customer at the end of a reporting period, the amount allocated to those performance obligations are deferred until control of these performance obligations is transferred to the customer. The following table presents the rollforward of the contract liabilities,&lt;font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;&amp;#160;&lt;/font&gt;which is included in the Company's current and long-term deferred revenue line items in the condensed consolidated balance sheets:&lt;/div&gt;&lt;div style="line-height: 11.4pt;"&gt;&lt;br style="line-height: 11.4pt;" /&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; line-height: 9.1pt;"&gt;&lt;font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"&gt;(in thousands)&lt;/font&gt;&lt;font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 88%; vertical-align: bottom; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; line-height: 9.1pt;"&gt;Balance at December 31, 2017&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;30,491&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 88%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; line-height: 9.1pt;"&gt;Adoption of new accounting standard (ASC 606)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;42,379&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 88%; vertical-align: bottom; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; line-height: 9.1pt;"&gt;Balance at January 1, 2018&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;72,870&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 88%; vertical-align: bottom; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; line-height: 9.1pt;"&gt;Deferral of revenue&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;18,384&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 88%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; line-height: 9.1pt;"&gt;Recognition of revenue included in beginning of year contract liability&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;(15,121&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 88%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; line-height: 9.1pt;"&gt;Balance at September 30, 2018&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;76,133&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height: 11.4pt;"&gt;&lt;br style="line-height: 11.4pt;" /&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock>
  <!--Cost of Goods and Services Sold-->
  <us-gaap:CostOfGoodsAndServicesSold contextRef="c20180701to20180930" unitRef="U002" decimals="-3">73232000</us-gaap:CostOfGoodsAndServicesSold>
  <!--Cost of Goods and Services Sold-->
  <us-gaap:CostOfGoodsAndServicesSold contextRef="c20170101to20170930" unitRef="U002" decimals="-3">125449000</us-gaap:CostOfGoodsAndServicesSold>
  <!--Cost of Goods and Services Sold-->
  <us-gaap:CostOfGoodsAndServicesSold contextRef="c20180101to20180930" unitRef="U002" decimals="-3">220449000</us-gaap:CostOfGoodsAndServicesSold>
  <!--Cost of Goods and Services Sold-->
  <us-gaap:CostOfGoodsAndServicesSold contextRef="c20170701to20170930" unitRef="U002" decimals="-3">44503000</us-gaap:CostOfGoodsAndServicesSold>
  <!--Adoption of new accounting standard (ASC 606), net of tax-Retained Earnings [Member]-ASC 606 [Member]-->
  <us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption contextRef="c20171231_AdjustmentsForNewAccountingPronouncementsAxis_AccountingStandardsUpdate201409Member_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="-3">-32527000</us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption>
  <!--Adoption of new accounting standard (ASC 606), net of tax-ASC 606 [Member]-->
  <us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption contextRef="c20171231_AdjustmentsForNewAccountingPronouncementsAxis_AccountingStandardsUpdate201409Member" unitRef="U002" decimals="-3">-32527000</us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption>
  <!--Disaggregation of Revenue-->
  <us-gaap:DisaggregationOfRevenueTableTextBlock contextRef="c20180101to20180930">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; line-height: 10.25pt; text-indent: 36pt;"&gt;We operate in one business segment. Therefore, results of our operations are reported on a consolidated basis for purposes of segment reporting, consistent with internal management reporting.&lt;font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;&amp;#160;&lt;/font&gt;For the three and nine months ended September 30, 2018, there was a nominal difference between revenues recognized under ASC 606 and revenues recognized based on the prior revenue recognition guidance for the same period. For the three and nine months ended September 30, 2018, the Company's&lt;font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;&amp;#160;&lt;/font&gt;revenues disaggregated by the major sources was as follows:&lt;/div&gt;&lt;div style="line-height: 10.25pt;"&gt;&lt;br style="line-height: 10.25pt;" /&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; line-height: 10.25pt;"&gt;&lt;font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"&gt;(in thousands)&lt;/font&gt;&lt;font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="10" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center; line-height: 10.25pt;"&gt;Three Months Ended September 30, 2018&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="10" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center; line-height: 10.25pt;"&gt;Nine Months Ended September 30, 2018&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center; line-height: 10.25pt;"&gt;U.S &lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center; line-height: 10.25pt;"&gt;Non-U.S. &lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center; line-height: 10.25pt;"&gt;U.S &lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center; line-height: 10.25pt;"&gt;Non-U.S. &lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center; line-height: 10.25pt;"&gt;Government&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center; line-height: 10.25pt;"&gt;Government&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center; line-height: 10.25pt;"&gt;Total&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center; line-height: 10.25pt;"&gt;Government&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center; line-height: 10.25pt;"&gt;Government&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center; line-height: 10.25pt;"&gt;Total&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 28%; vertical-align: bottom; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; line-height: 10.25pt;"&gt;Product sales&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 10.25pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 10.25pt;"&gt;127,332&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 10.25pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 10.25pt;"&gt;5,937&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 10.25pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 10.25pt;"&gt;133,269&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 10.25pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 10.25pt;"&gt;363,254&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 10.25pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 10.25pt;"&gt;25,861&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 10.25pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 10.25pt;"&gt;389,115&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 28%; vertical-align: bottom; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; line-height: 10.25pt;"&gt;Contract manufacturing&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 10.25pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 10.25pt;"&gt;22,172&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 10.25pt;"&gt;22,172&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 10.25pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 10.25pt;"&gt;71,963&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 10.25pt;"&gt;71,963&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 28%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; line-height: 10.25pt;"&gt;Contracts and grants&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 10.25pt;"&gt;16,656&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 10.25pt;"&gt;1,556&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 10.25pt;"&gt;18,212&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 10.25pt;"&gt;46,711&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 10.25pt;"&gt;3,878&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 10.25pt;"&gt;50,589&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 28%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; line-height: 10.25pt;"&gt;Total revenues&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 10.25pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 10.25pt;"&gt;143,988&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 10.25pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 10.25pt;"&gt;29,665&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 10.25pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 10.25pt;"&gt;173,653&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 10.25pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 10.25pt;"&gt;409,965&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 10.25pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 10.25pt;"&gt;101,702&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 10.25pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 10.25pt;"&gt;511,667&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height: 11.4pt;"&gt;&lt;br style="line-height: 11.4pt;" /&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
  <!--Debt instrument, basis spread on variable rate-Amended Credit Agreement [Member]-Base Rate [Member]-Subsequent Event [Member]-Minimum [Member]-->
  <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1 contextRef="c20181015to20181015_DebtInstrumentAxis_AmendedCreditAgreementMember_RangeAxis_MinimumMember_SubsequentEventTypeAxis_SubsequentEventMember_VariableRateAxis_BaseRateMember" unitRef="U006" decimals="INF">0.0025</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
  <!--Debt instrument, basis spread on variable rate-Amended Credit Agreement [Member]-Maximum [Member]-Base Rate [Member]-Subsequent Event [Member]-->
  <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1 contextRef="c20181015to20181015_DebtInstrumentAxis_AmendedCreditAgreementMember_RangeAxis_MaximumMember_SubsequentEventTypeAxis_SubsequentEventMember_VariableRateAxis_BaseRateMember" unitRef="U006" decimals="INF">0.0100</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
  <!--Debt instrument, basis spread on variable rate-Eurocurrency [Member]-Subsequent Event [Member]-Amended Credit Agreement [Member]-->
  <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1 contextRef="c20181015to20181015_DebtInstrumentAxis_AmendedCreditAgreementMember_SubsequentEventTypeAxis_SubsequentEventMember_VariableRateAxis_EurodollarMember" unitRef="U006" decimals="INF">0.01</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
  <!--Debt instrument, basis spread on variable rate-Amended Credit Agreement [Member]-Minimum [Member]-Subsequent Event [Member]-Eurocurrency [Member]-->
  <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1 contextRef="c20181015to20181015_DebtInstrumentAxis_AmendedCreditAgreementMember_RangeAxis_MinimumMember_SubsequentEventTypeAxis_SubsequentEventMember_VariableRateAxis_EurodollarMember" unitRef="U006" decimals="INF">0.0125</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
  <!--Debt instrument, basis spread on variable rate-Maximum [Member]-Eurocurrency [Member]-Subsequent Event [Member]-Amended Credit Agreement [Member]-->
  <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1 contextRef="c20181015to20181015_DebtInstrumentAxis_AmendedCreditAgreementMember_RangeAxis_MaximumMember_SubsequentEventTypeAxis_SubsequentEventMember_VariableRateAxis_EurodollarMember" unitRef="U006" decimals="INF">0.0200</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
  <!--Debt instrument, basis spread on variable rate-Federal Funds Effective Swap Rate [Member]-Amended Credit Agreement [Member]-Subsequent Event [Member]-->
  <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1 contextRef="c20181015to20181015_DebtInstrumentAxis_AmendedCreditAgreementMember_SubsequentEventTypeAxis_SubsequentEventMember_VariableRateAxis_FederalFundsEffectiveSwapRateMember" unitRef="U006" decimals="INF">0.0050</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
  <!--Interest rate percentage-Convertible debt [Member]-->
  <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="c20170930_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EmployeeStockOptionMember" unitRef="U006" decimals="INF">0.02875</us-gaap:DebtInstrumentInterestRateStatedPercentage>
  <!--Maturity date-Credit Agreement [Member]-->
  <us-gaap:DebtInstrumentMaturityDate contextRef="c20170929to20170929_DebtInstrumentAxis_CreditAgreementMember">2022-09-29</us-gaap:DebtInstrumentMaturityDate>
  <!--Maturity date-Amended Credit Agreement [Member]-Subsequent Event [Member]-Revolving Credit Facility [Member]-->
  <us-gaap:DebtInstrumentMaturityDate contextRef="c20181015to20181015_CreditFacilityAxis_RevolvingCreditFacilityMember_DebtInstrumentAxis_AmendedCreditAgreementMember_SubsequentEventTypeAxis_SubsequentEventMember">2023-10-13</us-gaap:DebtInstrumentMaturityDate>
  <!--Deferred costs-->
  <us-gaap:DeferredCostsCurrent contextRef="c20180930" unitRef="U002" decimals="-5">4000000</us-gaap:DeferredCostsCurrent>
  <!--Deferred costs-->
  <us-gaap:DeferredCostsCurrent contextRef="c20171231" unitRef="U002" decimals="-5">2900000</us-gaap:DeferredCostsCurrent>
  <!--Income taxes-->
  <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c20180101to20180930" unitRef="U002" decimals="-3">12761000</us-gaap:DeferredIncomeTaxExpenseBenefit>
  <!--Income taxes-->
  <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c20170101to20170930" unitRef="U002" decimals="-3">18618000</us-gaap:DeferredIncomeTaxExpenseBenefit>
  <!--Deferred Tax Assets, Net of Valuation Allowance, Noncurrent-->
  <us-gaap:DeferredTaxAssetsNetNoncurrent contextRef="c20180930" unitRef="U002" decimals="-3">12652000</us-gaap:DeferredTaxAssetsNetNoncurrent>
  <!--Deferred Tax Assets, Net of Valuation Allowance, Noncurrent-->
  <us-gaap:DeferredTaxAssetsNetNoncurrent contextRef="c20171231" unitRef="U002" decimals="-3">2834000</us-gaap:DeferredTaxAssetsNetNoncurrent>
  <!--Deferred tax assets-ASC 606 [Member]-Difference between Revenue Guidance in Effect before and after Topic 606 [Member]-CIADM [Member]-->
  <us-gaap:DeferredTaxAssetsNet contextRef="c20171231_AdjustmentsForNewAccountingPronouncementsAxis_AccountingStandardsUpdate201409Member_InitialApplicationPeriodCumulativeEffectTransitionAxis_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_CIADMMember" unitRef="U002" decimals="-5">9900000</us-gaap:DeferredTaxAssetsNet>
  <!--Depreciation and amortization-->
  <us-gaap:DepreciationDepletionAndAmortization contextRef="c20170101to20170930" unitRef="U002" decimals="-3">29899000</us-gaap:DepreciationDepletionAndAmortization>
  <!--Depreciation and amortization-->
  <us-gaap:DepreciationDepletionAndAmortization contextRef="c20180101to20180930" unitRef="U002" decimals="-3">37106000</us-gaap:DepreciationDepletionAndAmortization>
  <!--Earnings Per Share [Text Block]-->
  <us-gaap:EarningsPerShareTextBlock contextRef="c20180101to20180930">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: justify; line-height: 10.25pt;"&gt;10. Earnings per share&lt;/div&gt;&lt;div style="line-height: 11.4pt;"&gt;&lt;br style="line-height: 11.4pt;" /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; line-height: 10.25pt; text-indent: 36pt;"&gt;The following table presents the calculation of basic and diluted net income per share:&lt;/div&gt;&lt;div style="line-height: 10.25pt;"&gt;&lt;br style="line-height: 10.25pt;" /&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="6" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center; line-height: 9.1pt;"&gt;Three Months Ended September 30,&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="6" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center; line-height: 9.1pt;"&gt;Nine Months Ended September 30,&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: left; line-height: 9.1pt;"&gt;(in thousands, except share and per share data)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center; line-height: 9.1pt;"&gt;2018&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center; line-height: 9.1pt;"&gt;2017&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center; line-height: 9.1pt;"&gt;2018&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center; line-height: 9.1pt;"&gt;2017&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; line-height: 9.1pt;"&gt;Numerator:&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 52%; vertical-align: bottom; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; line-height: 9.1pt;"&gt;Net income&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;20,945&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;33,551&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;66,181&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;48,652&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 52%; vertical-align: bottom; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; line-height: 9.1pt;"&gt;Interest expense on convertible debt, net of tax&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;704&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;2,445&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 52%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; line-height: 9.1pt;"&gt;Amortization of convertible debt issuance costs, net of tax&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;195&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;586&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 52%; vertical-align: bottom; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; line-height: 9.1pt;"&gt;Net income, adjusted&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;20,945&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;34,450&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;66,181&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;51,683&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 52%; vertical-align: bottom; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 52%; vertical-align: bottom; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; line-height: 9.1pt;"&gt;Denominator:&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 52%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; line-height: 9.1pt;"&gt;Weighted-average number of shares&amp;#8212;basic&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;50,071,632&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;41,222,504&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;49,851,082&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;40,989,813&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 52%; vertical-align: bottom; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; line-height: 9.1pt;"&gt;Dilutive securities&amp;#8212;equity awards&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;1,415,364&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;1,148,857&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;1,338,598&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;1,003,794&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 52%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; line-height: 9.1pt;"&gt;Dilutive securities&amp;#8212;convertible debt&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;8,096,468&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;8,096,481&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 52%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; line-height: 9.1pt;"&gt;Weighted-average number of shares&amp;#8212;diluted&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;51,486,996&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;50,467,829&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;51,189,680&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;50,090,088&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 52%; vertical-align: bottom; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 52%; vertical-align: bottom; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; line-height: 9.1pt;"&gt;Net income per share - basic&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;0.42&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;0.81&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;1.33&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;1.19&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 52%; vertical-align: bottom; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; line-height: 9.1pt;"&gt;Net income per share - diluted&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;0.41&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;0.68&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;1.29&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;1.03&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height: 11.4pt;"&gt;&lt;br style="line-height: 11.4pt;" /&gt;&lt;/div&gt;&lt;div style="line-height: 0pt;"&gt;&lt;br style="line-height: 0pt;" /&gt;&lt;/div&gt;&lt;div style="margin-bottom: 3pt; font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; margin-top: 3pt; line-height: 10.25pt; text-indent: 36pt;"&gt;For the three and nine months ended September 30, 2018 and 2017, basic earnings per share is computed by dividing net income by the weighted average number of shares of common stock outstanding during the period.&lt;/div&gt;&lt;div style="margin-bottom: 3pt; margin-top: 3pt; line-height: 10.25pt;"&gt;&lt;br style="line-height: 10.25pt;" /&gt;&lt;/div&gt;&lt;div style="margin-bottom: 3pt; font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; margin-top: 3pt; line-height: 10.25pt; text-indent: 36pt;"&gt;For the three and nine months ended September 30, 2018, diluted earnings per share was computed using the "treasury method" by dividing the net income by the weighted average number of shares of common stock outstanding during the period. The weighted average number of shares is adjusted for the potential dilutive effect of the exercise of stock options, and the vesting of restricted stock units and performance stock units.&lt;/div&gt;&lt;div style="margin-bottom: 3pt; margin-top: 3pt; line-height: 10.25pt;"&gt;&lt;br style="line-height: 10.25pt;" /&gt;&lt;/div&gt;&lt;div style="margin-bottom: 3pt; font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; margin-top: 3pt; line-height: 10.25pt; text-indent: 36pt;"&gt;For the three and nine months ended September 30, 2017, diluted earnings per share is computed using the "if-converted" method by dividing the net income adjusted for interest expense and amortization of debt issuance cost, both net of tax, associated with the 2.875% Convertible Senior Notes due 2021 (the "Notes") by the weighted average number of shares of common stock outstanding during the period. The weighted average number of shares is adjusted for the potential dilutive effect of the exercise of stock options; and the vesting of restricted stock units and performance stock units along with the assumption of the conversion of the Notes, at the beginning of the period. The Company terminated the conversion rights under the Notes during the fourth quarter of 2017.&lt;/div&gt;&lt;div style="margin-bottom: 3pt; margin-top: 3pt; line-height: 10.25pt;"&gt;&lt;br style="line-height: 10.25pt;" /&gt;&lt;/div&gt;&lt;div style="margin-bottom: 3pt; font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; margin-top: 3pt; line-height: 10.25pt; text-indent: 36pt;"&gt;For the three and nine months ended September 30, 2018 and 2017, there were no stock options excluded from the calculation of diluted earnings per share.&lt;/div&gt;&lt;div style="margin-bottom: 3pt; margin-top: 3pt; line-height: 10.25pt;"&gt;&lt;br style="line-height: 10.25pt;" /&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
  <!--Net income per share - basic (in dollars per share)-->
  <us-gaap:EarningsPerShareBasic contextRef="c20170101to20170930" unitRef="U003" decimals="2">1.19</us-gaap:EarningsPerShareBasic>
  <!--Net income per share - basic (in dollars per share)-->
  <us-gaap:EarningsPerShareBasic contextRef="c20170701to20170930" unitRef="U003" decimals="2">0.81</us-gaap:EarningsPerShareBasic>
  <!--Net income per share - basic (in dollars per share)-->
  <us-gaap:EarningsPerShareBasic contextRef="c20180101to20180930" unitRef="U003" decimals="2">1.33</us-gaap:EarningsPerShareBasic>
  <!--Net income per share - basic (in dollars per share)-->
  <us-gaap:EarningsPerShareBasic contextRef="c20180701to20180930" unitRef="U003" decimals="2">0.42</us-gaap:EarningsPerShareBasic>
  <!--Net income per share-diluted (in dollars per share)-->
  <us-gaap:EarningsPerShareDiluted contextRef="c20170701to20170930" unitRef="U003" decimals="2" id="Item-3">0.68</us-gaap:EarningsPerShareDiluted>
  <!--Net income per share-diluted (in dollars per share)-->
  <us-gaap:EarningsPerShareDiluted contextRef="c20180701to20180930" unitRef="U003" decimals="2" id="Item-4">0.41</us-gaap:EarningsPerShareDiluted>
  <!--Net income per share-diluted (in dollars per share)-->
  <us-gaap:EarningsPerShareDiluted contextRef="c20170101to20170930" unitRef="U003" decimals="2" id="Item-5">1.03</us-gaap:EarningsPerShareDiluted>
  <!--Net income per share-diluted (in dollars per share)-->
  <us-gaap:EarningsPerShareDiluted contextRef="c20180101to20180930" unitRef="U003" decimals="2" id="Item-6">1.29</us-gaap:EarningsPerShareDiluted>
  <!--Effect of exchange rate changes on cash, cash equivalents and restricted cash-->
  <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents contextRef="c20170101to20170930" unitRef="U002" decimals="-3">-74000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
  <!--Effect of exchange rate changes on cash, cash equivalents and restricted cash-->
  <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents contextRef="c20180101to20180930" unitRef="U002" decimals="-3">-567000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
  <!--Federal corporate tax rate-->
  <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="c20180101to20180930" unitRef="U006" decimals="INF">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
  <!--Federal corporate tax rate-->
  <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="c20170101to20171231" unitRef="U006" decimals="INF">0.35</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
  <!--Effective annual tax rate-->
  <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c20170101to20170930" unitRef="U006" decimals="INF">0.32</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
  <!--Effective annual tax rate-->
  <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c20180101to20180930" unitRef="U006" decimals="INF">0.26</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
  <!--Employee-related Liabilities, Current-->
  <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c20180930" unitRef="U002" decimals="-3">41807000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
  <!--Employee-related Liabilities, Current-->
  <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c20171231" unitRef="U002" decimals="-3">37882000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
  <!--Discrete tax benefit-->
  <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense contextRef="c20170101to20170930" unitRef="U002" decimals="-5">3300000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
  <!--Discrete tax benefit-->
  <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense contextRef="c20180101to20180930" unitRef="U002" decimals="-5">8700000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
  <!--Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements-->
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements contextRef="c20180101to20180930" unitRef="U002" decimals="-3">2234000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
  <!--Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value-->
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="c20171231" unitRef="U002" decimals="-3">12274000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
  <!--Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value-->
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="c20180930" unitRef="U002" decimals="-3">11957000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
  <!--Fair Value Disclosures [Text Block]-->
  <us-gaap:FairValueDisclosuresTextBlock contextRef="c20180101to20180930">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; line-height: 10.25pt;"&gt;&lt;font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"&gt;4.&lt;/font&gt;&lt;font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"&gt;Fair value measurements&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height: 11.4pt;"&gt;&lt;br style="line-height: 11.4pt;" /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; line-height: 10.25pt; text-indent: 36pt;"&gt;Contingent consideration includes liabilities measured at fair value on a recurring basis. For the three and nine months ended September 30, 2018, the contingent purchase consideration obligations associated with RSDL increased by $0.2 million and $1.8 million, respectively. During the three and nine months ended September 30, 2017, the contingent purchase consideration obligations associated with RSDL increased by $0.9 million and $1.4 million, respectively. The changes in the fair value of the RSDL contingent consideration obligations are primarily due to the expected amount and timing of future net sales, which are inputs that have no observable market (Level 3). These changes are classified in the Company's statement of operations as cost of product sales and contract manufacturing.&lt;/div&gt;&lt;div style="line-height: 11.4pt;"&gt;&lt;br style="line-height: 11.4pt;" /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; line-height: 10.25pt; text-indent: 36pt;"&gt;The following table is a reconciliation of the beginning and ending balance of the liabilities, consisting only of contingent consideration, measured at fair value, using significant unobservable inputs (Level 3) during the nine months ended September 30, 2018.&lt;/div&gt;&lt;div style="line-height: 10.25pt;"&gt;&lt;br style="line-height: 10.25pt;" /&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: left; line-height: 9.1pt;"&gt;(in thousands)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 88%; vertical-align: bottom; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; line-height: 9.1pt;"&gt;Balance at December 31, 2017&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;12,274&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 88%; vertical-align: bottom; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; line-height: 9.1pt;"&gt;Expense included in earnings&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;1,917&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 88%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; line-height: 9.1pt;"&gt;Settlements&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;(2,234&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 88%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; line-height: 9.1pt;"&gt;Balance at September 30, 2018&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;11,957&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height: 11.4pt;"&gt;&lt;br style="line-height: 11.4pt;" /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; line-height: 10.25pt; text-indent: 36pt;"&gt;Separate disclosure is required for assets and liabilities measured at fair value on a recurring basis from those measured at fair value on a non-recurring basis. As of September 30, 2018 and 2017 and for the quarters then ended, the Company had no significant assets or liabilities that were measured at fair value on a non-recurring basis.&lt;/div&gt;&lt;div style="line-height: 11.4pt;"&gt;&lt;br style="line-height: 11.4pt;" /&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
  <!--Reconciliation of Liabilities Measured at Fair Value Using Significant Unobservable Inputs (Level 3)-->
  <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock contextRef="c20180101to20180930">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; line-height: 10.25pt; text-indent: 36pt;"&gt;The following table is a reconciliation of the beginning and ending balance of the liabilities, consisting only of contingent consideration, measured at fair value, using significant unobservable inputs (Level 3) during the nine months ended September 30, 2018.&lt;/div&gt;&lt;div style="line-height: 10.25pt;"&gt;&lt;br style="line-height: 10.25pt;" /&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: left; line-height: 9.1pt;"&gt;(in thousands)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 88%; vertical-align: bottom; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; line-height: 9.1pt;"&gt;Balance at December 31, 2017&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;12,274&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 88%; vertical-align: bottom; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; line-height: 9.1pt;"&gt;Expense included in earnings&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;1,917&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 88%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; line-height: 9.1pt;"&gt;Settlements&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;(2,234&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 88%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; line-height: 9.1pt;"&gt;Balance at September 30, 2018&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;11,957&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height: 11.4pt;"&gt;&lt;br style="line-height: 11.4pt;" /&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
  <!--Expense included in earnings-->
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings contextRef="c20180101to20180930" unitRef="U002" decimals="-3">1917000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
  <!--Amortization period of intangible asset-ACAM2000 [Member]-->
  <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c20171006to20171006_BusinessAcquisitionAxis_ACAM2000Member">P10Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
  <!--Goodwill-->
  <us-gaap:Goodwill contextRef="c20180930" unitRef="U002" decimals="-3">49130000</us-gaap:Goodwill>
  <!--Goodwill-->
  <us-gaap:Goodwill contextRef="c20171231" unitRef="U002" decimals="-3">49130000</us-gaap:Goodwill>
  <!--Goodwill-Sanofi [Member]-->
  <us-gaap:Goodwill contextRef="c20171006_BusinessAcquisitionAxis_SanofiMember" unitRef="U002" decimals="-3">8129000</us-gaap:Goodwill>
  <!--Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest-->
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="c20170701to20170930" unitRef="U002" decimals="-3">46314000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
  <!--Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest-->
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="c20170101to20170930" unitRef="U002" decimals="-3">66680000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
  <!--Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest-->
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="c20180701to20180930" unitRef="U002" decimals="-3">21559000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
  <!--Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest-->
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="c20180101to20180930" unitRef="U002" decimals="-3">77957000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
  <!--Provision for income taxes-->
  <us-gaap:IncomeTaxExpenseBenefit contextRef="c20170701to20170930" unitRef="U002" decimals="-3">12763000</us-gaap:IncomeTaxExpenseBenefit>
  <!--Provision for income taxes-->
  <us-gaap:IncomeTaxExpenseBenefit contextRef="c20180101to20180930" unitRef="U002" decimals="-3">11776000</us-gaap:IncomeTaxExpenseBenefit>
  <!--Provision for income taxes-->
  <us-gaap:IncomeTaxExpenseBenefit contextRef="c20180701to20180930" unitRef="U002" decimals="-3">614000</us-gaap:IncomeTaxExpenseBenefit>
  <!--Provision for income taxes-->
  <us-gaap:IncomeTaxExpenseBenefit contextRef="c20170101to20170930" unitRef="U002" decimals="-3">18028000</us-gaap:IncomeTaxExpenseBenefit>
  <!--Income Tax Disclosure [Text Block]-->
  <us-gaap:IncomeTaxDisclosureTextBlock contextRef="c20180101to20180930">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: justify; line-height: 10.25pt;"&gt;9. Income taxes&lt;/div&gt;&lt;div style="line-height: 11.4pt;"&gt;&lt;br style="line-height: 11.4pt;" /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; line-height: 10.25pt; text-indent: 36pt;"&gt;&lt;font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;The estimated effective annual tax rate for the Company, which excludes discrete adjustments, was 26% and 32% for the nine months ended September 30, 2018 and 2017, respectively. The decrease in the estimated effective annual tax rate is primarily due to the impact of the Tax Reform Act enacted on December 22, 2017, which reduced the U.S. federal corporate income tax rate from&amp;#160;35% to&amp;#160;21%&lt;/font&gt;, offset by state taxes, non-deductible expenses, international provisions from the U.S. tax reform and the impact of a change in the Company's jurisdictional mix of earnings. &lt;font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;For the nine months ended September 30, 2018 and 2017, the Company recorded a discrete tax benefit of $8.7 million and $3.3 million, respectively, primarily associated with equity awards activity and finalizing positions taken on the Company's 2017 US federal and state income tax filings.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height: 10.25pt;"&gt;&lt;br style="line-height: 10.25pt;" /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; line-height: 10.25pt; text-indent: 36pt;"&gt;On December 22, 2017, the SEC staff issued Staff Accounting Bulletin No. 118 to address the application of U.S. GAAP in situations when a registrant does not have the necessary information available, prepared, or analyzed (including computations) in reasonable detail to complete the accounting for certain income tax effects of the Tax Reform Act. For the&amp;#160;nine months ended September 30, 2018, the Company revised certain provisional estimates recognized in 2017 upon the filing of US federal and state income tax filings.&lt;font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"&gt;&amp;#160;&lt;/font&gt;As the Internal Revenue Service and state jurisdictions continue to issue and/or clarify guidance, additional work may be necessary for a more detailed analysis of the Company's deferred tax assets and liabilities, its historical foreign earnings,&amp;#160;as well as potential correlative adjustments. Any correlative adjustment to these amounts will be recorded to current tax expense in the final quarter of 2018 when the analysis is complete.&lt;/div&gt;&lt;div style="line-height: 11.4pt;"&gt;&lt;br style="line-height: 11.4pt;" /&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
  <!--Income tax receivable, net-->
  <us-gaap:IncomeTaxesReceivable contextRef="c20171231" unitRef="U002" decimals="-3">2432000</us-gaap:IncomeTaxesReceivable>
  <!--Income tax receivable, net-->
  <us-gaap:IncomeTaxesReceivable contextRef="c20180930" unitRef="U002" decimals="-3">0</us-gaap:IncomeTaxesReceivable>
  <!--Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest-->
  <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest contextRef="c20180101to20180930" unitRef="U002" decimals="-3">66181000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
  <!--Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest-->
  <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest contextRef="c20170101to20170930" unitRef="U002" decimals="-3">48652000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
  <!--Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest-->
  <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest contextRef="c20170701to20170930" unitRef="U002" decimals="-3">33551000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
  <!--Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest-->
  <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest contextRef="c20180701to20180930" unitRef="U002" decimals="-3">20945000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
  <!--Increase (Decrease) in Contract with Customer, Liability-->
  <us-gaap:IncreaseDecreaseInContractWithCustomerLiability contextRef="c20180101to20180930" unitRef="U002" decimals="-3">3262000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
  <!--Increase (Decrease) in Contract with Customer, Liability-->
  <us-gaap:IncreaseDecreaseInContractWithCustomerLiability contextRef="c20170101to20170930" unitRef="U002" decimals="-3">14006000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
  <!--Increase (Decrease) in Accounts Receivable-->
  <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c20180101to20180930" unitRef="U002" decimals="-3">-66455000</us-gaap:IncreaseDecreaseInAccountsReceivable>
  <!--Increase (Decrease) in Accounts Receivable-->
  <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c20170101to20170930" unitRef="U002" decimals="-3">-9411000</us-gaap:IncreaseDecreaseInAccountsReceivable>
  <!--Accounts payable-->
  <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c20170101to20170930" unitRef="U002" decimals="-3">2965000</us-gaap:IncreaseDecreaseInAccountsPayable>
  <!--Accounts payable-->
  <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c20180101to20180930" unitRef="U002" decimals="-3">-5695000</us-gaap:IncreaseDecreaseInAccountsPayable>
  <!--Accrued expenses and other liabilities-->
  <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="c20170101to20170930" unitRef="U002" decimals="-3">-2334000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
  <!--Accrued expenses and other liabilities-->
  <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="c20180101to20180930" unitRef="U002" decimals="-3">2457000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
  <!--Increase (Decrease) in Income Taxes Receivable-->
  <us-gaap:IncreaseDecreaseInIncomeTaxesReceivable contextRef="c20170101to20170930" unitRef="U002" decimals="-3">5515000</us-gaap:IncreaseDecreaseInIncomeTaxesReceivable>
  <!--Increase (Decrease) in Income Taxes Receivable-->
  <us-gaap:IncreaseDecreaseInIncomeTaxesReceivable contextRef="c20180101to20180930" unitRef="U002" decimals="-3">10130000</us-gaap:IncreaseDecreaseInIncomeTaxesReceivable>
  <!--Increase (Decrease) in Inventories-->
  <us-gaap:IncreaseDecreaseInInventories contextRef="c20170101to20170930" unitRef="U002" decimals="-3">-5113000</us-gaap:IncreaseDecreaseInInventories>
  <!--Increase (Decrease) in Inventories-->
  <us-gaap:IncreaseDecreaseInInventories contextRef="c20180101to20180930" unitRef="U002" decimals="-3">-17067000</us-gaap:IncreaseDecreaseInInventories>
  <!--Accrued compensation-->
  <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities contextRef="c20170101to20170930" unitRef="U002" decimals="-3">-1902000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
  <!--Accrued compensation-->
  <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities contextRef="c20180101to20180930" unitRef="U002" decimals="-3">3925000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
  <!--Increase (Decrease) in Prepaid Expense and Other Assets-->
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c20170101to20170930" unitRef="U002" decimals="-3">2157000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <!--Increase (Decrease) in Prepaid Expense and Other Assets-->
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c20180101to20180930" unitRef="U002" decimals="-3">5921000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <!--Dilutive securities-equity awards (in shares)-->
  <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="c20180701to20180930" unitRef="U001" decimals="0">1415364</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
  <!--Dilutive securities-equity awards (in shares)-->
  <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="c20180101to20180930" unitRef="U001" decimals="0">1338598</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
  <!--Dilutive securities-equity awards (in shares)-->
  <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="c20170701to20170930" unitRef="U001" decimals="0">1148857</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
  <!--Dilutive securities-equity awards (in shares)-->
  <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="c20170101to20170930" unitRef="U001" decimals="0">1003794</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
  <!--Dilutive securities-convertible debt (in shares)-->
  <us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities contextRef="c20180701to20180930" unitRef="U001" decimals="0">0</us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities>
  <!--Dilutive securities-convertible debt (in shares)-->
  <us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities contextRef="c20170701to20170930" unitRef="U001" decimals="0">8096468</us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities>
  <!--Dilutive securities-convertible debt (in shares)-->
  <us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities contextRef="c20170101to20170930" unitRef="U001" decimals="0">8096481</us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities>
  <!--Dilutive securities-convertible debt (in shares)-->
  <us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities contextRef="c20180101to20180930" unitRef="U001" decimals="0">0</us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities>
  <!--Intangible assets-->
  <us-gaap:IntangibleAssetsDisclosureTextBlock contextRef="c20180101to20180930">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; line-height: 10.25pt;"&gt;&lt;font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"&gt;7.&lt;/font&gt;&lt;font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"&gt;Intangible assets&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height: 11.4pt;"&gt;&lt;br style="line-height: 11.4pt;" /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; line-height: 10.25pt; text-indent: 36pt;"&gt;During the three months ended September 30, 2018 and 2017, the Company recorded amortization expense for intangible assets of $3.9 million and $1.6 million, respectively. During the nine months ended September 30, 2018 and 2017, the Company recorded amortization expense for intangible assets of $11.7 million and $4.7 million, respectively. Amortization expense has been recorded in operating expenses, specifically selling, general and administrative and cost of product sales and contract manufacturing. As of September 30, 2018, the weighted average amortization period remaining for intangible assets was 8.2 years.&lt;/div&gt;&lt;div style="line-height: 11.4pt;"&gt;&lt;br style="line-height: 11.4pt;" /&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:IntangibleAssetsDisclosureTextBlock>
  <!--Intangible assets, net-->
  <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c20180930" unitRef="U002" decimals="-3">107861000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
  <!--Intangible assets, net-->
  <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c20171231" unitRef="U002" decimals="-3">119597000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
  <!--Interest Expense-->
  <us-gaap:InterestExpense contextRef="c20180701to20180930" unitRef="U002" decimals="-3">642000</us-gaap:InterestExpense>
  <!--Interest Expense-->
  <us-gaap:InterestExpense contextRef="c20170701to20170930" unitRef="U002" decimals="-3">1991000</us-gaap:InterestExpense>
  <!--Interest Expense-->
  <us-gaap:InterestExpense contextRef="c20170101to20170930" unitRef="U002" decimals="-3">5734000</us-gaap:InterestExpense>
  <!--Interest Expense-->
  <us-gaap:InterestExpense contextRef="c20180101to20180930" unitRef="U002" decimals="-3">1884000</us-gaap:InterestExpense>
  <!--Interest expense, net of tax-->
  <us-gaap:InterestOnConvertibleDebtNetOfTax contextRef="c20170101to20170930" unitRef="U002" decimals="-3">2445000</us-gaap:InterestOnConvertibleDebtNetOfTax>
  <!--Interest expense, net of tax-->
  <us-gaap:InterestOnConvertibleDebtNetOfTax contextRef="c20180701to20180930" unitRef="U002" decimals="-3">0</us-gaap:InterestOnConvertibleDebtNetOfTax>
  <!--Interest expense, net of tax-->
  <us-gaap:InterestOnConvertibleDebtNetOfTax contextRef="c20170701to20170930" unitRef="U002" decimals="-3">704000</us-gaap:InterestOnConvertibleDebtNetOfTax>
  <!--Interest expense, net of tax-->
  <us-gaap:InterestOnConvertibleDebtNetOfTax contextRef="c20180101to20180930" unitRef="U002" decimals="-3">0</us-gaap:InterestOnConvertibleDebtNetOfTax>
  <!--Inventory Disclosure [Text Block]-->
  <us-gaap:InventoryDisclosureTextBlock contextRef="c20180101to20180930">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; line-height: 10.25pt;"&gt;&lt;font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"&gt;5.&lt;/font&gt;&lt;font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"&gt;Inventories&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height: 11.4pt;"&gt;&lt;br style="line-height: 11.4pt;" /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; line-height: 10.25pt; text-indent: 36pt;"&gt;Inventories consisted of the following:&lt;/div&gt;&lt;div style="line-height: 13.7pt;"&gt;&lt;br style="line-height: 13.7pt;" /&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center; line-height: 9.1pt;"&gt;September 30,&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center; line-height: 9.1pt;"&gt;December 31,&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: left; line-height: 9.1pt;"&gt;(in thousands)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center; line-height: 9.1pt;"&gt;2018&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center; line-height: 9.1pt;"&gt;2017&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 76%; vertical-align: bottom; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; line-height: 9.1pt;"&gt;Raw materials and supplies&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;33,845&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;36,069&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 76%; vertical-align: bottom; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; line-height: 9.1pt;"&gt;Work-in-process&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;64,825&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;76,610&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 76%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; line-height: 9.1pt;"&gt;Finished goods&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;27,075&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;30,133&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 76%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; line-height: 9.1pt;"&gt;Total inventories&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;125,745&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;142,812&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height: 11.4pt;"&gt;&lt;br style="line-height: 11.4pt;" /&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:InventoryDisclosureTextBlock>
  <!--Finished goods-->
  <us-gaap:InventoryFinishedGoodsNetOfReserves contextRef="c20171231" unitRef="U002" decimals="-3">30133000</us-gaap:InventoryFinishedGoodsNetOfReserves>
  <!--Finished goods-->
  <us-gaap:InventoryFinishedGoodsNetOfReserves contextRef="c20180930" unitRef="U002" decimals="-3">27075000</us-gaap:InventoryFinishedGoodsNetOfReserves>
  <!--Inventory, Net-->
  <us-gaap:InventoryNet contextRef="c20171231" unitRef="U002" decimals="-3">142812000</us-gaap:InventoryNet>
  <!--Inventory, Net-->
  <us-gaap:InventoryNet contextRef="c20180930" unitRef="U002" decimals="-3">125745000</us-gaap:InventoryNet>
  <!--Raw materials and supplies-->
  <us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves contextRef="c20180930" unitRef="U002" decimals="-3">33845000</us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves>
  <!--Raw materials and supplies-->
  <us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves contextRef="c20171231" unitRef="U002" decimals="-3">36069000</us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves>
  <!--Work-in-process-->
  <us-gaap:InventoryWorkInProcessNetOfReserves contextRef="c20180930" unitRef="U002" decimals="-3">64825000</us-gaap:InventoryWorkInProcessNetOfReserves>
  <!--Work-in-process-->
  <us-gaap:InventoryWorkInProcessNetOfReserves contextRef="c20171231" unitRef="U002" decimals="-3">76610000</us-gaap:InventoryWorkInProcessNetOfReserves>
  <!--Interest income-->
  <us-gaap:InvestmentIncomeInterest contextRef="c20180101to20180930" unitRef="U002" decimals="-3">1229000</us-gaap:InvestmentIncomeInterest>
  <!--Interest income-->
  <us-gaap:InvestmentIncomeInterest contextRef="c20170101to20170930" unitRef="U002" decimals="-3">1593000</us-gaap:InvestmentIncomeInterest>
  <!--Interest income-->
  <us-gaap:InvestmentIncomeInterest contextRef="c20170701to20170930" unitRef="U002" decimals="-3">637000</us-gaap:InvestmentIncomeInterest>
  <!--Interest income-->
  <us-gaap:InvestmentIncomeInterest contextRef="c20180701to20180930" unitRef="U002" decimals="-3">701000</us-gaap:InvestmentIncomeInterest>
  <!--Litigation-->
  <us-gaap:LegalMattersAndContingenciesTextBlock contextRef="c20180101to20180930">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: left; line-height: 10.25pt;"&gt;11. Litigation&lt;/div&gt;&lt;div style="line-height: 10.25pt;"&gt;&lt;br style="line-height: 10.25pt;" /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: justify; line-height: 10.25pt; text-indent: 36pt;"&gt;Shareholder Class Action Lawsuit filed July 19, 2016&lt;/div&gt;&lt;div style="line-height: 10.25pt;"&gt;&lt;br style="line-height: 10.25pt;" /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; line-height: 10.25pt; text-indent: 36pt;"&gt;On July 19, 2016, Plaintiff William Sponn ("Sponn"), filed a putative class action complaint in the United States District Court for the District of Maryland on behalf of purchasers of the Company's common stock between January 11, 2016 and June 21, 2016, inclusive (the "Class Period"), seeking to pursue remedies under the Securities Exchange Act of 1934 against the Company and certain of its senior officers and directors, collectively, the Defendants. The complaint alleges, among other things, that the Company made materially false and misleading statements about the government's demand for BioThrax and expectations that the Company's five-year exclusive procurement contract with HHS would be renewed and omitted certain material facts. Sponn is seeking unspecified damages, including legal costs. On October 25, 2016, the Court added City of Cape Coral Municipal Firefighters' Retirement Plan and City of Sunrise Police Officers' Retirement Plan as plaintiffs and appointed them Lead Plaintiffs and Robins Geller Rudman &amp;amp; Dowd LLP as Lead Counsel. On December 27, 2016, the Plaintiffs filed an amended complaint that cites the same class period, names the same defendants and makes similar allegations to the original complaint. The Company filed a Motion to Dismiss on February 27, 2017. The Plaintiffs filed an opposition brief on April 28, 2017. The Company's Motion to Dismiss was heard and denied on July 6, 2017. The Company filed its answer on July 28, 2017. The parties then engaged in the process of exchanging discovery. The Plaintiffs filed an amended motion for class certification and appointment of Sponn and Geoffrey L. Flagstad as lead plaintiffs on December 20, 2017. A hearing on that motion was heard on May 2, 2018. On June 8, 2018 the Court granted class certification with a shortened class period, May 5, 2016 to June 21, 2016.&amp;#160; The Defendants have denied, and continue to deny any and all allegations of fault, liability, wrongdoing, or damages. However, recognizing the risk, time, and expense of litigating any case to trial, on August 27, 2018, the Company reached an agreement in principle with Plaintiffs to settle all of the related claims of any individual plaintiff that purchased Company stock from January 11, 2016 to June 21, 2016, for $6.5 million, an amount that will be paid by the Company's insurance carrier. The settlement requires no payment by any of the Defendants. The Company and Defendants continue to deny any and all liability. The parties executed the settlement agreement on October 16, 2018, and filed the agreement with the court on October 17, 2018. The court granted preliminary approval of the settlement on October 18, 2018 and has scheduled a hearing regarding final approval for January 22, 2019. Although the court has granted preliminary approval, the court could decide not to grant final approval of the settlement or change terms of the settlement, and the law requires that individual plaintiffs have the right to opt-out of the settlement and bring their own, individual claims. The Company, therefore, at this time, cannot predict the results of this lawsuit and possible other legal proceedings with certainty. Defendants continue to believe that the allegations in the complaint are without merit. As of the date of this filing, the range of potential loss cannot be determined or estimated.&lt;/div&gt;&lt;div style="text-align: justify; line-height: 10.25pt; text-indent: 36pt;"&gt;&lt;br style="line-height: 10.25pt;" /&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:LegalMattersAndContingenciesTextBlock>
  <!--Liabilities-->
  <us-gaap:Liabilities contextRef="c20180930" unitRef="U002" decimals="-3">206974000</us-gaap:Liabilities>
  <!--Liabilities-->
  <us-gaap:Liabilities contextRef="c20171231" unitRef="U002" decimals="-3">157861000</us-gaap:Liabilities>
  <!--Liabilities and Equity-->
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c20171231" unitRef="U002" decimals="-3">1070206000</us-gaap:LiabilitiesAndStockholdersEquity>
  <!--Liabilities and Equity-->
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c20180930" unitRef="U002" decimals="-3">1173623000</us-gaap:LiabilitiesAndStockholdersEquity>
  <!--Liabilities, Current-->
  <us-gaap:LiabilitiesCurrent contextRef="c20180930" unitRef="U002" decimals="-3">102014000</us-gaap:LiabilitiesCurrent>
  <!--Liabilities, Current-->
  <us-gaap:LiabilitiesCurrent contextRef="c20171231" unitRef="U002" decimals="-3">100068000</us-gaap:LiabilitiesCurrent>
  <!--Commitment fee percentage-Subsequent Event [Member]-Maximum [Member]-Amended Credit Agreement [Member]-->
  <us-gaap:LineOfCreditFacilityCommitmentFeePercentage contextRef="c20181015to20181015_DebtInstrumentAxis_AmendedCreditAgreementMember_RangeAxis_MaximumMember_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="U006" decimals="5">0.00300</us-gaap:LineOfCreditFacilityCommitmentFeePercentage>
  <!--Commitment fee percentage-Minimum [Member]-Amended Credit Agreement [Member]-Subsequent Event [Member]-->
  <us-gaap:LineOfCreditFacilityCommitmentFeePercentage contextRef="c20181015to20181015_DebtInstrumentAxis_AmendedCreditAgreementMember_RangeAxis_MinimumMember_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="U006" decimals="5">0.00150</us-gaap:LineOfCreditFacilityCommitmentFeePercentage>
  <!--Current borrowing capacity-Credit Agreement [Member]-->
  <us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity contextRef="c20170929_DebtInstrumentAxis_CreditAgreementMember" unitRef="U002" decimals="-6">200000000</us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity>
  <!--Current borrowing capacity-Subsequent Event [Member]-Term Loan Facility [Member]-Amended Credit Agreement [Member]-->
  <us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity contextRef="c20181015_CreditFacilityAxis_TermLoanFacilityMember_DebtInstrumentAxis_AmendedCreditAgreementMember_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="U002" decimals="-6">450000000</us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity>
  <!--Current borrowing capacity-Amended Credit Agreement [Member]-Subsequent Event [Member]-Revolving Credit Facility [Member]-->
  <us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity contextRef="c20181015_CreditFacilityAxis_RevolvingCreditFacilityMember_DebtInstrumentAxis_AmendedCreditAgreementMember_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="U002" decimals="-6">600000000</us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity>
  <!--Outstanding credit facility-Subsequent Event [Member]-Revolving Credit Facility [Member]-Amended Credit Agreement [Member]-->
  <us-gaap:LineOfCredit contextRef="c20181004_CreditFacilityAxis_RevolvingCreditFacilityMember_DebtInstrumentAxis_AmendedCreditAgreementMember_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="U002" decimals="-6">100000000</us-gaap:LineOfCredit>
  <!--Outstanding credit facility-Amended Credit Agreement [Member]-Subsequent Event [Member]-Revolving Credit Facility [Member]-->
  <us-gaap:LineOfCredit contextRef="c20181015_CreditFacilityAxis_RevolvingCreditFacilityMember_DebtInstrumentAxis_AmendedCreditAgreementMember_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="U002" decimals="-6">318000000</us-gaap:LineOfCredit>
  <!--Line of Credit Facility, Fair Value of Amount Outstanding-Subsequent Event [Member]-Credit Agreement [Member]-->
  <us-gaap:LineOfCreditFacilityFairValueOfAmountOutstanding contextRef="c20181004_DebtInstrumentAxis_CreditAgreementMember_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="U002" decimals="-6">100000000</us-gaap:LineOfCreditFacilityFairValueOfAmountOutstanding>
  <!--Maximum borrowing capacity-Credit Agreement [Member]-->
  <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="c20170929_DebtInstrumentAxis_CreditAgreementMember" unitRef="U002" decimals="-6">300000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
  <!--Long-term Debt, Excluding Current Maturities-->
  <us-gaap:LongTermDebtNoncurrent contextRef="c20180930" unitRef="U002" decimals="-3">13495000</us-gaap:LongTermDebtNoncurrent>
  <!--Long-term Debt, Excluding Current Maturities-->
  <us-gaap:LongTermDebtNoncurrent contextRef="c20171231" unitRef="U002" decimals="-3">13457000</us-gaap:LongTermDebtNoncurrent>
  <!--Net Cash Provided by (Used in) Financing Activities-->
  <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c20170101to20170930" unitRef="U002" decimals="-3">-18681000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <!--Net Cash Provided by (Used in) Financing Activities-->
  <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c20180101to20180930" unitRef="U002" decimals="-3">2720000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <!--Net Cash Provided by (Used in) Investing Activities-->
  <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c20170101to20170930" unitRef="U002" decimals="-3">-42381000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <!--Net Cash Provided by (Used in) Investing Activities-->
  <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c20180101to20180930" unitRef="U002" decimals="-3">-48651000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <!--Net Cash Provided by (Used in) Operating Activities-->
  <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c20180101to20180930" unitRef="U002" decimals="-3">207564000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <!--Net Cash Provided by (Used in) Operating Activities-->
  <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c20170101to20170930" unitRef="U002" decimals="-3">130614000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <!--Net income-->
  <us-gaap:NetIncomeLoss contextRef="c20170701to20170930" unitRef="U002" decimals="-3">33551000</us-gaap:NetIncomeLoss>
  <!--Net income-->
  <us-gaap:NetIncomeLoss contextRef="c20170101to20170930" unitRef="U002" decimals="-3">48652000</us-gaap:NetIncomeLoss>
  <!--Net income-->
  <us-gaap:NetIncomeLoss contextRef="c20180701to20180930" unitRef="U002" decimals="-3">20945000</us-gaap:NetIncomeLoss>
  <!--Net income-->
  <us-gaap:NetIncomeLoss contextRef="c20180101to20180930" unitRef="U002" decimals="-3">66181000</us-gaap:NetIncomeLoss>
  <!--Net income-Retained Earnings [Member]-->
  <us-gaap:NetIncomeLoss contextRef="c20180101to20180930_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="-3">66181000</us-gaap:NetIncomeLoss>
  <!--New Accounting Pronouncement or Change in Accounting Principle, Cumulative Effect of Change on Equity or Net Assets-Difference between Revenue Guidance in Effect before and after Topic 606 [Member]-CIADM [Member]-ASC 606 [Member]-->
  <us-gaap:NewAccountingPronouncementOrChangeInAccountingPrincipleCumulativeEffectOfChangeOnEquityOrNetAssets1 contextRef="c20171231_AdjustmentsForNewAccountingPronouncementsAxis_AccountingStandardsUpdate201409Member_InitialApplicationPeriodCumulativeEffectTransitionAxis_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_CIADMMember" unitRef="U002" decimals="-5">32500000</us-gaap:NewAccountingPronouncementOrChangeInAccountingPrincipleCumulativeEffectOfChangeOnEquityOrNetAssets1>
  <!--Recently issued accounting standards-->
  <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="c20180101to20180930">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; font-style: italic; text-align: justify; line-height: 10.25pt; text-indent: 36pt;"&gt;Recently issued accounting standards&lt;/div&gt;&lt;div style="line-height: 10.25pt;"&gt;&lt;br style="line-height: 10.25pt;" /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic; text-align: justify; line-height: 10.25pt; text-indent: 36pt;"&gt;&lt;u&gt;Recently Adopted&lt;/u&gt;&lt;/div&gt;&lt;div style="line-height: 10.25pt;"&gt;&lt;br style="line-height: 10.25pt;" /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; line-height: 10.25pt; text-indent: 36pt;"&gt;ASU 2016-15,&lt;font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;"&gt;&amp;#160;Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height: 10.25pt;"&gt;&lt;br style="line-height: 10.25pt;" /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; line-height: 10.25pt; text-indent: 36pt;"&gt;In August 2016, the Financial Accounting Standards Board ("FASB") issued Accounting Standard Update ("ASU") 2016-15,&amp;#160;&lt;font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;"&gt;Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments &lt;/font&gt;(&lt;font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;"&gt;"&lt;/font&gt;ASU 2016-15"). &amp;#160;ASU 2016-15 eliminates the diversity in practice related to the classification of certain cash receipts and payments for debt prepayments or extinguishment costs, the maturing of a zero-coupon bond, the settlement of contingent liabilities arising from a business combination, proceeds from insurance settlements, distributions from certain equity method investees and beneficial interests obtained in a financial asset securitization. ASU 2016-15 designates the appropriate cash flow classification, including requirements to allocate certain components of these cash receipts and payments among operating, investing and financing activities. The Company adopted the new standard effective January 1, 2018 and has determined the impact of ASU No. 2016-15 on its condensed consolidated financial statements will be related to the settlement of contingent liabilities arising from a business combination.&lt;/div&gt;&lt;div style="line-height: 10.25pt;"&gt;&lt;br style="line-height: 10.25pt;" /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; line-height: 10.25pt; text-indent: 36pt;"&gt;ASU 2016-18,&amp;#160;&lt;font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;"&gt;Restricted Cash (Topic 230): Statement of Cash Flows&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height: 10.25pt;"&gt;&lt;br style="line-height: 10.25pt;" /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; line-height: 10.25pt; text-indent: 36pt;"&gt;In November 2016, the FASB issued ASU 2016-18, &lt;font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;"&gt;Restricted Cash (Topic 230): Statement of Cash Flows &lt;/font&gt;(&lt;font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;"&gt;"&lt;/font&gt;ASU 2016-18"). ASU 2016-18 requires that a statement of cash flows explain the change during the period in the total of cash, cash equivalents and amounts generally described as restricted cash or restricted cash equivalents.&amp;#160;Restricted cash and restricted cash equivalents will be included with cash and cash equivalents when reconciling the beginning of period and end of period balances on the statement of cash flows upon adoption of this standard. The Company adopted the new standard effective January 1, 2018. Restricted cash primarily consists of collateralized cash for a standby letter of credit and guarantee arrangement with a bank.&lt;/div&gt;&lt;div style="line-height: 10.25pt;"&gt;&lt;br style="line-height: 10.25pt;" /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; line-height: 10.25pt; text-indent: 36pt;"&gt;ASU No. 2017-09, &lt;font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;"&gt;Compensation-Stock Compensation (Topic 718):&lt;/font&gt;&amp;#160;&lt;font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;"&gt;Scope of Modification Accounting&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height: 10.25pt;"&gt;&lt;br style="line-height: 10.25pt;" /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; line-height: 10.25pt; text-indent: 36pt;"&gt;In May 2017, the FASB issued ASU 2017-09, &lt;font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;"&gt;Compensation-Stock Compensation (Topic 718): Scope of Modification Accounting &lt;/font&gt;("ASU 2017-09"). ASU 2017-09 clarifies which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in Topic 718. The Company adopted the new standard effective January 1, 2018, which did not have a material impact on its condensed consolidated financial statements.&lt;/div&gt;&lt;div style="line-height: 10.25pt;"&gt;&lt;br style="line-height: 10.25pt;" /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; line-height: 10.25pt; text-indent: 36pt;"&gt;ASU No. 2018-07, &lt;font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;"&gt;Compensation-Stock Compensation (Topic 718):&lt;/font&gt;&amp;#160;&lt;font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;"&gt;Improvements to Nonemployee Share-based Payment Accounting&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height: 10.25pt;"&gt;&lt;br style="line-height: 10.25pt;" /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; line-height: 10.25pt; text-indent: 36pt;"&gt;In June 2018, the FASB issued ASU 2018-07, &lt;font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;"&gt;Compensation-Stock Compensation (Topic 718): Improvements to Nonemployee Share-based Payment Accounting &lt;/font&gt;("ASU 2018-07"). ASU 2018-07 expands the scope of Topic 718 to include share-based payments issued to nonemployees for goods and services. ASU No. 2018-07 is intended to reduce cost and complexity and to improve financial reporting for share-based payments issued to nonemployees (for example, service providers, external legal counsel, suppliers, etc.). The standard will be effective after December 15, 2018 for the Company, with early adoption permitted, but no earlier than the Company's adoption date of Topic 606. The Company early adopted the new standard effective April 1, 2018. The adoption of this standard did not have a material impact on the Company's condensed consolidated financial statements.&lt;/div&gt;&lt;div style="line-height: 10.25pt;"&gt;&lt;br style="line-height: 10.25pt;" /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic; text-align: justify; line-height: 10.25pt; text-indent: 36pt;"&gt;&lt;u&gt;Not Yet Adopted&lt;/u&gt;&lt;/div&gt;&lt;div style="line-height: 10.25pt;"&gt;&lt;br style="line-height: 10.25pt;" /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; line-height: 10.25pt; text-indent: 36pt;"&gt;ASU 2016-02,&amp;#160;&lt;font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;"&gt;Leases (Topic 842)&lt;/font&gt;&amp;#160;&lt;/div&gt;&lt;div style="line-height: 10.25pt;"&gt;&lt;br style="line-height: 10.25pt;" /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; line-height: 10.25pt; text-indent: 36pt;"&gt;In February 2016, the FASB issued ASU 2016-02,&lt;font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;"&gt;&amp;#160;Leases (Topic 842)&lt;/font&gt;&amp;#160;(&lt;font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;"&gt;"&lt;/font&gt;ASU 2016-02"). ASU 2016-02 increases transparency and comparability among organizations by requiring the recognition of lease assets and lease liabilities on the balance sheet and disclosure of key information about leasing arrangements for both lessees and lessors. The standard will be effective January 1, 2019, with early adoption permitted. The standard will be applied using a modified retrospective approach to the beginning of the earliest period presented in the financial statements. The Company's adoption efforts are primarily focused on the review of its existing lease contracts, identification of other contracts that may fall under the scope of the new guidance and performing a gap analysis on the current state of lease-related activities compared with the future state of lease-related activities. The Company has identified the lease agreements that will be impacted by the new standard and is currently evaluating the overall impact on its condensed consolidated financial statements and related disclosures.&lt;/div&gt;&lt;div style="line-height: 10.25pt;"&gt;&lt;br style="line-height: 10.25pt;" /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; line-height: 10.25pt; text-indent: 36pt;"&gt;ASU 2016-16,&amp;#160;&lt;font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;"&gt;Income Taxes (Topic 740): Intra-Entity Transfers of Assets Other Than Inventory&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height: 10.25pt;"&gt;&lt;br style="line-height: 10.25pt;" /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; line-height: 10.25pt; text-indent: 36pt;"&gt;In October 2016, the FASB issued ASU 2016-16, &lt;font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;"&gt;Income Taxes (Topic 740): Intra-Entity Transfers of Assets Other Than Inventory&lt;/font&gt; ("ASU 2016-16"). ASU 2016-16 improves the accounting for the income tax consequences of intra-entity transfers of assets other than inventory. The new standard will require entities to recognize the income tax consequences of an intra-entity transfer of a non-inventory asset when the transfer occurs. The guidance is effective for fiscal years beginning after December 15, 2017, and early adoption is permitted. The Company is currently evaluating the effects of adopting ASU 2016-16 on its condensed consolidated financial statements but the adoption is not expected to have a significant impact as of the filing of this report.&lt;/div&gt;&lt;div style="line-height: 10.25pt;"&gt;&lt;br style="line-height: 10.25pt;" /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; line-height: 10.25pt; text-indent: 36pt;"&gt;ASU 2017-04,&amp;#160;&lt;font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;"&gt;Intangibles - Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height: 10.25pt;"&gt;&lt;br style="line-height: 10.25pt;" /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; line-height: 10.25pt; text-indent: 36pt;"&gt;In January 2017, the FASB issued ASU 2017-04,&amp;#160;&lt;font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;"&gt;Intangibles - Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment&lt;/font&gt;&amp;#160;("ASU 2017-04"). ASU 2017-04 simplifies the subsequent measurement of goodwill and eliminates Step 2 from the goodwill impairment test. ASU 2017-04 is effective for annual and interim goodwill tests beginning after December 15, 2019. Early adoption is permitted for interim or annual goodwill impairment tests performed on testing dates on or after January 1, 2017. The Company is currently evaluating the impact that the adoption of this standard will have on its condensed consolidated financial statements.&lt;/div&gt;&lt;div style="line-height: 10.25pt;"&gt;&lt;br style="line-height: 10.25pt;" /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; line-height: 10.25pt; text-indent: 36pt;"&gt;ASU 2018-02,&amp;#160;&lt;font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;"&gt;Income Statement&amp;#8212;Reporting Comprehensive Income (Topic 220):&amp;#160;Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height: 10.25pt;"&gt;&lt;br style="line-height: 10.25pt;" /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; line-height: 10.25pt; text-indent: 36pt;"&gt;In February 2018, the FASB issued ASU 2018-02,&lt;font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;"&gt;&amp;#160;Income Statement&amp;#8212;Reporting Comprehensive Income (Topic 220):&amp;#160;Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income &lt;/font&gt;("ASU 2018-02"). ASU 2018-02 provides the option to reclassify certain income tax effects related to the Tax Cuts and Jobs Act passed in December of 2017 between accumulated other comprehensive income and retained earnings and also requires additional disclosures.&amp;#160;ASU 2018-02 is effective for all entities for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years, with early adoption permitted.&amp;#160;Adoption of ASU 2018-02 is to be applied either in the period of adoption or retrospectively to each period in which the effect of the change in the tax laws or rates were recognized.&amp;#160;The Company is currently evaluating the impact of adopting ASU 2018-02 on its condensed consolidated financial statements.&lt;/div&gt;&lt;div style="line-height: 10.25pt;"&gt;&lt;br style="line-height: 10.25pt;" /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; line-height: 10.25pt; text-indent: 36pt;"&gt;ASU 2018-11,&amp;#160;&lt;font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;"&gt;Leases (Topic 842)&lt;/font&gt;: &lt;font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;"&gt;Targeted Improvements&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height: 10.25pt;"&gt;&lt;br style="line-height: 10.25pt;" /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; line-height: 10.25pt; text-indent: 36pt;"&gt;In July 2018, the FASB issued ASU 2018-11,&lt;font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;"&gt;&amp;#160;Leases (Topic 842): Targeted Improvements &lt;/font&gt;("ASU 2018-11"). In issuing ASU 2018-11,&amp;#160;the&amp;#160;FASB&amp;#160;decided to provide another transition method in addition to the existing transition method by allowing entities to initially apply the&amp;#160;new leases standard at the adoption date and recognize a cumulative-effect adjustment to the opening balance of retained earnings in the period&amp;#160;of adoption.&amp;#160;The Company is currently evaluating the impact that ASU 2016-02&amp;#160;and ASU 2018-11&amp;#160;will have on its condensed consolidated financial&amp;#160;statements.&lt;/div&gt;&lt;div style="line-height: 10.25pt;"&gt;&lt;br style="line-height: 10.25pt;" /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; line-height: 10.25pt; text-indent: 36pt;"&gt;There are no other recently issued accounting pronouncements that are expected to have a material impact on the Company's financial position, results of operations or cash flows.&lt;/div&gt;&lt;div style="line-height: 11.4pt;"&gt;&lt;br style="line-height: 11.4pt;" /&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
  <!--Nonoperating Income (Expense)-->
  <us-gaap:NonoperatingIncomeExpense contextRef="c20180101to20180930" unitRef="U002" decimals="-3">-644000</us-gaap:NonoperatingIncomeExpense>
  <!--Nonoperating Income (Expense)-->
  <us-gaap:NonoperatingIncomeExpense contextRef="c20170701to20170930" unitRef="U002" decimals="-3">-1455000</us-gaap:NonoperatingIncomeExpense>
  <!--Nonoperating Income (Expense)-->
  <us-gaap:NonoperatingIncomeExpense contextRef="c20170101to20170930" unitRef="U002" decimals="-3">-4528000</us-gaap:NonoperatingIncomeExpense>
  <!--Nonoperating Income (Expense)-->
  <us-gaap:NonoperatingIncomeExpense contextRef="c20180701to20180930" unitRef="U002" decimals="-3">249000</us-gaap:NonoperatingIncomeExpense>
  <!--Number of operating segments-->
  <us-gaap:NumberOfOperatingSegments contextRef="c20180101to20180930" unitRef="U005" decimals="INF">1</us-gaap:NumberOfOperatingSegments>
  <!--Operating Income (Loss)-->
  <us-gaap:OperatingIncomeLoss contextRef="c20180701to20180930" unitRef="U002" decimals="-3">21310000</us-gaap:OperatingIncomeLoss>
  <!--Operating Income (Loss)-->
  <us-gaap:OperatingIncomeLoss contextRef="c20170101to20170930" unitRef="U002" decimals="-3">71208000</us-gaap:OperatingIncomeLoss>
  <!--Operating Income (Loss)-->
  <us-gaap:OperatingIncomeLoss contextRef="c20170701to20170930" unitRef="U002" decimals="-3">47769000</us-gaap:OperatingIncomeLoss>
  <!--Operating Income (Loss)-->
  <us-gaap:OperatingIncomeLoss contextRef="c20180101to20180930" unitRef="U002" decimals="-3">78601000</us-gaap:OperatingIncomeLoss>
  <!--Foreign currency translations, net of tax-->
  <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c20170101to20170930" unitRef="U002" decimals="-3">516000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
  <!--Foreign currency translations, net of tax-->
  <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c20170701to20170930" unitRef="U002" decimals="-3">-296000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
  <!--Foreign currency translations, net of tax-->
  <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c20180101to20180930" unitRef="U002" decimals="-3">-968000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
  <!--Foreign currency translations, net of tax-->
  <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c20180701to20180930" unitRef="U002" decimals="-3">-250000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
  <!--Foreign currency translations, net of tax-Accumulated Other Comprehensive Loss [Member]-->
  <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c20180101to20180930_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="U002" decimals="-3">-968000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
  <!--Other Noncash Income (Expense)-->
  <us-gaap:OtherNoncashIncomeExpense contextRef="c20170101to20170930" unitRef="U002" decimals="-3">-703000</us-gaap:OtherNoncashIncomeExpense>
  <!--Other Noncash Income (Expense)-->
  <us-gaap:OtherNoncashIncomeExpense contextRef="c20180101to20180930" unitRef="U002" decimals="-3">-1515000</us-gaap:OtherNoncashIncomeExpense>
  <!--Other assets-->
  <us-gaap:OtherAssetsNoncurrent contextRef="c20180930" unitRef="U002" decimals="-3">5757000</us-gaap:OtherAssetsNoncurrent>
  <!--Other assets-->
  <us-gaap:OtherAssetsNoncurrent contextRef="c20171231" unitRef="U002" decimals="-3">6046000</us-gaap:OtherAssetsNoncurrent>
  <!--Other liabilities-->
  <us-gaap:OtherLiabilitiesNoncurrent contextRef="c20171231" unitRef="U002" decimals="-3">4675000</us-gaap:OtherLiabilitiesNoncurrent>
  <!--Other liabilities-->
  <us-gaap:OtherLiabilitiesNoncurrent contextRef="c20180930" unitRef="U002" decimals="-3">4619000</us-gaap:OtherLiabilitiesNoncurrent>
  <!--Other income (expense), net-->
  <us-gaap:OtherNonoperatingIncomeExpense contextRef="c20180101to20180930" unitRef="U002" decimals="-3">11000</us-gaap:OtherNonoperatingIncomeExpense>
  <!--Other income (expense), net-->
  <us-gaap:OtherNonoperatingIncomeExpense contextRef="c20180701to20180930" unitRef="U002" decimals="-3">190000</us-gaap:OtherNonoperatingIncomeExpense>
  <!--Other income (expense), net-->
  <us-gaap:OtherNonoperatingIncomeExpense contextRef="c20170701to20170930" unitRef="U002" decimals="-3">-101000</us-gaap:OtherNonoperatingIncomeExpense>
  <!--Other income (expense), net-->
  <us-gaap:OtherNonoperatingIncomeExpense contextRef="c20170101to20170930" unitRef="U002" decimals="-3">-387000</us-gaap:OtherNonoperatingIncomeExpense>
  <!--Payments Related to Tax Withholding for Share-based Compensation-->
  <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="c20180101to20180930" unitRef="U002" decimals="-3">6303000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
  <!--Payments Related to Tax Withholding for Share-based Compensation-->
  <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="c20170101to20170930" unitRef="U002" decimals="-3">4184000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
  <!--Payments for Repurchase of Common Stock-->
  <us-gaap:PaymentsForRepurchaseOfCommonStock contextRef="c20180101to20180930" unitRef="U002" decimals="-3">145000</us-gaap:PaymentsForRepurchaseOfCommonStock>
  <!--Payments for Repurchase of Common Stock-->
  <us-gaap:PaymentsForRepurchaseOfCommonStock contextRef="c20170101to20170930" unitRef="U002" decimals="-3">83000</us-gaap:PaymentsForRepurchaseOfCommonStock>
  <!--Payments to Acquire Businesses, Gross-Sanofi [Member]-->
  <us-gaap:PaymentsToAcquireBusinessesGross contextRef="c20171006to20171006_BusinessAcquisitionAxis_SanofiMember" unitRef="U002" decimals="-3">117500000</us-gaap:PaymentsToAcquireBusinessesGross>
  <!--Payments to Acquire Businesses, Gross-Adapt Pharma [Member]-Subsequent Event [Member]-->
  <us-gaap:PaymentsToAcquireBusinessesGross contextRef="c20181015to20181015_BusinessAcquisitionAxis_AdaptPharmaMember_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="U002" decimals="-6">575000000</us-gaap:PaymentsToAcquireBusinessesGross>
  <!--Payments to Acquire Businesses, Gross-PaxVax [Member]-Subsequent Event [Member]-->
  <us-gaap:PaymentsToAcquireBusinessesGross contextRef="c20181004to20181004_BusinessAcquisitionAxis_PaxVaxMember_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="U002" decimals="-6">270000000</us-gaap:PaymentsToAcquireBusinessesGross>
  <!--Payments of Debt Issuance Costs-->
  <us-gaap:PaymentsOfDebtIssuanceCosts contextRef="c20170101to20170930" unitRef="U002" decimals="-3">1426000</us-gaap:PaymentsOfDebtIssuanceCosts>
  <!--Payments of Debt Issuance Costs-->
  <us-gaap:PaymentsOfDebtIssuanceCosts contextRef="c20180101to20180930" unitRef="U002" decimals="-3">0</us-gaap:PaymentsOfDebtIssuanceCosts>
  <!--Payments to Acquire Property, Plant, and Equipment-->
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c20180101to20180930" unitRef="U002" decimals="-3">51275000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <!--Payments to Acquire Property, Plant, and Equipment-->
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c20170101to20170930" unitRef="U002" decimals="-3">42381000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <!--Preferred stock, par value (in dollars per share)-->
  <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="c20171231" unitRef="U003" decimals="INF">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
  <!--Preferred stock, par value (in dollars per share)-->
  <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="c20180930" unitRef="U003" decimals="INF">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
  <!--Preferred stock, shares authorized (in shares)-->
  <us-gaap:PreferredStockSharesAuthorized contextRef="c20171231" unitRef="U001" decimals="0">15000000</us-gaap:PreferredStockSharesAuthorized>
  <!--Preferred stock, shares authorized (in shares)-->
  <us-gaap:PreferredStockSharesAuthorized contextRef="c20180930" unitRef="U001" decimals="0">15000000</us-gaap:PreferredStockSharesAuthorized>
  <!--Preferred stock, shares issued (in shares)-->
  <us-gaap:PreferredStockSharesIssued contextRef="c20171231" unitRef="U001" decimals="0">0</us-gaap:PreferredStockSharesIssued>
  <!--Preferred stock, shares issued (in shares)-->
  <us-gaap:PreferredStockSharesIssued contextRef="c20180930" unitRef="U001" decimals="0">0</us-gaap:PreferredStockSharesIssued>
  <!--Preferred stock, $0.001 par value; 15,000,000 shares authorized, 0 shares issued and outstanding at both September 30, 2018 and December 31, 2017-->
  <us-gaap:PreferredStockValue contextRef="c20180930" unitRef="U002" decimals="-3">0</us-gaap:PreferredStockValue>
  <!--Preferred stock, $0.001 par value; 15,000,000 shares authorized, 0 shares issued and outstanding at both September 30, 2018 and December 31, 2017-->
  <us-gaap:PreferredStockValue contextRef="c20171231" unitRef="U002" decimals="-3">0</us-gaap:PreferredStockValue>
  <!--Preferred stock, shares outstanding (in shares)-->
  <us-gaap:PreferredStockSharesOutstanding contextRef="c20171231" unitRef="U001" decimals="0">0</us-gaap:PreferredStockSharesOutstanding>
  <!--Preferred stock, shares outstanding (in shares)-->
  <us-gaap:PreferredStockSharesOutstanding contextRef="c20180930" unitRef="U001" decimals="0">0</us-gaap:PreferredStockSharesOutstanding>
  <!--Prepaid expenses and other current assets-->
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c20171231" unitRef="U002" decimals="-3">17157000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <!--Prepaid expenses and other current assets-->
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c20180930" unitRef="U002" decimals="-3">20047000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <!--Proceeds from (Repayments of) Restricted Cash, Financing Activities-->
  <us-gaap:ProceedsFromRepaymentsOfRestrictedCashFinancingActivities contextRef="c20170101to20170930" unitRef="U002" decimals="-3">-1043000</us-gaap:ProceedsFromRepaymentsOfRestrictedCashFinancingActivities>
  <!--Proceeds from (Repayments of) Restricted Cash, Financing Activities-->
  <us-gaap:ProceedsFromRepaymentsOfRestrictedCashFinancingActivities contextRef="c20180101to20180930" unitRef="U002" decimals="-3">0</us-gaap:ProceedsFromRepaymentsOfRestrictedCashFinancingActivities>
  <!--Proceeds from sale of assets-->
  <us-gaap:ProceedsFromSaleOfProductiveAssets contextRef="c20170101to20170930" unitRef="U002" decimals="-3">0</us-gaap:ProceedsFromSaleOfProductiveAssets>
  <!--Proceeds from sale of assets-->
  <us-gaap:ProceedsFromSaleOfProductiveAssets contextRef="c20180101to20180930" unitRef="U002" decimals="-3">2624000</us-gaap:ProceedsFromSaleOfProductiveAssets>
  <!--Issuance of common stock upon exercise of stock options-->
  <us-gaap:ProceedsFromStockOptionsExercised contextRef="c20180101to20180930" unitRef="U002" decimals="-3">11402000</us-gaap:ProceedsFromStockOptionsExercised>
  <!--Issuance of common stock upon exercise of stock options-->
  <us-gaap:ProceedsFromStockOptionsExercised contextRef="c20170101to20170930" unitRef="U002" decimals="-3">10799000</us-gaap:ProceedsFromStockOptionsExercised>
  <!--Net Income (Loss), Including Portion Attributable to Noncontrolling Interest-->
  <us-gaap:ProfitLoss contextRef="c20170101to20170930" unitRef="U002" decimals="-3">48652000</us-gaap:ProfitLoss>
  <!--Net Income (Loss), Including Portion Attributable to Noncontrolling Interest-->
  <us-gaap:ProfitLoss contextRef="c20180101to20180930" unitRef="U002" decimals="-3">66181000</us-gaap:ProfitLoss>
  <!--Property, Plant and Equipment Disclosure [Text Block]-->
  <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="c20180101to20180930">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: left; line-height: 10.25pt;"&gt;6. Property, plant and equipment&lt;/div&gt;&lt;div style="line-height: 11.4pt;"&gt;&lt;br style="line-height: 11.4pt;" /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; line-height: 10.25pt; text-indent: 36pt;"&gt;Property, plant and equipment consisted of the following:&lt;/div&gt;&lt;div style="line-height: 11.4pt;"&gt;&lt;br style="line-height: 11.4pt;" /&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center; line-height: 9.1pt;"&gt;September 30,&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center; line-height: 9.1pt;"&gt;December 31,&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; line-height: 9.1pt;"&gt;&lt;font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"&gt;(in thousands)&lt;/font&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center; line-height: 9.1pt;"&gt;2018&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center; line-height: 9.1pt;"&gt;2017&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 76%; vertical-align: bottom; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; line-height: 9.1pt;"&gt;Land and improvements&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;21,848&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;21,843&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 76%; vertical-align: bottom; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; line-height: 9.1pt;"&gt;Buildings, building improvements and leasehold improvements&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;161,175&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;160,005&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 76%; vertical-align: bottom; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; line-height: 9.1pt;"&gt;Furniture and equipment&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;217,908&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;206,819&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 76%; vertical-align: bottom; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; line-height: 9.1pt;"&gt;Software&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;53,180&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;50,829&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 76%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; line-height: 9.1pt;"&gt;Construction-in-progress&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;141,348&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;100,088&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 76%; vertical-align: bottom; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; line-height: 9.1pt;"&gt;Property, plant and equipment, gross&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;595,459&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;539,584&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 76%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; line-height: 9.1pt;"&gt;Less: Accumulated depreciation and amortization&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;(160,384&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;(132,374&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 76%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; line-height: 9.1pt;"&gt;Total property, plant and equipment, net&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;435,075&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;407,210&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height: 10.25pt;"&gt;&lt;br style="line-height: 10.25pt;" /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; line-height: 10.25pt; text-indent: 36pt;"&gt;In the table presented above, as of September 30, 2018 and December 31, 2017, construction-in-progress primarily includes costs related to construction of the Company's CIADM facility.&lt;/div&gt;&lt;div style="text-align: justify; line-height: 10.25pt; text-indent: 36pt;"&gt;&lt;br style="line-height: 10.25pt;" /&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
  <!--Property, Plant and Equipment, Gross-Buildings, Building Improvements and Leasehold Improvements [Member]-->
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="c20180930_PropertyPlantAndEquipmentByTypeAxis_BuildingAndBuildingImprovementsMember" unitRef="U002" decimals="-3">161175000</us-gaap:PropertyPlantAndEquipmentGross>
  <!--Property, Plant and Equipment, Gross-Construction-In-Progress [Member]-->
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="c20180930_PropertyPlantAndEquipmentByTypeAxis_ConstructionInProgressMember" unitRef="U002" decimals="-3">141348000</us-gaap:PropertyPlantAndEquipmentGross>
  <!--Property, Plant and Equipment, Gross-Construction-In-Progress [Member]-->
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="c20171231_PropertyPlantAndEquipmentByTypeAxis_ConstructionInProgressMember" unitRef="U002" decimals="-3">100088000</us-gaap:PropertyPlantAndEquipmentGross>
  <!--Property, Plant and Equipment, Gross-->
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="c20171231" unitRef="U002" decimals="-3">539584000</us-gaap:PropertyPlantAndEquipmentGross>
  <!--Property, Plant and Equipment, Gross-Furniture and Fixtures [Member]-->
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="c20180930_PropertyPlantAndEquipmentByTypeAxis_FurnitureAndFixturesMember" unitRef="U002" decimals="-3">217908000</us-gaap:PropertyPlantAndEquipmentGross>
  <!--Property, Plant and Equipment, Gross-Software [Member]-->
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="c20171231_PropertyPlantAndEquipmentByTypeAxis_ComputerSoftwareIntangibleAssetMember" unitRef="U002" decimals="-3">50829000</us-gaap:PropertyPlantAndEquipmentGross>
  <!--Property, Plant and Equipment, Gross-Buildings, Building Improvements and Leasehold Improvements [Member]-->
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="c20171231_PropertyPlantAndEquipmentByTypeAxis_BuildingAndBuildingImprovementsMember" unitRef="U002" decimals="-3">160005000</us-gaap:PropertyPlantAndEquipmentGross>
  <!--Property, Plant and Equipment, Gross-Furniture and Fixtures [Member]-->
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="c20171231_PropertyPlantAndEquipmentByTypeAxis_FurnitureAndFixturesMember" unitRef="U002" decimals="-3">206819000</us-gaap:PropertyPlantAndEquipmentGross>
  <!--Property, Plant and Equipment, Gross-Land and Improvements [Member]-->
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="c20180930_PropertyPlantAndEquipmentByTypeAxis_LandAndLandImprovementsMember" unitRef="U002" decimals="-3">21848000</us-gaap:PropertyPlantAndEquipmentGross>
  <!--Property, Plant and Equipment, Gross-Land and Improvements [Member]-->
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="c20171231_PropertyPlantAndEquipmentByTypeAxis_LandAndLandImprovementsMember" unitRef="U002" decimals="-3">21843000</us-gaap:PropertyPlantAndEquipmentGross>
  <!--Property, Plant and Equipment, Gross-->
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="c20180930" unitRef="U002" decimals="-3">595459000</us-gaap:PropertyPlantAndEquipmentGross>
  <!--Property, Plant and Equipment, Gross-Software [Member]-->
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="c20180930_PropertyPlantAndEquipmentByTypeAxis_ComputerSoftwareIntangibleAssetMember" unitRef="U002" decimals="-3">53180000</us-gaap:PropertyPlantAndEquipmentGross>
  <!--Property, Plant and Equipment [Table Text Block]-->
  <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="c20180101to20180930">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; line-height: 10.25pt; text-indent: 36pt;"&gt;Property, plant and equipment consisted of the following:&lt;/div&gt;&lt;div style="line-height: 11.4pt;"&gt;&lt;br style="line-height: 11.4pt;" /&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center; line-height: 9.1pt;"&gt;September 30,&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center; line-height: 9.1pt;"&gt;December 31,&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; line-height: 9.1pt;"&gt;&lt;font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"&gt;(in thousands)&lt;/font&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center; line-height: 9.1pt;"&gt;2018&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center; line-height: 9.1pt;"&gt;2017&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 76%; vertical-align: bottom; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; line-height: 9.1pt;"&gt;Land and improvements&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;21,848&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;21,843&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 76%; vertical-align: bottom; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; line-height: 9.1pt;"&gt;Buildings, building improvements and leasehold improvements&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;161,175&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;160,005&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 76%; vertical-align: bottom; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; line-height: 9.1pt;"&gt;Furniture and equipment&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;217,908&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;206,819&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 76%; vertical-align: bottom; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; line-height: 9.1pt;"&gt;Software&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;53,180&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;50,829&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 76%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; line-height: 9.1pt;"&gt;Construction-in-progress&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;141,348&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;100,088&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 76%; vertical-align: bottom; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; line-height: 9.1pt;"&gt;Property, plant and equipment, gross&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;595,459&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;539,584&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 76%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; line-height: 9.1pt;"&gt;Less: Accumulated depreciation and amortization&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;(160,384&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;(132,374&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 76%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; line-height: 9.1pt;"&gt;Total property, plant and equipment, net&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;435,075&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;407,210&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height: 10.25pt;"&gt;&lt;br style="line-height: 10.25pt;" /&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
  <!--Property, plant and equipment, net-->
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="c20171231" unitRef="U002" decimals="-3">407210000</us-gaap:PropertyPlantAndEquipmentNet>
  <!--Property, plant and equipment, net-->
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="c20180930" unitRef="U002" decimals="-3">435075000</us-gaap:PropertyPlantAndEquipmentNet>
  <!--Repayments of Notes Payable-->
  <us-gaap:RepaymentsOfNotesPayable contextRef="c20170101to20170930" unitRef="U002" decimals="-3">20000000</us-gaap:RepaymentsOfNotesPayable>
  <!--Repayments of Notes Payable-->
  <us-gaap:RepaymentsOfNotesPayable contextRef="c20180101to20180930" unitRef="U002" decimals="-3">0</us-gaap:RepaymentsOfNotesPayable>
  <!--Research and development-->
  <us-gaap:ResearchAndDevelopmentExpense contextRef="c20180701to20180930" unitRef="U002" decimals="-3">37006000</us-gaap:ResearchAndDevelopmentExpense>
  <!--Research and development-->
  <us-gaap:ResearchAndDevelopmentExpense contextRef="c20180101to20180930" unitRef="U002" decimals="-3">90802000</us-gaap:ResearchAndDevelopmentExpense>
  <!--Research and development-->
  <us-gaap:ResearchAndDevelopmentExpense contextRef="c20170701to20170930" unitRef="U002" decimals="-3">22659000</us-gaap:ResearchAndDevelopmentExpense>
  <!--Research and development-->
  <us-gaap:ResearchAndDevelopmentExpense contextRef="c20170101to20170930" unitRef="U002" decimals="-3">68886000</us-gaap:ResearchAndDevelopmentExpense>
  <!--Restricted cash-->
  <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue contextRef="c20180930" unitRef="U002" decimals="-3">1043000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
  <!--Restricted cash-->
  <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue contextRef="c20171231" unitRef="U002" decimals="-3">1043000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
  <!--Retained earnings-->
  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c20180930" unitRef="U002" decimals="-3">370728000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <!--Retained earnings-->
  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c20171231" unitRef="U002" decimals="-3">337074000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <!--Total revenues-Product [Member]-->
  <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c20180101to20180930_ProductOrServiceAxis_ProductMember" unitRef="U002" decimals="-3">389115000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
  <!--Total revenues-->
  <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c20180701to20180930" unitRef="U002" decimals="-3">173653000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
  <!--Total revenues-->
  <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c20180101to20180930" unitRef="U002" decimals="-3">511667000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
  <!--Total revenues-Contracts and Grants [Member]-->
  <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c20180701to20180930_ProductOrServiceAxis_ContractsAndGrantsMember" unitRef="U002" decimals="-3">18212000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
  <!--Total revenues-Contract Manufacturing [Member]-->
  <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c20180101to20180930_ProductOrServiceAxis_ContractManufacturingMember" unitRef="U002" decimals="-3">71963000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
  <!--Total revenues-Product [Member]-->
  <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c20170101to20170930_ProductOrServiceAxis_ProductMember" unitRef="U002" decimals="-3">259875000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
  <!--Total revenues-Contract Manufacturing [Member]-->
  <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c20170701to20170930_ProductOrServiceAxis_ContractManufacturingMember" unitRef="U002" decimals="-3">18912000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
  <!--Total revenues-Contracts and Grants [Member]-->
  <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c20180101to20180930_ProductOrServiceAxis_ContractsAndGrantsMember" unitRef="U002" decimals="-3">50589000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
  <!--Total revenues-->
  <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c20170701to20170930" unitRef="U002" decimals="-3">149434000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
  <!--Total revenues-->
  <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c20170101to20170930" unitRef="U002" decimals="-3">367064000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
  <!--Total revenues-Contract Manufacturing [Member]-->
  <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c20180701to20180930_ProductOrServiceAxis_ContractManufacturingMember" unitRef="U002" decimals="-3">22172000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
  <!--Total revenues-Product [Member]-->
  <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c20180701to20180930_ProductOrServiceAxis_ProductMember" unitRef="U002" decimals="-3">133269000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
  <!--Total revenues-Product [Member]-->
  <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c20170701to20170930_ProductOrServiceAxis_ProductMember" unitRef="U002" decimals="-3">114296000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
  <!--Total revenues-Contracts and Grants [Member]-->
  <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c20170701to20170930_ProductOrServiceAxis_ContractsAndGrantsMember" unitRef="U002" decimals="-3">16226000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
  <!--Total revenues-Contract Manufacturing [Member]-->
  <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c20170101to20170930_ProductOrServiceAxis_ContractManufacturingMember" unitRef="U002" decimals="-3">52700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
  <!--Total revenues-Contracts and Grants [Member]-->
  <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c20170101to20170930_ProductOrServiceAxis_ContractsAndGrantsMember" unitRef="U002" decimals="-3">54489000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
  <!--Total revenues-Non-U.S. Government [Member]-Contracts and Grants [Member]-->
  <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c20180101to20180930_ProductOrServiceAxis_ContractsAndGrantsMember_StatementGeographicalAxis_NonUsMember" unitRef="U002" decimals="-3">3878000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
  <!--Total revenues-Non-U.S. Government [Member]-->
  <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c20180101to20180930_StatementGeographicalAxis_NonUsMember" unitRef="U002" decimals="-3">101702000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
  <!--Total revenues-U.S. Government [Member]-Product [Member]-->
  <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c20180101to20180930_ProductOrServiceAxis_ProductMember_StatementGeographicalAxis_US" unitRef="U002" decimals="-3">363254000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
  <!--Total revenues-U.S. Government [Member]-->
  <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c20180101to20180930_StatementGeographicalAxis_US" unitRef="U002" decimals="-3">409965000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
  <!--Total revenues-Non-U.S. Government [Member]-Contract Manufacturing [Member]-->
  <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c20180701to20180930_ProductOrServiceAxis_ContractManufacturingMember_StatementGeographicalAxis_NonUsMember" unitRef="U002" decimals="-3">22172000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
  <!--Total revenues-Contracts and Grants [Member]-U.S. Government [Member]-->
  <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c20180101to20180930_ProductOrServiceAxis_ContractsAndGrantsMember_StatementGeographicalAxis_US" unitRef="U002" decimals="-3">46711000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
  <!--Total revenues-Product [Member]-Non-U.S. Government [Member]-->
  <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c20180101to20180930_ProductOrServiceAxis_ProductMember_StatementGeographicalAxis_NonUsMember" unitRef="U002" decimals="-3">25861000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
  <!--Total revenues-Contract Manufacturing [Member]-Non-U.S. Government [Member]-->
  <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c20180101to20180930_ProductOrServiceAxis_ContractManufacturingMember_StatementGeographicalAxis_NonUsMember" unitRef="U002" decimals="-3">71963000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
  <!--Total revenues-U.S. Government [Member]-->
  <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c20180701to20180930_StatementGeographicalAxis_US" unitRef="U002" decimals="-3">143988000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
  <!--Total revenues-U.S. Government [Member]-Contract Manufacturing [Member]-->
  <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c20180701to20180930_ProductOrServiceAxis_ContractManufacturingMember_StatementGeographicalAxis_US" unitRef="U002" decimals="-3">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
  <!--Total revenues-U.S. Government [Member]-Contract Manufacturing [Member]-->
  <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c20180101to20180930_ProductOrServiceAxis_ContractManufacturingMember_StatementGeographicalAxis_US" unitRef="U002" decimals="-3">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
  <!--Total revenues-U.S. Government [Member]-Product [Member]-->
  <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c20180701to20180930_ProductOrServiceAxis_ProductMember_StatementGeographicalAxis_US" unitRef="U002" decimals="-3">127332000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
  <!--Total revenues-Non-U.S. Government [Member]-->
  <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c20180701to20180930_StatementGeographicalAxis_NonUsMember" unitRef="U002" decimals="-3">29665000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
  <!--Total revenues-Contracts and Grants [Member]-Non-U.S. Government [Member]-->
  <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c20180701to20180930_ProductOrServiceAxis_ContractsAndGrantsMember_StatementGeographicalAxis_NonUsMember" unitRef="U002" decimals="-3">1556000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
  <!--Total revenues-U.S. Government [Member]-Contracts and Grants [Member]-->
  <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c20180701to20180930_ProductOrServiceAxis_ContractsAndGrantsMember_StatementGeographicalAxis_US" unitRef="U002" decimals="-3">16656000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
  <!--Total revenues-Non-U.S. Government [Member]-Product [Member]-->
  <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c20180701to20180930_ProductOrServiceAxis_ProductMember_StatementGeographicalAxis_NonUsMember" unitRef="U002" decimals="-3">5937000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
  <!--Transaction price-->
  <us-gaap:RevenueRemainingPerformanceObligation contextRef="c20180930" unitRef="U002" decimals="-6">599000000</us-gaap:RevenueRemainingPerformanceObligation>
  <!--Revenue from Contract with Customer [Text Block]-->
  <us-gaap:RevenueFromContractWithCustomerTextBlock contextRef="c20180101to20180930">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; line-height: 10.25pt;"&gt;&lt;font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"&gt;2.&lt;/font&gt;&lt;font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;&amp;#160; &lt;/font&gt;&lt;font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"&gt;Revenue recognition&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height: 10.25pt;"&gt;&lt;br style="line-height: 10.25pt;" /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; line-height: 10.25pt; text-indent: 36pt;"&gt;In May 2014, the FASB issued ASU No. 2014-09, &lt;font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;"&gt;Revenue from Contracts with Customers (Topic 606) &lt;/font&gt;(&lt;font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;"&gt;"&lt;/font&gt;ASU No. 2014-09"). ASU No. 2014-09 (known as ASC 606) supersedes the revenue recognition requirements in &lt;font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;"&gt;Topic 605, Revenue Recognition&lt;/font&gt;, as well as most industry-specific guidance, and significantly enhances comparability of revenue recognition practices across entities and industries by providing a principles-based, comprehensive framework for addressing revenue recognition issues. In order for a provider of promised goods or services to recognize as revenue the consideration that it expects to receive in exchange for the promised goods or services, the provider should apply the following five steps: (1) identify the contract with a customer(s); (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to the performance obligations in the contract; and (5) recognize revenue when (or as) the entity satisfies a performance obligation. ASU No. 2014-09 also specifies the accounting for some costs to obtain or fulfill a contract with a customer and provides enhanced disclosure requirements. The Company adopted the requirements of the new standard as of January 1, 2018 using the modified retrospective method. The modified retrospective method requires companies to recognize the cumulative effect of initially applying the new standard as an adjustment to opening retained earnings.&lt;/div&gt;&lt;div style="line-height: 10.25pt;"&gt;&lt;br style="line-height: 10.25pt;" /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; line-height: 10.25pt; text-indent: 36pt;"&gt;A performance obligation is a promise in a contract to transfer a distinct product or service to a customer and is the unit of account under ASC 606. For contracts with multiple performance obligations, the Company allocates the contract's transaction price to each performance obligation on a relative standalone selling price basis using the Company's best estimate of the standalone selling price of each distinct product or service in the contract. The primary method used to estimate standalone selling price is the price observed in standalone sales to customers, however when prices in standalone sales are not available the Company may use third-party pricing for similar products or services or estimate the standalone selling price. Allocation of the transaction price is determined at the contracts' inception.&lt;/div&gt;&lt;div style="line-height: 10.25pt;"&gt;&lt;br style="line-height: 10.25pt;" /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; line-height: 10.25pt; text-indent: 36pt;"&gt;Once the performance obligations in the contract have been identified, the Company estimates the transaction price of the contract. The estimate includes amounts that are fixed as well as those that can vary based on expected outcomes of the activities or contractual terms. The Company's variable consideration primarily includes consideration transferred under its development contracts with the U.S. government as consideration received can vary based on developmental progression of the product candidate(s). When a contract's transaction price includes variable consideration, the Company evaluates the estimate of the variable consideration to determine whether the estimate needs to be constrained; therefore, the Company includes the variable consideration in the transaction price only to the extent that it is probable that a significant reversal of the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. Variable consideration estimates are updated at each reporting date. There were no constraints or material changes to the Company's variable consideration estimates as of or during the nine months ended September 30, 2018.&lt;/div&gt;&lt;div style="line-height: 11.4pt;"&gt;&lt;br style="line-height: 11.4pt;" /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; line-height: 10.25pt; text-indent: 36pt;"&gt;To indicate the transfer of control for the Company's product sales and contract manufacturing services, it must have a present right to payment, legal title must have passed to the customer, and the customer must have the significant risks and rewards of ownership. Revenue for long-term development contracts is generally recognized based upon the cost-to-cost measure of progress, provided that the Company meets the criteria associated with transferring control of the good or service over time.&lt;/div&gt;&lt;div style="line-height: 10.25pt;"&gt;&lt;br style="line-height: 10.25pt;" /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; line-height: 10.25pt; text-indent: 36pt;"&gt;The Company derives revenues primarily from the sale of its marketed medical countermeasures ("MCMs") products and contract revenues associated with development of its MCMs. The primary customer for the Company's MCM products and the primary source of funding for the development of the Company's MCM product candidate portfolio is the U.S. government. The Company's contracts for the sale of its MCM products generally have single performance obligation. Certain product sales contracts with the U.S. government include multiple performance obligations, which generally include the marketed product, stability testing associated with that product, expiry extensions and plasma collection. The Company's development contracts for its MCM product candidates generally are cost plus fixed fee arrangements, which the Company treats a single performance obligation with variable consideration. The U.S. government contracts for the sale and development of the Company's MCM products and product candidates are normally multi-year contracts.&lt;/div&gt;&lt;div style="line-height: 10.25pt;"&gt;&lt;br style="line-height: 10.25pt;" /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; line-height: 10.25pt; text-indent: 36pt;"&gt;In addition, the Company performs contract manufacturing services for third parties, which includes pharmaceutical product process development, manufacturing and filling services for injectable and other sterile products, inclusive of process design, technical transfer, manufacturing validations, laboratory analytical development support, aseptic filling, lyophilization, final packaging and accelerated and ongoing stability studies. These contracts generally include a single performance obligation with a duration that is less than one-year.&lt;/div&gt;&lt;div style="line-height: 10.25pt;"&gt;&lt;br style="line-height: 10.25pt;" /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; line-height: 10.25pt; text-indent: 36pt;"&gt;The Company finalized the review of its portfolio of revenue contracts that were not complete as of the adoption date and made its determination of its revenue streams as well as completed extensive contract specific reviews to determine the impact of the new standard on its historical and prospective revenue recognition. Because many of the Company's contracts with customers have unique contract terms, the Company reviewed all of its non-standard agreements in order to determine the effect of adoption.&lt;/div&gt;&lt;div style="line-height: 10.25pt;"&gt;&lt;br style="line-height: 10.25pt;" /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; line-height: 10.25pt; text-indent: 36pt;"&gt;The Company determined its Centers for Innovation in Advanced Development and Manufacturing ("CIADM") contract with the &amp;#8203;&amp;#8203;Biomedical Advanced Research and Development Authority ("BARDA") will have a material change in revenue recognition under the new guidance. Under ASC 606 at January 1, 2018, the Company determined that there was one performance obligation to provide ongoing manufacturing capability to the U.S. government and would recognize the consideration received in the base period on a straight-line basis over a 24-year period as the capability being created during the base period of the contract is being provided to the customer over both the base period contract term as well as 17 additional option periods. In addition, the Company determined the CIADM contract includes a significant financing component which is included in the transaction price. The Company calculated the financing component using an interest rate the Company had on its other debt obligations at inception of the contract. Prior to the adoption of ASC 606, the Company recognized revenue under the CIADM contract on a straight-line basis, based upon its estimate of the total payments to be received under the contract. The Company analyzed the estimated payments to be received on a quarterly basis to determine if an adjustment to revenue was required. As a result of the adoption of ASC 606, as of January 1, 2018, there was an increase in the deferred revenue liability of $42.4 million and an increase in deferred tax assets of $9.9 million&lt;font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;&amp;#160;&lt;/font&gt;with an offsetting reduction to retained earnings of $32.5 million.&lt;/div&gt;&lt;div style="line-height: 10.25pt;"&gt;&lt;br style="line-height: 10.25pt;" /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; line-height: 10.25pt; text-indent: 36pt;"&gt;In September 2018, the Company modified the CIADM contract under which one of the modifications reduced the 17 additional option periods to seven with the contract now scheduled to expire in June 2027. The Company determined the modification will be accounted for prospectively as a termination of the existing contract and the creation of a new contract.&lt;/div&gt;&lt;div style="line-height: 10.25pt;"&gt;&lt;br style="line-height: 10.25pt;" /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; line-height: 10.25pt; text-indent: 36pt;"&gt;The Company considers accounts receivables and deferred costs associated with revenue generating contracts, that are not included in inventory or property, plant and equipment, as contract assets. As of September 30, 2018 and December 31, 2017, the Company had $77.0 million and $143.7 million, respectively, in contract assets associated with accounts receivable,&lt;font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;&amp;#160;&lt;/font&gt;which is included in accounts receivable on the Company's condensed consolidated balance sheets. As of September 30, 2018 and December 31, 2017, the Company had contract assets associated with deferred costs of $4.0 million and $2.9 million, respectively, &lt;!--Anchor--&gt;which is included in prepaid expenses and other current assets on the Company's condensed consolidated balance sheets.&lt;/div&gt;&lt;div style="line-height: 11.4pt;"&gt;&lt;br style="line-height: 11.4pt;" /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; line-height: 10.25pt; text-indent: 36pt;"&gt;When performance obligations are not transferred to a customer at the end of a reporting period, the amount allocated to those performance obligations are deferred until control of these performance obligations is transferred to the customer. The following table presents the rollforward of the contract liabilities,&lt;font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;&amp;#160;&lt;/font&gt;which is included in the Company's current and long-term deferred revenue line items in the condensed consolidated balance sheets:&lt;/div&gt;&lt;div style="line-height: 11.4pt;"&gt;&lt;br style="line-height: 11.4pt;" /&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; line-height: 9.1pt;"&gt;&lt;font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"&gt;(in thousands)&lt;/font&gt;&lt;font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 88%; vertical-align: bottom; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; line-height: 9.1pt;"&gt;Balance at December 31, 2017&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;30,491&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 88%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; line-height: 9.1pt;"&gt;Adoption of new accounting standard (ASC 606)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;42,379&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 88%; vertical-align: bottom; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; line-height: 9.1pt;"&gt;Balance at January 1, 2018&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;72,870&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 88%; vertical-align: bottom; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; line-height: 9.1pt;"&gt;Deferral of revenue&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;18,384&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 88%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; line-height: 9.1pt;"&gt;Recognition of revenue included in beginning of year contract liability&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;(15,121&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 88%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; line-height: 9.1pt;"&gt;Balance at September 30, 2018&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;76,133&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height: 11.4pt;"&gt;&lt;br style="line-height: 11.4pt;" /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; line-height: 10.25pt; text-indent: 36pt;"&gt;We operate in one business segment. Therefore, results of our operations are reported on a consolidated basis for purposes of segment reporting, consistent with internal management reporting.&lt;font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;&amp;#160;&lt;/font&gt;For the three and nine months ended September 30, 2018, there was a nominal difference between revenues recognized under ASC 606 and revenues recognized based on the prior revenue recognition guidance for the same period. For the three and nine months ended September 30, 2018, the Company's&lt;font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;&amp;#160;&lt;/font&gt;revenues disaggregated by the major sources was as follows:&lt;/div&gt;&lt;div style="line-height: 10.25pt;"&gt;&lt;br style="line-height: 10.25pt;" /&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; line-height: 10.25pt;"&gt;&lt;font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"&gt;(in thousands)&lt;/font&gt;&lt;font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="10" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center; line-height: 10.25pt;"&gt;Three Months Ended September 30, 2018&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="10" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center; line-height: 10.25pt;"&gt;Nine Months Ended September 30, 2018&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center; line-height: 10.25pt;"&gt;U.S &lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center; line-height: 10.25pt;"&gt;Non-U.S. &lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center; line-height: 10.25pt;"&gt;U.S &lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center; line-height: 10.25pt;"&gt;Non-U.S. &lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center; line-height: 10.25pt;"&gt;Government&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center; line-height: 10.25pt;"&gt;Government&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center; line-height: 10.25pt;"&gt;Total&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center; line-height: 10.25pt;"&gt;Government&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center; line-height: 10.25pt;"&gt;Government&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center; line-height: 10.25pt;"&gt;Total&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 28%; vertical-align: bottom; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; line-height: 10.25pt;"&gt;Product sales&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 10.25pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 10.25pt;"&gt;127,332&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 10.25pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 10.25pt;"&gt;5,937&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 10.25pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 10.25pt;"&gt;133,269&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 10.25pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 10.25pt;"&gt;363,254&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 10.25pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 10.25pt;"&gt;25,861&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 10.25pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 10.25pt;"&gt;389,115&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 28%; vertical-align: bottom; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; line-height: 10.25pt;"&gt;Contract manufacturing&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 10.25pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 10.25pt;"&gt;22,172&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 10.25pt;"&gt;22,172&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 10.25pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 10.25pt;"&gt;71,963&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 10.25pt;"&gt;71,963&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 28%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; line-height: 10.25pt;"&gt;Contracts and grants&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 10.25pt;"&gt;16,656&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 10.25pt;"&gt;1,556&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 10.25pt;"&gt;18,212&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 10.25pt;"&gt;46,711&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 10.25pt;"&gt;3,878&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 10.25pt;"&gt;50,589&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 28%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; line-height: 10.25pt;"&gt;Total revenues&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 10.25pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 10.25pt;"&gt;143,988&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 10.25pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 10.25pt;"&gt;29,665&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 10.25pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 10.25pt;"&gt;173,653&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 10.25pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 10.25pt;"&gt;409,965&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 10.25pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 10.25pt;"&gt;101,702&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 10.25pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 10.25pt;"&gt;511,667&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height: 11.4pt;"&gt;&lt;br style="line-height: 11.4pt;" /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; line-height: 10.25pt; text-indent: 36pt;"&gt;&lt;!--Anchor--&gt;As of September 30, 2018, the Company had expected future revenues associated with performance obligations that have not been satisfied of approximately $599 million. The Company expects to recognize a majority of these revenues within the next 24 months, with the remainder recognized thereafter. However, the amount and timing of revenue recognition for unsatisfied performance obligations can materially change due to timing of funding appropriations from the U.S. government and the overall success of the Company's development activities associated with its MCM product candidates that are then receiving development funding support from the government under development contracts. In addition, the amount of future revenues associated with unsatisfied performance obligations excludes the value associated with unexercised option periods in the Company's contracts (which are not performance obligations as of September 30, 2018).&lt;/div&gt;&lt;div style="line-height: 11.4pt;"&gt;&lt;br style="line-height: 11.4pt;" /&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
  <!--Revenue, remaining performance obligation, expected timing of satisfaction, period-2018-04-01 [Member]-->
  <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1 contextRef="c20180930_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_Two0180401Member">P24M</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1>
  <!--Schedule of Inventory, Current [Table Text Block]-->
  <us-gaap:ScheduleOfInventoryCurrentTableTextBlock contextRef="c20180101to20180930">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; line-height: 10.25pt; text-indent: 36pt;"&gt;Inventories consisted of the following:&lt;/div&gt;&lt;div style="line-height: 13.7pt;"&gt;&lt;br style="line-height: 13.7pt;" /&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center; line-height: 9.1pt;"&gt;September 30,&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center; line-height: 9.1pt;"&gt;December 31,&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: left; line-height: 9.1pt;"&gt;(in thousands)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center; line-height: 9.1pt;"&gt;2018&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center; line-height: 9.1pt;"&gt;2017&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 76%; vertical-align: bottom; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; line-height: 9.1pt;"&gt;Raw materials and supplies&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;33,845&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;36,069&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 76%; vertical-align: bottom; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; line-height: 9.1pt;"&gt;Work-in-process&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;64,825&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;76,610&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 76%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; line-height: 9.1pt;"&gt;Finished goods&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;27,075&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;30,133&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 76%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; line-height: 9.1pt;"&gt;Total inventories&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;125,745&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;142,812&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height: 11.4pt;"&gt;&lt;br style="line-height: 11.4pt;" /&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
  <!--Basic and Diluted Net Income per Share-->
  <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="c20180101to20180930">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; line-height: 10.25pt; text-indent: 36pt;"&gt;The following table presents the calculation of basic and diluted net income per share:&lt;/div&gt;&lt;div style="line-height: 10.25pt;"&gt;&lt;br style="line-height: 10.25pt;" /&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="6" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center; line-height: 9.1pt;"&gt;Three Months Ended September 30,&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="6" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center; line-height: 9.1pt;"&gt;Nine Months Ended September 30,&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: left; line-height: 9.1pt;"&gt;(in thousands, except share and per share data)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center; line-height: 9.1pt;"&gt;2018&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center; line-height: 9.1pt;"&gt;2017&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center; line-height: 9.1pt;"&gt;2018&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center; line-height: 9.1pt;"&gt;2017&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; line-height: 9.1pt;"&gt;Numerator:&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 52%; vertical-align: bottom; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; line-height: 9.1pt;"&gt;Net income&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;20,945&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;33,551&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;66,181&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;48,652&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 52%; vertical-align: bottom; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; line-height: 9.1pt;"&gt;Interest expense on convertible debt, net of tax&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;704&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;2,445&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 52%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; line-height: 9.1pt;"&gt;Amortization of convertible debt issuance costs, net of tax&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;195&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;586&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 52%; vertical-align: bottom; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; line-height: 9.1pt;"&gt;Net income, adjusted&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;20,945&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;34,450&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;66,181&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;51,683&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 52%; vertical-align: bottom; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 52%; vertical-align: bottom; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; line-height: 9.1pt;"&gt;Denominator:&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 52%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; line-height: 9.1pt;"&gt;Weighted-average number of shares&amp;#8212;basic&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;50,071,632&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;41,222,504&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;49,851,082&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;40,989,813&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 52%; vertical-align: bottom; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; line-height: 9.1pt;"&gt;Dilutive securities&amp;#8212;equity awards&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;1,415,364&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;1,148,857&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;1,338,598&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;1,003,794&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 52%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; line-height: 9.1pt;"&gt;Dilutive securities&amp;#8212;convertible debt&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;8,096,468&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;8,096,481&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 52%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; line-height: 9.1pt;"&gt;Weighted-average number of shares&amp;#8212;diluted&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;51,486,996&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;50,467,829&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;51,189,680&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;50,090,088&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 52%; vertical-align: bottom; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 52%; vertical-align: bottom; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; line-height: 9.1pt;"&gt;Net income per share - basic&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;0.42&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;0.81&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;1.33&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;1.19&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 52%; vertical-align: bottom; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; line-height: 9.1pt;"&gt;Net income per share - diluted&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;0.41&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;0.68&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;1.29&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;1.03&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height: 11.4pt;"&gt;&lt;br style="line-height: 11.4pt;" /&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
  <!--Allocation of Purchase Price Based Upon Estimated Fair Values of Assets Acquired and Liabilities Assumed-->
  <us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock contextRef="c20180101to20180930">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; line-height: 10.25pt; text-indent: 36pt;"&gt;The table below summarizes the allocation of the purchase price based upon the estimated fair values of assets acquired at October 6, 2017. The Company did not assume any liabilities in the acquisition. The Company has finalized the purchase price allocation related to this acquisition.&lt;/div&gt;&lt;div style="line-height: 10.25pt;"&gt;&lt;br style="line-height: 10.25pt;" /&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: left; line-height: 9.1pt;"&gt;(in thousands)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; line-height: 9.1pt;"&gt;Fair value of tangible assets acquired:&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 88%; vertical-align: bottom; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; line-height: 9.1pt;"&gt;Inventory&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;74,876&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 88%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; line-height: 9.1pt;"&gt;Property, plant and equipment&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;19,995&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 88%; vertical-align: bottom; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; line-height: 9.1pt;"&gt;Total fair value of tangible assets acquired&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;94,871&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 88%; vertical-align: bottom; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; line-height: 9.1pt;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 88%; vertical-align: bottom; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; line-height: 9.1pt;"&gt;Acquired intangible asset&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;16,700&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 88%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; line-height: 9.1pt;"&gt;Goodwill&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;8,129&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 88%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; line-height: 9.1pt;"&gt;Total purchase price&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;119,700&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height: 11.4pt;"&gt;&lt;br style="line-height: 11.4pt;" /&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock>
  <!--Schedule of Business Acquisitions, by Acquisition [Table Text Block]-->
  <us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock contextRef="c20180101to20180930">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; line-height: 10.25pt; text-indent: 36pt;"&gt;The total purchase price is summarized below:&lt;/div&gt;&lt;div style="line-height: 11.4pt;"&gt;&lt;br style="line-height: 11.4pt;" /&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; line-height: 9.1pt;"&gt;&lt;font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"&gt;(in thousands)&lt;/font&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: middle; border-bottom: #000000 2px solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 88%; vertical-align: middle; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; line-height: 9.1pt;"&gt;Amount of cash paid to Sanofi&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;117,500&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 88%; vertical-align: middle; padding-bottom: 2px; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; line-height: 9.1pt;"&gt;Fair value of contingent purchase consideration&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;2,200&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 88%; vertical-align: middle; padding-bottom: 4px; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; line-height: 9.1pt;"&gt;Total purchase price&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; line-height: 9.1pt;"&gt;119,700&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height: 11.4pt;"&gt;&lt;br style="line-height: 11.4pt;" /&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock>
  <!--Selling, General and Administrative Expense-->
  <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c20170101to20170930" unitRef="U002" decimals="-3">101521000</us-gaap:SellingGeneralAndAdministrativeExpense>
  <!--Selling, General and Administrative Expense-->
  <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c20180701to20180930" unitRef="U002" decimals="-3">42105000</us-gaap:SellingGeneralAndAdministrativeExpense>
  <!--Selling, General and Administrative Expense-->
  <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c20180101to20180930" unitRef="U002" decimals="-3">121815000</us-gaap:SellingGeneralAndAdministrativeExpense>
  <!--Selling, General and Administrative Expense-->
  <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c20170701to20170930" unitRef="U002" decimals="-3">34503000</us-gaap:SellingGeneralAndAdministrativeExpense>
  <!--Increase in number of shares issuable under the plan (in shares)-Emergent BioSolutions Inc. 2006 Stock Incentive Plan [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized contextRef="c20180524to20180524_PlanNameAxis_EmergentBiosolutionsInc2006StockIncentivePlanMember" unitRef="U001" decimals="-5">3000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
  <!--Extended plan term date-Emergent BioSolutions Inc. 2006 Stock Incentive Plan [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate contextRef="c20180524to20180524_PlanNameAxis_EmergentBiosolutionsInc2006StockIncentivePlanMember">2028-05-23</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate>
  <!--Stock-based compensation expense-->
  <us-gaap:ShareBasedCompensation contextRef="c20170101to20170930" unitRef="U002" decimals="-3">11805000</us-gaap:ShareBasedCompensation>
  <!--Stock-based compensation expense-->
  <us-gaap:ShareBasedCompensation contextRef="c20180101to20180930" unitRef="U002" decimals="-3">16664000</us-gaap:ShareBasedCompensation>
  <!--Restricted stock units granted (in shares)-Emergent BioSolutions Inc. 2006 Stock Incentive Plan [Member]-Restricted Stock Units [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="c20180101to20180930_AwardTypeAxis_RestrictedStockUnitsRSUMember_PlanNameAxis_EmergentBiosolutionsInc2006StockIncentivePlanMember" unitRef="U001" decimals="-5">400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
  <!--Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures-Emergent BioSolutions Inc. 2006 Stock Incentive Plan [Member]-Convertible debt [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod contextRef="c20180101to20180930_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EmergentBiosolutionsInc2006StockIncentivePlanMember" unitRef="U001" decimals="-5">400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
  <!--Total number of shares issuable under the plan (in shares)-Emergent BioSolutions Inc. 2006 Stock Incentive Plan [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized contextRef="c20180524_PlanNameAxis_EmergentBiosolutionsInc2006StockIncentivePlanMember" unitRef="U001" decimals="-5">21900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
  <!--Significant Accounting Policies [Text Block]-->
  <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="c20180101to20180930">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; line-height: 10.25pt;"&gt;&lt;font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"&gt;1.&lt;/font&gt;&lt;font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"&gt;Summary of significant accounting policies&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height: 11.4pt;"&gt;&lt;br style="line-height: 11.4pt;" /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: justify; line-height: 10.25pt; text-indent: 36pt;"&gt;Basis of presentation and consolidation&lt;/div&gt;&lt;div style="line-height: 10.25pt;"&gt;&lt;br style="line-height: 10.25pt;" /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; line-height: 10.25pt; text-indent: 36pt;"&gt;The accompanying unaudited condensed consolidated financial statements include the accounts of Emergent BioSolutions Inc. ("Emergent" or the "Company") and its wholly owned and majority owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation. The unaudited consolidated financial statements included herein have been prepared in accordance with U.S. generally accepted accounting principles for interim financial information and in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X issued by the Securities and Exchange Commission ("SEC"). Certain information and footnote disclosures normally included in consolidated financial statements prepared in accordance with U.S. generally accepted accounting principles have been condensed or omitted pursuant to such rules and regulations. These consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto contained in the Company's Annual Report on Form 10-K for the year ended December 31, 2017, as filed with the SEC.&lt;/div&gt;&lt;div style="line-height: 10.25pt;"&gt;&lt;br style="line-height: 10.25pt;" /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; line-height: 10.25pt; text-indent: 36pt;"&gt;In the opinion of the Company's management, any adjustments contained in the accompanying unaudited condensed consolidated financial statements are of a normal recurring nature and are necessary to present fairly the financial position of the Company as of September 30, 2018. Interim results are not necessarily indicative of results that may be expected for any other interim period or for an entire year.&lt;/div&gt;&lt;div style="line-height: 11.4pt;"&gt;&lt;br style="line-height: 11.4pt;" /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; font-style: italic; text-align: justify; line-height: 10.25pt; text-indent: 36pt;"&gt;Significant accounting policies&lt;/div&gt;&lt;div style="line-height: 11.4pt;"&gt;&lt;br style="line-height: 11.4pt;" /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; line-height: 10.25pt; text-indent: 36pt;"&gt;During the nine months ended September 30, 2018, there have been no significant changes to the Company's summary of significant accounting policies contained in the Company's Annual Report on Form 10-K for the year ended December 31, 2017, as filed with the SEC, except for the new revenue recognition standard the Company adopted effective January 1, 2018. See Note 2. "Revenue recognition" for further details.&lt;/div&gt;&lt;div style="line-height: 11.4pt;"&gt;&lt;br style="line-height: 11.4pt;" /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; font-style: italic; text-align: justify; line-height: 10.25pt; text-indent: 36pt;"&gt;Recently issued accounting standards&lt;/div&gt;&lt;div style="line-height: 10.25pt;"&gt;&lt;br style="line-height: 10.25pt;" /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic; text-align: justify; line-height: 10.25pt; text-indent: 36pt;"&gt;&lt;u&gt;Recently Adopted&lt;/u&gt;&lt;/div&gt;&lt;div style="line-height: 10.25pt;"&gt;&lt;br style="line-height: 10.25pt;" /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; line-height: 10.25pt; text-indent: 36pt;"&gt;ASU 2016-15,&lt;font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;"&gt;&amp;#160;Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height: 10.25pt;"&gt;&lt;br style="line-height: 10.25pt;" /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; line-height: 10.25pt; text-indent: 36pt;"&gt;In August 2016, the Financial Accounting Standards Board ("FASB") issued Accounting Standard Update ("ASU") 2016-15,&amp;#160;&lt;font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;"&gt;Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments &lt;/font&gt;(&lt;font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;"&gt;"&lt;/font&gt;ASU 2016-15"). &amp;#160;ASU 2016-15 eliminates the diversity in practice related to the classification of certain cash receipts and payments for debt prepayments or extinguishment costs, the maturing of a zero-coupon bond, the settlement of contingent liabilities arising from a business combination, proceeds from insurance settlements, distributions from certain equity method investees and beneficial interests obtained in a financial asset securitization. ASU 2016-15 designates the appropriate cash flow classification, including requirements to allocate certain components of these cash receipts and payments among operating, investing and financing activities. The Company adopted the new standard effective January 1, 2018 and has determined the impact of ASU No. 2016-15 on its condensed consolidated financial statements will be related to the settlement of contingent liabilities arising from a business combination.&lt;/div&gt;&lt;div style="line-height: 10.25pt;"&gt;&lt;br style="line-height: 10.25pt;" /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; line-height: 10.25pt; text-indent: 36pt;"&gt;ASU 2016-18,&amp;#160;&lt;font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;"&gt;Restricted Cash (Topic 230): Statement of Cash Flows&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height: 10.25pt;"&gt;&lt;br style="line-height: 10.25pt;" /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; line-height: 10.25pt; text-indent: 36pt;"&gt;In November 2016, the FASB issued ASU 2016-18, &lt;font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;"&gt;Restricted Cash (Topic 230): Statement of Cash Flows &lt;/font&gt;(&lt;font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;"&gt;"&lt;/font&gt;ASU 2016-18"). ASU 2016-18 requires that a statement of cash flows explain the change during the period in the total of cash, cash equivalents and amounts generally described as restricted cash or restricted cash equivalents.&amp;#160;Restricted cash and restricted cash equivalents will be included with cash and cash equivalents when reconciling the beginning of period and end of period balances on the statement of cash flows upon adoption of this standard. The Company adopted the new standard effective January 1, 2018. Restricted cash primarily consists of collateralized cash for a standby letter of credit and guarantee arrangement with a bank.&lt;/div&gt;&lt;div style="line-height: 10.25pt;"&gt;&lt;br style="line-height: 10.25pt;" /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; line-height: 10.25pt; text-indent: 36pt;"&gt;ASU No. 2017-09, &lt;font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;"&gt;Compensation-Stock Compensation (Topic 718):&lt;/font&gt;&amp;#160;&lt;font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;"&gt;Scope of Modification Accounting&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height: 10.25pt;"&gt;&lt;br style="line-height: 10.25pt;" /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; line-height: 10.25pt; text-indent: 36pt;"&gt;In May 2017, the FASB issued ASU 2017-09, &lt;font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;"&gt;Compensation-Stock Compensation (Topic 718): Scope of Modification Accounting &lt;/font&gt;("ASU 2017-09"). ASU 2017-09 clarifies which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in Topic 718. The Company adopted the new standard effective January 1, 2018, which did not have a material impact on its condensed consolidated financial statements.&lt;/div&gt;&lt;div style="line-height: 10.25pt;"&gt;&lt;br style="line-height: 10.25pt;" /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; line-height: 10.25pt; text-indent: 36pt;"&gt;ASU No. 2018-07, &lt;font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;"&gt;Compensation-Stock Compensation (Topic 718):&lt;/font&gt;&amp;#160;&lt;font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;"&gt;Improvements to Nonemployee Share-based Payment Accounting&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height: 10.25pt;"&gt;&lt;br style="line-height: 10.25pt;" /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; line-height: 10.25pt; text-indent: 36pt;"&gt;In June 2018, the FASB issued ASU 2018-07, &lt;font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;"&gt;Compensation-Stock Compensation (Topic 718): Improvements to Nonemployee Share-based Payment Accounting &lt;/font&gt;("ASU 2018-07"). ASU 2018-07 expands the scope of Topic 718 to include share-based payments issued to nonemployees for goods and services. ASU No. 2018-07 is intended to reduce cost and complexity and to improve financial reporting for share-based payments issued to nonemployees (for example, service providers, external legal counsel, suppliers, etc.). The standard will be effective after December 15, 2018 for the Company, with early adoption permitted, but no earlier than the Company's adoption date of Topic 606. The Company early adopted the new standard effective April 1, 2018. The adoption of this standard did not have a material impact on the Company's condensed consolidated financial statements.&lt;/div&gt;&lt;div style="line-height: 10.25pt;"&gt;&lt;br style="line-height: 10.25pt;" /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic; text-align: justify; line-height: 10.25pt; text-indent: 36pt;"&gt;&lt;u&gt;Not Yet Adopted&lt;/u&gt;&lt;/div&gt;&lt;div style="line-height: 10.25pt;"&gt;&lt;br style="line-height: 10.25pt;" /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; line-height: 10.25pt; text-indent: 36pt;"&gt;ASU 2016-02,&amp;#160;&lt;font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;"&gt;Leases (Topic 842)&lt;/font&gt;&amp;#160;&lt;/div&gt;&lt;div style="line-height: 10.25pt;"&gt;&lt;br style="line-height: 10.25pt;" /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; line-height: 10.25pt; text-indent: 36pt;"&gt;In February 2016, the FASB issued ASU 2016-02,&lt;font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;"&gt;&amp;#160;Leases (Topic 842)&lt;/font&gt;&amp;#160;(&lt;font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;"&gt;"&lt;/font&gt;ASU 2016-02"). ASU 2016-02 increases transparency and comparability among organizations by requiring the recognition of lease assets and lease liabilities on the balance sheet and disclosure of key information about leasing arrangements for both lessees and lessors. The standard will be effective January 1, 2019, with early adoption permitted. The standard will be applied using a modified retrospective approach to the beginning of the earliest period presented in the financial statements. The Company's adoption efforts are primarily focused on the review of its existing lease contracts, identification of other contracts that may fall under the scope of the new guidance and performing a gap analysis on the current state of lease-related activities compared with the future state of lease-related activities. The Company has identified the lease agreements that will be impacted by the new standard and is currently evaluating the overall impact on its condensed consolidated financial statements and related disclosures.&lt;/div&gt;&lt;div style="line-height: 10.25pt;"&gt;&lt;br style="line-height: 10.25pt;" /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; line-height: 10.25pt; text-indent: 36pt;"&gt;ASU 2016-16,&amp;#160;&lt;font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;"&gt;Income Taxes (Topic 740): Intra-Entity Transfers of Assets Other Than Inventory&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height: 10.25pt;"&gt;&lt;br style="line-height: 10.25pt;" /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; line-height: 10.25pt; text-indent: 36pt;"&gt;In October 2016, the FASB issued ASU 2016-16, &lt;font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;"&gt;Income Taxes (Topic 740): Intra-Entity Transfers of Assets Other Than Inventory&lt;/font&gt; ("ASU 2016-16"). ASU 2016-16 improves the accounting for the income tax consequences of intra-entity transfers of assets other than inventory. The new standard will require entities to recognize the income tax consequences of an intra-entity transfer of a non-inventory asset when the transfer occurs. The guidance is effective for fiscal years beginning after December 15, 2017, and early adoption is permitted. The Company is currently evaluating the effects of adopting ASU 2016-16 on its condensed consolidated financial statements but the adoption is not expected to have a significant impact as of the filing of this report.&lt;/div&gt;&lt;div style="line-height: 10.25pt;"&gt;&lt;br style="line-height: 10.25pt;" /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; line-height: 10.25pt; text-indent: 36pt;"&gt;ASU 2017-04,&amp;#160;&lt;font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;"&gt;Intangibles - Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height: 10.25pt;"&gt;&lt;br style="line-height: 10.25pt;" /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; line-height: 10.25pt; text-indent: 36pt;"&gt;In January 2017, the FASB issued ASU 2017-04,&amp;#160;&lt;font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;"&gt;Intangibles - Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment&lt;/font&gt;&amp;#160;("ASU 2017-04"). ASU 2017-04 simplifies the subsequent measurement of goodwill and eliminates Step 2 from the goodwill impairment test. ASU 2017-04 is effective for annual and interim goodwill tests beginning after December 15, 2019. Early adoption is permitted for interim or annual goodwill impairment tests performed on testing dates on or after January 1, 2017. The Company is currently evaluating the impact that the adoption of this standard will have on its condensed consolidated financial statements.&lt;/div&gt;&lt;div style="line-height: 10.25pt;"&gt;&lt;br style="line-height: 10.25pt;" /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; line-height: 10.25pt; text-indent: 36pt;"&gt;ASU 2018-02,&amp;#160;&lt;font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;"&gt;Income Statement&amp;#8212;Reporting Comprehensive Income (Topic 220):&amp;#160;Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height: 10.25pt;"&gt;&lt;br style="line-height: 10.25pt;" /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; line-height: 10.25pt; text-indent: 36pt;"&gt;In February 2018, the FASB issued ASU 2018-02,&lt;font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;"&gt;&amp;#160;Income Statement&amp;#8212;Reporting Comprehensive Income (Topic 220):&amp;#160;Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income &lt;/font&gt;("ASU 2018-02"). ASU 2018-02 provides the option to reclassify certain income tax effects related to the Tax Cuts and Jobs Act passed in December of 2017 between accumulated other comprehensive income and retained earnings and also requires additional disclosures.&amp;#160;ASU 2018-02 is effective for all entities for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years, with early adoption permitted.&amp;#160;Adoption of ASU 2018-02 is to be applied either in the period of adoption or retrospectively to each period in which the effect of the change in the tax laws or rates were recognized.&amp;#160;The Company is currently evaluating the impact of adopting ASU 2018-02 on its condensed consolidated financial statements.&lt;/div&gt;&lt;div style="line-height: 10.25pt;"&gt;&lt;br style="line-height: 10.25pt;" /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; line-height: 10.25pt; text-indent: 36pt;"&gt;ASU 2018-11,&amp;#160;&lt;font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;"&gt;Leases (Topic 842)&lt;/font&gt;: &lt;font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;"&gt;Targeted Improvements&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height: 10.25pt;"&gt;&lt;br style="line-height: 10.25pt;" /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; line-height: 10.25pt; text-indent: 36pt;"&gt;In July 2018, the FASB issued ASU 2018-11,&lt;font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;"&gt;&amp;#160;Leases (Topic 842): Targeted Improvements &lt;/font&gt;("ASU 2018-11"). In issuing ASU 2018-11,&amp;#160;the&amp;#160;FASB&amp;#160;decided to provide another transition method in addition to the existing transition method by allowing entities to initially apply the&amp;#160;new leases standard at the adoption date and recognize a cumulative-effect adjustment to the opening balance of retained earnings in the period&amp;#160;of adoption.&amp;#160;The Company is currently evaluating the impact that ASU 2016-02&amp;#160;and ASU 2018-11&amp;#160;will have on its condensed consolidated financial&amp;#160;statements.&lt;/div&gt;&lt;div style="line-height: 10.25pt;"&gt;&lt;br style="line-height: 10.25pt;" /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; line-height: 10.25pt; text-indent: 36pt;"&gt;There are no other recently issued accounting pronouncements that are expected to have a material impact on the Company's financial position, results of operations or cash flows.&lt;/div&gt;&lt;div style="line-height: 11.4pt;"&gt;&lt;br style="line-height: 11.4pt;" /&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
  <!--Employee equity plans activity (in shares)-Common Stock [Member]-->
  <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation contextRef="c20180101to20180930_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="0">783777</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
  <!--Stock Repurchased During Period, Value-->
  <us-gaap:StockRepurchasedDuringPeriodValue contextRef="c20180101to20180930" unitRef="U002" decimals="-3">145000</us-gaap:StockRepurchasedDuringPeriodValue>
  <!--Stock Repurchased During Period, Value-Treasury Stock [Member]-->
  <us-gaap:StockRepurchasedDuringPeriodValue contextRef="c20180101to20180930_StatementEquityComponentsAxis_TreasuryStockMember" unitRef="U002" decimals="-3">145000</us-gaap:StockRepurchasedDuringPeriodValue>
  <!--Stock Repurchased During Period, Shares-Treasury Stock [Member]-->
  <us-gaap:StockRepurchasedDuringPeriodShares contextRef="c20180101to20180930_StatementEquityComponentsAxis_TreasuryStockMember" unitRef="U001" decimals="0">2843</us-gaap:StockRepurchasedDuringPeriodShares>
  <!--Employee equity plans activity-Additional Paid-in Capital [Member]-->
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c20180101to20180930_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="-3">21762000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
  <!--Employee equity plans activity-Common Stock [Member]-->
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c20180101to20180930_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="-3">1000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
  <!--Employee equity plans activity-->
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c20180101to20180930" unitRef="U002" decimals="-3">21763000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
  <!--Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest-->
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c20180930" unitRef="U002" decimals="-3">966649000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <!--Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest-->
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c20171231" unitRef="U002" decimals="-3">912345000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <!--Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest-Retained Earnings [Member]-->
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c20171231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="-3">337074000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <!--Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest-Accumulated Other Comprehensive Loss [Member]-->
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c20171231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="U002" decimals="-3">-3698000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <!--Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest-Treasury Stock [Member]-ASC 606 [Member]-->
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c20171231_AdjustmentsForNewAccountingPronouncementsAxis_AccountingStandardsUpdate201409Member_StatementEquityComponentsAxis_TreasuryStockMember" unitRef="U002" decimals="-3">-39497000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <!--Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest-ASC 606 [Member]-->
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c20171231_AdjustmentsForNewAccountingPronouncementsAxis_AccountingStandardsUpdate201409Member" unitRef="U002" decimals="-3">879818000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <!--Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest-Accumulated Other Comprehensive Loss [Member]-ASC 606 [Member]-->
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c20171231_AdjustmentsForNewAccountingPronouncementsAxis_AccountingStandardsUpdate201409Member_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="U002" decimals="-3">-3698000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <!--Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest-Additional Paid-in Capital [Member]-->
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c20171231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="-3">618416000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <!--Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest-Common Stock [Member]-->
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c20171231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="-3">50000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <!--Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest-ASC 606 [Member]-Retained Earnings [Member]-->
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c20171231_AdjustmentsForNewAccountingPronouncementsAxis_AccountingStandardsUpdate201409Member_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="-3">304547000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <!--Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest-Treasury Stock [Member]-->
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c20171231_StatementEquityComponentsAxis_TreasuryStockMember" unitRef="U002" decimals="-3">-39497000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <!--Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest-Additional Paid-in Capital [Member]-ASC 606 [Member]-->
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c20171231_AdjustmentsForNewAccountingPronouncementsAxis_AccountingStandardsUpdate201409Member_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="-3">618416000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <!--Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest-ASC 606 [Member]-Common Stock [Member]-->
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c20171231_AdjustmentsForNewAccountingPronouncementsAxis_AccountingStandardsUpdate201409Member_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="-3">50000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <!--Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest-Common Stock [Member]-->
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c20180930_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="-3">51000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <!--Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest-Retained Earnings [Member]-->
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c20180930_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="-3">370728000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <!--Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest-Additional Paid-in Capital [Member]-->
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c20180930_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="-3">640178000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <!--Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest-Treasury Stock [Member]-->
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c20180930_StatementEquityComponentsAxis_TreasuryStockMember" unitRef="U002" decimals="-3">-39642000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <!--Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest-Accumulated Other Comprehensive Loss [Member]-->
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c20180930_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="U002" decimals="-3">-4666000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <!--Equity-->
  <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="c20180101to20180930">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; line-height: 10.25pt;"&gt;&lt;font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"&gt;8. &lt;/font&gt;&lt;font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"&gt;Equity&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height: 11.4pt;"&gt;&lt;br style="line-height: 11.4pt;" /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; line-height: 10.25pt; text-indent: 36pt;"&gt;During the nine months ended September 30, 2018, the Company granted 0.4 million shares of stock options and 0.4 million shares of restricted stock units under the Fourth Amended and Restated Emergent BioSolutions Inc. 2006 Stock Incentive Plan (the "Plan"). The grants vest over three equal annual installments beginning on the day prior to the anniversary of the grant date. On May 24, 2018, the Company's stockholders approved an increase in the number of shares issuable under the Plan by 3.0 million shares, to a total of 21.9 million shares, and extended the plan term to May 23, 2028.&lt;/div&gt;&lt;div style="line-height: 11.4pt;"&gt;&lt;br style="line-height: 11.4pt;" /&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
  <!--Subsequent events-->
  <us-gaap:SubsequentEventsTextBlock contextRef="c20180101to20180930">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: justify; line-height: 10.25pt;"&gt;12. Subsequent events&lt;/div&gt;&lt;div style="margin-bottom: 3pt; margin-top: 3pt; line-height: 10.25pt;"&gt;&lt;br style="line-height: 10.25pt;" /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; font-style: italic; text-align: justify; line-height: 10.25pt; text-indent: 36pt;"&gt;Acquisitions&lt;/div&gt;&lt;div style="line-height: 10.25pt;"&gt;&lt;br style="line-height: 10.25pt;" /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic; text-align: justify; line-height: 10.25pt; text-indent: 36pt;"&gt;&lt;u&gt;Acquisition of PaxVax&lt;/u&gt;&lt;/div&gt;&lt;div style="line-height: 10.25pt;"&gt;&lt;br style="line-height: 10.25pt;" /&gt;&lt;/div&gt;&lt;div style="margin-bottom: 3pt; font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; margin-top: 3pt; line-height: 10.25pt; text-indent: 36pt;"&gt;On October 4, 2018, the Company completed the acquisition of PaxVax Holding Company Ltd. ("PaxVax"), a company focused on developing, manufacturing, and commercializing specialty vaccines that protect against existing and emerging infectious diseases. This acquisition includes Vivotif&amp;#174; (Typhoid Vaccine Live Oral Ty21a), the only oral vaccine licensed by the FDA for the prevention of typhoid fever, Vaxchora&amp;#174; (Cholera Vaccine, Live, Oral), the only FDA-licensed vaccine for the prevention of cholera, an adenovirus 4/7 vaccine candidate being developed for military personnel under contract with the DoD, and additional clinical-stage vaccine candidates targeting chikungunya and other emerging infectious diseases, European-based current good manufacturing practices ("cGMP") biologics manufacturing facilities, and approximately 250 employees including those in research and development, manufacturing, and commercial operations with a specialty vaccines salesforce in the U.S. and in select European countries.&lt;/div&gt;&lt;div style="margin-bottom: 3pt; margin-top: 3pt; line-height: 10.25pt;"&gt;&lt;br style="line-height: 10.25pt;" /&gt;&lt;/div&gt;&lt;div style="margin-bottom: 3pt; font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; margin-top: 3pt; line-height: 10.25pt; text-indent: 36pt;"&gt;At the closing, the Company paid a cash purchase price of $270 million, using a combination of cash-on-hand and borrowings under the Company's senior secured credit agreement. This transaction will be accounted for by the Company under the acquisition method of accounting, with the Company as the acquirer. Under the acquisition method of accounting, the assets and liabilities of PaxVax will be recorded as of October 4, 2018, the acquisition date, at their respective fair values, and combined with those of the Company. &lt;!--Anchor--&gt;As of the date of this filing, the Company has not completed the initial accounting for the PaxVax acquisition due to the Company's need to continue to gather data necessary to complete the fair value valuation of the assets acquired and liabilities assumed.&lt;/div&gt;&lt;div style="margin-bottom: 3pt; margin-top: 3pt; line-height: 10.25pt;"&gt;&lt;br style="line-height: 10.25pt;" /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic; text-align: justify; line-height: 10.25pt; text-indent: 36pt;"&gt;&lt;u&gt;Acquisition of Adapt&lt;/u&gt;&lt;/div&gt;&lt;div style="line-height: 10.25pt;"&gt;&lt;br style="line-height: 10.25pt;" /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; line-height: 10.25pt; text-indent: 36pt;"&gt;On October 15, 2018, the Company completed the acquisition of Adapt Pharma Limited ("Adapt") and its NARCAN&amp;#174; (naloxone HCl) Nasal Spray marketed product, the first and only needle-free formulation of naloxone approved by the FDA and Health Canada, for the emergency treatment of known or suspected opioid overdose as manifested by respiratory and/or central nervous system depression. This acquisition includes the NARCAN Nasal Spray marketed product and a development pipeline of new treatment and delivery options to address opioid overdose, and approximately 50 employees, located in the U.S., Canada, and Ireland, including those responsible for supply chain management, research and development, government affairs, and commercial operations.&lt;/div&gt;&lt;div style="line-height: 10.25pt;"&gt;&lt;br style="line-height: 10.25pt;" /&gt;&lt;/div&gt;&lt;div style="margin-bottom: 3pt; font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; margin-top: 3pt; line-height: 10.25pt; text-indent: 36pt;"&gt;&lt;!--Anchor--&gt;The Company paid approximately $575 million in cash at the closing (exclusive of closing adjustments) and issued 733,309 shares of Common Stock, based on the volume-weighted average price per share of the Common Stock as reported on the New York Stock Exchange for the ten-trading day period ending two days before closing, or $65.28 per share (an aggregate total of $47.9 million, inclusive of adjustments). The remaining consideration payable for the acquisition consists of up to $100 million in cash based on the achievement of certain sales milestones through 2022. The Company funded the cash portion of the payments made at closing using a combination of cash-on-hand and borrowings under its Amended Credit Agreement, as described in the &lt;font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;"&gt;Long-term debt&lt;/font&gt; section below.&lt;/div&gt;&lt;div style="margin-bottom: 3pt; margin-top: 3pt; line-height: 10.25pt;"&gt;&lt;br style="line-height: 10.25pt;" /&gt;&lt;/div&gt;&lt;div style="margin-bottom: 3pt; font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; margin-top: 3pt; line-height: 10.25pt; text-indent: 36pt;"&gt;This transaction will be accounted for by the Company under the acquisition method of accounting, with the Company as the acquirer. Under the acquisition method of accounting, the assets and liabilities of Adapt will be recorded as of October 15, 2018, the acquisition date, at their respective fair values, and combined with those of the Company. As of the date of this filing, the Company has not completed the initial accounting for the Adapt acquisition due to the Company's need to continue to gather data necessary to complete the fair value valuation of the assets acquired and liabilities assumed.&lt;/div&gt;&lt;div style="margin-bottom: 3pt; margin-top: 3pt; line-height: 11.4pt;"&gt;&lt;br style="line-height: 11.4pt;" /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; font-style: italic; text-align: justify; line-height: 10.25pt; text-indent: 36pt;"&gt;Legal proceedings associated with the acquisition of Adapt&lt;/div&gt;&lt;div style="line-height: 10.25pt;"&gt;&lt;br style="line-height: 10.25pt;" /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic; text-align: justify; line-height: 10.25pt; text-indent: 36pt;"&gt;&lt;u&gt;ANDA Litigation&lt;/u&gt;&lt;/div&gt;&lt;div style="line-height: 10.25pt;"&gt;&lt;br style="line-height: 10.25pt;" /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; line-height: 10.25pt; text-indent: 36pt;"&gt;On September 14, 2018, Adapt Pharma Inc., Adapt Pharma Operations Limited and Adapt Pharma Ltd. (collectively, "Adapt Pharma") and Opiant Pharmaceuticals, Inc. ("Opiant") received notice from Perrigo UK FINCO Limited Partnership ("Perrigo"), that Perrigo had filed an Abbreviated New Drug Application ("ANDA"), with the United States Food and Drug Administration (the "FDA"), seeking regulatory approval to market a generic version of NARCAN&amp;#174; &amp;#160;(naloxone hydrochloride) Nasal Spray 4mg/spray before the expiration of U.S. Patent Nos. 9,211,253 (the "'253 Patent"), 9,468,747 (the "'747 Patent"), 9,561,177 (the "'177 Patent"), 9,629,965 (the "'965 Patent") and 9,775,838 (the "'838 Patent"). Perrigo's notice letter asserts that its generic product will not infringe any valid and enforceable claim of these patents.&lt;/div&gt;&lt;div style="line-height: 10.25pt;"&gt;&lt;br style="line-height: 10.25pt;" /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; line-height: 10.25pt; text-indent: 36pt;"&gt;On October 25, 2018, Emergent BioSolutions' Adapt Pharma subsidiaries and Opiant (collectively, the "Plaintiffs") filed a complaint for patent infringement against Perrigo in the United States District Court for the District of New Jersey arising from Perrigo's ANDA filing with the FDA. As a result of timely filing the lawsuit in accordance with the Hatch-Waxman Act, a 30-month stay of approval will be imposed by the FDA on Perrigo's ANDA, which is expected to remain in effect until March 2021 absent an earlier judgment, unfavorable to the Plaintiffs, by the Court.&amp;#160; The Plaintiffs seek, among other relief, an order that the effective date of FDA approval of the ANDA be a date no earlier than the expiration of each of the '253 Patent, the '747 Patent, the '177 Patent, the '965 Patent and the '838 Patent, as well as equitable relief enjoining Perrigo from infringing these patents, and monetary relief as a result of any such infringement. Emergent continues to vigorously enforce the intellectual property portfolio related to NARCAN&amp;#174; Nasal Spray.&lt;/div&gt;&lt;div style="line-height: 10.25pt;"&gt;&lt;br style="line-height: 10.25pt;" /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; line-height: 10.25pt; text-indent: 36pt;"&gt;&lt;!--Anchor--&gt;On or about February 27, 2018, Adapt Pharma Inc. and Adapt Pharma Operations Limited and Opiant received notice from Teva Pharmaceuticals Industries Ltd. and Teva Pharmaceuticals USA, Inc., or collectively Teva, that Teva had filed an ANDA with the FDA seeking regulatory approval to market a generic version of NARCAN&amp;#174; (naloxone hydrochloride) Nasal Spray 2 mg/spray before the expiration of U.S. Patent No. 9,480,644 (the "'644 Patent"), and U.S. Patent No. 9,707,226 (the "'226 Patent") Teva's notice letter asserts that the commercial manufacture, use or sale of its generic drug product described in its ANDA will not infringe the '644 Patent or the '226 Patent, or that the '644 Patent and '226 Patent are invalid or unenforceable. Adapt Pharma Inc. and Adapt Pharma Operations Limited and Opiant filed a complaint for patent infringement against Teva in the United States District Court for the District of New Jersey.&lt;/div&gt;&lt;div style="line-height: 10.25pt;"&gt;&lt;br style="line-height: 10.25pt;" /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; line-height: 10.25pt; text-indent: 36pt;"&gt;On or about September 13, 2016, Adapt Pharma Inc. and Adapt Pharma Operations Limited and Opiant received notice from Teva that Teva had filed an ANDA with the FDA seeking regulatory approval to market a generic version of NARCAN&amp;#174; (naloxone hydrochloride) Nasal Spray 4 mg/spray before the expiration of U.S. Patent No. 9,211,253&amp;#160; (the "'253 Patent"). Adapt Pharma Inc. and Adapt Pharma Operations Limited and Opiant received additional notices from Teva relating to the '747, the '177, the '965, and the '838 Patents. Teva's notice letters assert that the commercial manufacture, use or sale of its generic drug product described in its ANDA will not infringe the '253, the '747, the '177, the '965, or the '838 Patent, or that the '253, the '747, the '177, the '965, and the '838 Patents are invalid or unenforceable. Adapt Pharma Inc., Adapt Pharma Operations Limited and Opiant filed a complaint for patent infringement against Teva in the United States District Court for the District of New Jersey with respect to the '253 Patent. Adapt Pharma Inc. and Adapt Pharma Operations Limited and Opiant also filed complaints for patent infringement against Teva in the United States District Court for the District of New Jersey with respect to the '747, the '177, the '965, and the '838 Patents. All five proceedings have been consolidated.&lt;/div&gt;&lt;div style="line-height: 10.25pt;"&gt;&lt;br style="line-height: 10.25pt;" /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; line-height: 10.25pt; text-indent: 36pt;"&gt;In the complaints described in the prior two paragraphs above, the Plaintiffs seek, among other relief, an order that the effective date of FDA approval of the Teva ANDA be a date not earlier than the expiration of the applicable patent, as well as equitable relief enjoining Teva from making, using, offering to sell, selling, or importing the product that is the subject of the Teva ANDA until after the expiration of the applicable patent, and monetary relief as a result of any such infringement.&lt;/div&gt;&lt;div style="line-height: 10.25pt;"&gt;&lt;br style="line-height: 10.25pt;" /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; line-height: 10.25pt; text-indent: 36pt;"&gt;As of the date of this filing, the range of potential gain cannot be determined or estimated for the above mentioned complaints.&lt;/div&gt;&lt;div style="text-align: justify; line-height: 10.25pt; text-indent: 36pt;"&gt;&lt;br style="line-height: 10.25pt;" /&gt;&lt;/div&gt;&lt;div style="line-height: 0pt;"&gt;&lt;br style="line-height: 0pt;" /&gt;&lt;/div&gt;&lt;div style="margin-bottom: 3pt; font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; font-style: italic; text-align: justify; margin-top: 3pt; line-height: 10.25pt; text-indent: 36pt;"&gt;Long-term debt&lt;/div&gt;&lt;div style="margin-bottom: 3pt; margin-top: 3pt; line-height: 10.25pt;"&gt;&lt;br style="line-height: 10.25pt;" /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; line-height: 10.25pt; text-indent: 36pt;"&gt;On September 29, 2017, the Company entered into a senior secured credit agreement (the "2017 Credit Agreement") with four lending financial institutions. The 2017 Credit Agreement provided for a senior secured credit facility of up to $200 million through September 29, 2022. The 2017 Credit Agreement also included a $100 million accordion feature, which provided for an additional $100 million in revolver or incremental term loans, at the option of the Company, resulting in a potential aggregate commitment of up to $300 million. On October 4, 2018, the Company drew down $100 million under the 2017 Credit Agreement to pay for a portion of the purchase price of PaxVax.&lt;/div&gt;&lt;div style="line-height: 10.25pt;"&gt;&lt;br style="line-height: 10.25pt;" /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; line-height: 10.25pt; text-indent: 36pt;"&gt;On October 15, 2018, the Company entered into an Amended and Restated Credit Agreement, dated as of October 15, 2018 (the "Amended Credit Agreement"), which amended and restated the Company's 2017 Credit Agreement, dated as of September 29, 2017.&lt;/div&gt;&lt;div style="text-align: justify; line-height: 10.25pt; text-indent: 36pt;"&gt;&lt;br style="line-height: 10.25pt;" /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; line-height: 10.25pt; text-indent: 36pt;"&gt;The Amended Credit Agreement (i) increased the revolving credit facility (the "Revolving Credit Facility") from $200 million to $600 million, (ii) extended the maturity of the Revolving Credit Facility from September 29, 2022 to October 13, 2023, (iii) provided for a term loan in the original principal amount of $450 million (the "Term Loan Facility," and together with the Revolving Credit Facility, the "Senior Secured Credit Facility"), (iv) added several additional lenders, (v) amended the applicable margin such that borrowings with respect to the Revolving Credit Facility will bear interest at the annual rate described below, (vi) amended the provision relating to incremental credit facilities such that the Company may request one or more incremental term loan facilities, or one or more increases in the commitments under the Revolving Credit Facility (each an "Incremental Loan"), in any amount if, on a pro forma basis, the Company's consolidated secured net leverage ratio does not exceed 2.50 to 1.00 after such incurrence, plus $200 million and (vii) amended the maximum consolidated net leverage ratio financial covenant from 3.50 to 1.0 (subject to 0.50% step up in connection with material acquisitions) to the maximum consolidated net leverage ratio described below.&lt;/div&gt;&lt;div style="line-height: 10.25pt;"&gt;&lt;br style="line-height: 10.25pt;" /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; line-height: 10.25pt; text-indent: 36pt;"&gt;Prior to entering into the Amended Credit Agreement, the outstanding principal balance under the Revolving Credit Facility was $100 million. On October 15, 2018, the Company borrowed an additional $218 million, bringing the total borrowings under the Revolving Credit Facility to $318 million and the full $450 million under the Term Loan Facility. Such borrowings were used to finance a portion of the consideration for the Adapt acquisition and related fees, costs and expenses and the remainder will be used for general corporate purposes.&lt;/div&gt;&lt;div style="line-height: 10.25pt;"&gt;&lt;br style="line-height: 10.25pt;" /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; line-height: 10.25pt; text-indent: 36pt;"&gt;The Revolving Credit Facility may be utilized for working capital, permitted acquisitions, capital expenditures and other general corporate purposes. The Revolving Credit Facility is available for borrowing through October 12, 2023 (unless earlier terminated). Borrowings under the Revolving Credit Facility and the Term Loan Facility will bear interest at a rate per annum equal to (a) a eurocurrency rate plus a margin ranging from 1.25% to 2.00% per annum, depending on the Company's consolidated net leverage ratio or (b) a base rate (which is the highest of the prime rate, the federal funds rate plus 0.50%, and a eurocurrency rate for an interest period of one month plus 1%) plus a margin ranging from 0.25% to 1.00%, depending on the Company's consolidated net leverage ratio.&lt;/div&gt;&lt;div style="line-height: 10.25pt;"&gt;&lt;br style="line-height: 10.25pt;" /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; line-height: 10.25pt; text-indent: 36pt;"&gt;The Company is required to make quarterly payments under the Amended Credit Agreement for accrued and unpaid interest on the outstanding principal balance under the Revolving Credit Facility and the Term Loan Facility, based on the above interest rates. In addition, the Company is required to pay commitment fees ranging from 0.15% to 0.30% per annum, depending on the Company's consolidated net leverage ratio, in respect of the average daily unused commitments under the Revolving Credit Facility. The Company is to repay the outstanding principal amount of the Term Loan Facility in quarterly installments based on an annual percentage equal to 2.5% of the original principal amount of the Term Loan Facility during each of the first two years of the Term Loan Facility, 5% of the original principal amount of the Term Loan Facility during the third year of the Term Loan Facility and 7.5% of the original principal amount of the Term Loan Facility during each year of the remainder of the term of the Term Loan Facility until the maturity date of the Term Loan Facility, at which time the entire unpaid principal balance of the Term Loan Facility will be due and payable. The Company has the right to prepay the Term Loan Facility without premium or penalty. The Revolving Credit Facility and the Term Loan Facility mature (unless earlier terminated) on October 13, 2023.&lt;/div&gt;&lt;div style="line-height: 10.25pt;"&gt;&lt;br style="line-height: 10.25pt;" /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; line-height: 10.25pt; text-indent: 36pt;"&gt;The Amended Credit Agreement also provides for mandatory prepayments of the Term Loan Facility in the event the Company or its Subsidiaries (a) incur indebtedness not otherwise permitted under the Amended Credit Agreement or (b) receive cash proceeds in excess of $100 million during the term of the Senior Secured Credit Facility from certain dispositions of property or from casualty events involving their property, subject to certain reinvestment rights.&lt;/div&gt;&lt;div style="line-height: 10.25pt;"&gt;&lt;br style="line-height: 10.25pt;" /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; line-height: 10.25pt; text-indent: 36pt;"&gt;The Amended Credit Agreement contains affirmative and negative covenants customary for financings of this type. Negative covenants in the Amended Credit Agreement, among other things, limit the ability of the Company to: incur indebtedness and liens; dispose of assets; make investments including loans, advances, guarantees, or acquisitions (other than permitted acquisitions, subject to compliance with the financial covenants and certain other conditions); and enter into certain merger or consolidation transactions. The Amended Credit Agreement also contains financial covenants, including (1) a minimum consolidated debt service coverage ratio of 2.50 to 1.00, and (2) a maximum consolidated net leverage ratio of 4.00 to 1.00 through September 29, 2019, 3.75 to 1.00 from September 30, 2019 through September 29, 2020 and 3.50 to 1.00 thereafter, which may be adjusted to 4.00 to 1.00 for a four quarter period in connection with a material permitted acquisition, subject to the terms and conditions of the Amended Credit Agreement. Each of the ratios referred to in the foregoing clauses (1) and (2) is calculated on a consolidated basis for each consecutive four fiscal quarter period.&lt;/div&gt;&lt;div style="line-height: 11.4pt;"&gt;&lt;br style="line-height: 11.4pt;" /&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
  <!--Income taxes payable, net-->
  <us-gaap:TaxesPayableCurrent contextRef="c20180930" unitRef="U002" decimals="-3">164000</us-gaap:TaxesPayableCurrent>
  <!--Income taxes payable, net-->
  <us-gaap:TaxesPayableCurrent contextRef="c20171231" unitRef="U002" decimals="-3">0</us-gaap:TaxesPayableCurrent>
  <!--Treasury Stock, Value-->
  <us-gaap:TreasuryStockValue contextRef="c20180930" unitRef="U002" decimals="-3">39642000</us-gaap:TreasuryStockValue>
  <!--Treasury Stock, Value-->
  <us-gaap:TreasuryStockValue contextRef="c20171231" unitRef="U002" decimals="-3">39497000</us-gaap:TreasuryStockValue>
  <!--Treasury stock ( in shares)-->
  <us-gaap:TreasuryStockShares contextRef="c20171231" unitRef="U001" decimals="0">1214443</us-gaap:TreasuryStockShares>
  <!--Treasury stock ( in shares)-->
  <us-gaap:TreasuryStockShares contextRef="c20180930" unitRef="U001" decimals="0">1217286</us-gaap:TreasuryStockShares>
  <!--Weighted-average number of shares - basic (in shares)-->
  <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c20170701to20170930" unitRef="U001" decimals="0">41222504</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
  <!--Weighted-average number of shares - basic (in shares)-->
  <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c20180701to20180930" unitRef="U001" decimals="0">50071632</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
  <!--Weighted-average number of shares - basic (in shares)-->
  <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c20180101to20180930" unitRef="U001" decimals="0">49851082</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
  <!--Weighted-average number of shares - basic (in shares)-->
  <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c20170101to20170930" unitRef="U001" decimals="0">40989813</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
  <!--Weighted-average number of shares - diluted (in shares)-->
  <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c20180101to20180930" unitRef="U001" decimals="0">51189680</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
  <!--Weighted-average number of shares - diluted (in shares)-->
  <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c20170701to20170930" unitRef="U001" decimals="0">50467829</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
  <!--Weighted-average number of shares - diluted (in shares)-->
  <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c20170101to20170930" unitRef="U001" decimals="0">50090088</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
  <!--Weighted-average number of shares - diluted (in shares)-->
  <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c20180701to20180930" unitRef="U001" decimals="0">51486996</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
  <!--Change In Fair Value Of Contingent Consideration-->
  <ebs:ChangeInFairValueOfContingentConsideration contextRef="c20180101to20180930" unitRef="U002" decimals="-3">1917000</ebs:ChangeInFairValueOfContingentConsideration>
  <!--Change In Fair Value Of Contingent Consideration-->
  <ebs:ChangeInFairValueOfContingentConsideration contextRef="c20170101to20170930" unitRef="U002" decimals="-3">1350000</ebs:ChangeInFairValueOfContingentConsideration>
  <!--Contingent value right payment-->
  <ebs:ContingentValueRightPayment contextRef="c20170101to20170930" unitRef="U002" decimals="-3">2744000</ebs:ContingentValueRightPayment>
  <!--Contingent value right payment-->
  <ebs:ContingentValueRightPayment contextRef="c20180101to20180930" unitRef="U002" decimals="-3">2234000</ebs:ContingentValueRightPayment>
  <!--Number of installments-Emergent BioSolutions Inc. 2006 Stock Incentive Plan [Member]-->
  <ebs:NumberOfInstallments contextRef="c20180930_PlanNameAxis_EmergentBiosolutionsInc2006StockIncentivePlanMember" unitRef="U007" decimals="INF">3</ebs:NumberOfInstallments>
  <!--Contingent Consideration Current Portion-->
  <ebs:ContingentConsiderationCurrentPortion contextRef="c20180930" unitRef="U002" decimals="-3">2954000</ebs:ContingentConsiderationCurrentPortion>
  <!--Contingent Consideration Current Portion-->
  <ebs:ContingentConsiderationCurrentPortion contextRef="c20171231" unitRef="U002" decimals="-3">2372000</ebs:ContingentConsiderationCurrentPortion>
  <!--Contingent Consideration Net Of Current Portion-->
  <ebs:ContingentConsiderationNetOfCurrentPortion contextRef="c20180930" unitRef="U002" decimals="-3">9003000</ebs:ContingentConsiderationNetOfCurrentPortion>
  <!--Contingent Consideration Net Of Current Portion-->
  <ebs:ContingentConsiderationNetOfCurrentPortion contextRef="c20171231" unitRef="U002" decimals="-3">9902000</ebs:ContingentConsiderationNetOfCurrentPortion>
  <!--Term of contract-CIADM [Member]-->
  <ebs:TermOfContract contextRef="c20170101to20171231_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_CIADMMember">P24Y</ebs:TermOfContract>
  <!--Number of additional option periods-->
  <ebs:NumberOfAdditionalOptionPeriods contextRef="c20180101to20180930" unitRef="U004" decimals="INF">7</ebs:NumberOfAdditionalOptionPeriods>
  <!--Number of additional option periods-->
  <ebs:NumberOfAdditionalOptionPeriods contextRef="c20170101to20171231" unitRef="U004" decimals="INF">17</ebs:NumberOfAdditionalOptionPeriods>
  <!--Contract with Customer, Liability, Additions-->
  <ebs:ContractWithCustomerLiabilityAdditions contextRef="c20180101to20180930" unitRef="U002" decimals="-3">18384000</ebs:ContractWithCustomerLiabilityAdditions>
  <!--Change In Fair Value Of Contingent Obligations-RSDL [Member]-->
  <ebs:ChangeInFairValueOfContingentObligations contextRef="c20180101to20180930_SubsegmentsAxis_RsdlMember" unitRef="U002" decimals="-5">1800000</ebs:ChangeInFairValueOfContingentObligations>
  <!--Change In Fair Value Of Contingent Obligations-RSDL [Member]-->
  <ebs:ChangeInFairValueOfContingentObligations contextRef="c20170701to20170930_SubsegmentsAxis_RsdlMember" unitRef="U002" decimals="-5">900000</ebs:ChangeInFairValueOfContingentObligations>
  <!--Change In Fair Value Of Contingent Obligations-RSDL [Member]-->
  <ebs:ChangeInFairValueOfContingentObligations contextRef="c20180701to20180930_SubsegmentsAxis_RsdlMember" unitRef="U002" decimals="-5">200000</ebs:ChangeInFairValueOfContingentObligations>
  <!--Change In Fair Value Of Contingent Obligations-RSDL [Member]-->
  <ebs:ChangeInFairValueOfContingentObligations contextRef="c20170101to20170930_SubsegmentsAxis_RsdlMember" unitRef="U002" decimals="-5">1400000</ebs:ChangeInFairValueOfContingentObligations>
  <!--Adjusted net loss-->
  <ebs:AdjustedNetLoss contextRef="c20180701to20180930" unitRef="U002" decimals="-3">20945000</ebs:AdjustedNetLoss>
  <!--Adjusted net loss-->
  <ebs:AdjustedNetLoss contextRef="c20170701to20170930" unitRef="U002" decimals="-3">34450000</ebs:AdjustedNetLoss>
  <!--Adjusted net loss-->
  <ebs:AdjustedNetLoss contextRef="c20180101to20180930" unitRef="U002" decimals="-3">66181000</ebs:AdjustedNetLoss>
  <!--Adjusted net loss-->
  <ebs:AdjustedNetLoss contextRef="c20170101to20170930" unitRef="U002" decimals="-3">51683000</ebs:AdjustedNetLoss>
  <!--Amortization of issuance cost on convertible debt net of tax-->
  <ebs:AmortizationOfIssuanceCostOnConvertibleDebtNetOfTax contextRef="c20170701to20170930" unitRef="U002" decimals="-3">195000</ebs:AmortizationOfIssuanceCostOnConvertibleDebtNetOfTax>
  <!--Amortization of issuance cost on convertible debt net of tax-->
  <ebs:AmortizationOfIssuanceCostOnConvertibleDebtNetOfTax contextRef="c20170101to20170930" unitRef="U002" decimals="-3">586000</ebs:AmortizationOfIssuanceCostOnConvertibleDebtNetOfTax>
  <!--Amortization of issuance cost on convertible debt net of tax-->
  <ebs:AmortizationOfIssuanceCostOnConvertibleDebtNetOfTax contextRef="c20180701to20180930" unitRef="U002" decimals="-3">0</ebs:AmortizationOfIssuanceCostOnConvertibleDebtNetOfTax>
  <!--Amortization of issuance cost on convertible debt net of tax-->
  <ebs:AmortizationOfIssuanceCostOnConvertibleDebtNetOfTax contextRef="c20180101to20180930" unitRef="U002" decimals="-3">0</ebs:AmortizationOfIssuanceCostOnConvertibleDebtNetOfTax>
  <!--Term of contract under acquisition-ACAM2000 [Member]-->
  <ebs:TermOfContractUnderAcquisition contextRef="c20171006to20171006_BusinessAcquisitionAxis_ACAM2000Member">P10Y</ebs:TermOfContractUnderAcquisition>
  <!--Value of contract-ACAM2000 [Member]-->
  <ebs:ValueOfContract contextRef="c20171006_BusinessAcquisitionAxis_ACAM2000Member" unitRef="U002" decimals="-6">425000000</ebs:ValueOfContract>
  <!--Amount for deliveries of product-ACAM2000 [Member]-->
  <ebs:AmountForDeliveriesOfProduct contextRef="c20171006_BusinessAcquisitionAxis_ACAM2000Member" unitRef="U002" decimals="-6">160000000</ebs:AmountForDeliveriesOfProduct>
  <!--Upfront Payments-ACAM2000 [Member]-->
  <ebs:UpfrontPayments contextRef="c20171006to20171006_BusinessAcquisitionAxis_ACAM2000Member" unitRef="U002" decimals="-5">97500000</ebs:UpfrontPayments>
  <!--Amount of payment for manufacturing related milestones-ACAM2000 [Member]-->
  <ebs:AmountOfPaymentForManufacturingRelatedMilestones contextRef="c20171006_BusinessAcquisitionAxis_ACAM2000Member" unitRef="U002" decimals="-6">20000000</ebs:AmountOfPaymentForManufacturingRelatedMilestones>
  <!--Amount of payment for regulatory related milestones-ACAM2000 [Member]-->
  <ebs:AmountOfPaymentForRegulatoryRelatedMilestones contextRef="c20171231_BusinessAcquisitionAxis_ACAM2000Member" unitRef="U002" decimals="-5">7500000</ebs:AmountOfPaymentForRegulatoryRelatedMilestones>
  <!--Amount of payment for regulatory related milestones-ACAM2000 [Member]-->
  <ebs:AmountOfPaymentForRegulatoryRelatedMilestones contextRef="c20171006_BusinessAcquisitionAxis_ACAM2000Member" unitRef="U002" decimals="-5">7500000</ebs:AmountOfPaymentForRegulatoryRelatedMilestones>
  <!--Present Value, Discount Rate-Discount Rate [Member]-ACAM2000 [Member]-->
  <ebs:PresentValueDiscountRate contextRef="c20171006to20171006_BusinessAcquisitionAxis_ACAM2000Member_MeasurementInputTypeAxis_MeasurementInputDiscountRateMember" unitRef="U006" decimals="4">0.1550</ebs:PresentValueDiscountRate>
  <!--Percentage of Debt Covenant, Net Leverage Ratio, Step Up in Connection with Material Acquisitions-Amended Credit Agreement [Member]-Subsequent Event [Member]-Revolving Credit Facility [Member]-->
  <ebs:PercentageOfDebtCovenantNetLeverageRatioStepUpInConnectionWithMaterialAcquisitions contextRef="c20181015to20181015_CreditFacilityAxis_RevolvingCreditFacilityMember_DebtInstrumentAxis_AmendedCreditAgreementMember_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="U006" decimals="4">0.0050</ebs:PercentageOfDebtCovenantNetLeverageRatioStepUpInConnectionWithMaterialAcquisitions>
  <!--Number of lending institutions-Credit Agreement [Member]-->
  <ebs:NumberOfLendingInstitutions contextRef="c20170929to20170929_DebtInstrumentAxis_CreditAgreementMember" unitRef="U009" decimals="INF">4</ebs:NumberOfLendingInstitutions>
  <!--Percentage of Original Principal Amount Required to Repay Remaining Years-Term Loan Facility [Member]-Subsequent Event [Member]-Amended Credit Agreement [Member]-->
  <ebs:PercentageOfOriginalPrincipalAmountRequiredToRepayRemainingYears contextRef="c20181015to20181015_CreditFacilityAxis_TermLoanFacilityMember_DebtInstrumentAxis_AmendedCreditAgreementMember_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="U006" decimals="3">0.075</ebs:PercentageOfOriginalPrincipalAmountRequiredToRepayRemainingYears>
  <!--Amount Required for Net Leverage Ratio-Amended Credit Agreement [Member]-Subsequent Event [Member]-Revolving Credit Facility [Member]-->
  <ebs:AmountRequiredForNetLeverageRatio contextRef="c20181015to20181015_CreditFacilityAxis_RevolvingCreditFacilityMember_DebtInstrumentAxis_AmendedCreditAgreementMember_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="U002" decimals="-6">200000000</ebs:AmountRequiredForNetLeverageRatio>
  <!--Debt Covenant, Net Leverage Ratio, Three-Revolving Credit Facility [Member]-Amended Credit Agreement [Member]-Subsequent Event [Member]-Maximum [Member]-->
  <ebs:DebtCovenantNetLeverageRatioThree contextRef="c20181015to20181015_CreditFacilityAxis_RevolvingCreditFacilityMember_DebtInstrumentAxis_AmendedCreditAgreementMember_RangeAxis_MaximumMember_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="U006" decimals="INF">3.50</ebs:DebtCovenantNetLeverageRatioThree>
  <!--Debt Covenant, Net Leverage Ratio, Four-Revolving Credit Facility [Member]-Amended Credit Agreement [Member]-Subsequent Event [Member]-Maximum [Member]-->
  <ebs:DebtCovenantNetLeverageRatioFour contextRef="c20181015to20181015_CreditFacilityAxis_RevolvingCreditFacilityMember_DebtInstrumentAxis_AmendedCreditAgreementMember_RangeAxis_MaximumMember_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="U006" decimals="INF">4.00</ebs:DebtCovenantNetLeverageRatioFour>
  <!--Debt Instrument, covenant, debt service coverage ratio-Amended Credit Agreement [Member]-Subsequent Event [Member]-Minimum [Member]-Revolving Credit Facility [Member]-->
  <ebs:DebtInstrumentCovenantDebtServiceCoverageRatio contextRef="c20181015to20181015_CreditFacilityAxis_RevolvingCreditFacilityMember_DebtInstrumentAxis_AmendedCreditAgreementMember_RangeAxis_MinimumMember_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="U006" decimals="INF">2.50</ebs:DebtInstrumentCovenantDebtServiceCoverageRatio>
  <!--Debt Covenant, Net Leverage Ratio, Two-Revolving Credit Facility [Member]-Amended Credit Agreement [Member]-Subsequent Event [Member]-Maximum [Member]-->
  <ebs:DebtCovenantNetLeverageRatioTwo contextRef="c20181015to20181015_CreditFacilityAxis_RevolvingCreditFacilityMember_DebtInstrumentAxis_AmendedCreditAgreementMember_RangeAxis_MaximumMember_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="U006" decimals="INF">3.75</ebs:DebtCovenantNetLeverageRatioTwo>
  <!--Consolidated Secured, Net Leverage Ratio-Amended Credit Agreement [Member]-Subsequent Event [Member]-Revolving Credit Facility [Member]-->
  <ebs:ConsolidatedSecuredNetLeverageRatio contextRef="c20181015to20181015_CreditFacilityAxis_RevolvingCreditFacilityMember_DebtInstrumentAxis_AmendedCreditAgreementMember_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="U006" decimals="INF">2.50</ebs:ConsolidatedSecuredNetLeverageRatio>
  <!--Debt Covenant, Net Leverage Ratio, One-Revolving Credit Facility [Member]-Amended Credit Agreement [Member]-Subsequent Event [Member]-Maximum [Member]-->
  <ebs:DebtCovenantNetLeverageRatioOne contextRef="c20181015to20181015_CreditFacilityAxis_RevolvingCreditFacilityMember_DebtInstrumentAxis_AmendedCreditAgreementMember_RangeAxis_MaximumMember_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="U006" decimals="INF">4.00</ebs:DebtCovenantNetLeverageRatioOne>
  <!--Percentage of Original Principal Amount Required to Repay in First Two Years-Term Loan Facility [Member]-Subsequent Event [Member]-Amended Credit Agreement [Member]-->
  <ebs:PercentageOfOriginalPrincipalAmountRequiredToRepayInFirstTwoYears contextRef="c20181015to20181015_CreditFacilityAxis_TermLoanFacilityMember_DebtInstrumentAxis_AmendedCreditAgreementMember_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="U006" decimals="3">0.025</ebs:PercentageOfOriginalPrincipalAmountRequiredToRepayInFirstTwoYears>
  <!--Percentage of Original Principal Amount Required to Repay During the Third Year-Term Loan Facility [Member]-Subsequent Event [Member]-Amended Credit Agreement [Member]-->
  <ebs:PercentageOfOriginalPrincipalAmountRequiredToRepayDuringTheThirdYear contextRef="c20181015to20181015_CreditFacilityAxis_TermLoanFacilityMember_DebtInstrumentAxis_AmendedCreditAgreementMember_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="U006" decimals="2">0.05</ebs:PercentageOfOriginalPrincipalAmountRequiredToRepayDuringTheThirdYear>
  <!--Debt Instrument, covenant, leverage ratio-Amended Credit Agreement [Member]-Subsequent Event [Member]-Revolving Credit Facility [Member]-->
  <ebs:DebtInstrumentCovenantLeverageRatio contextRef="c20181015to20181015_CreditFacilityAxis_RevolvingCreditFacilityMember_DebtInstrumentAxis_AmendedCreditAgreementMember_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="U006" decimals="INF">3.50</ebs:DebtInstrumentCovenantLeverageRatio>
  <!--Line of Credit Facility, Additional Borrowing Capacity-Amended Credit Agreement [Member]-Subsequent Event [Member]-Revolving Credit Facility [Member]-->
  <ebs:LineOfCreditFacilityAdditionalBorrowingCapacity contextRef="c20181015_CreditFacilityAxis_RevolvingCreditFacilityMember_DebtInstrumentAxis_AmendedCreditAgreementMember_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="U002" decimals="-6">218000000</ebs:LineOfCreditFacilityAdditionalBorrowingCapacity>
  <!--Line of credit facility, additional borrowing capacity, accordion feature-Credit Agreement [Member]-->
  <ebs:LineOfCreditFacilityAdditionalBorrowingCapacityAccordionFeature contextRef="c20170929_DebtInstrumentAxis_CreditAgreementMember" unitRef="U002" decimals="-6">100000000</ebs:LineOfCreditFacilityAdditionalBorrowingCapacityAccordionFeature>
  <!--Debt Instrument Term of Variable Rate-Eurocurrency [Member]-Subsequent Event [Member]-Amended Credit Agreement [Member]-->
  <ebs:DebtInstrumentTermOfVariableRate contextRef="c20181015to20181015_DebtInstrumentAxis_AmendedCreditAgreementMember_SubsequentEventTypeAxis_SubsequentEventMember_VariableRateAxis_EurodollarMember">P1M</ebs:DebtInstrumentTermOfVariableRate>
  <!--Cash Proceeds Excess Amount from Dispositions of Property or Casualty Events Subject to Certain Reinvestment Right-Term Loan Facility [Member]-Subsequent Event [Member]-Amended Credit Agreement [Member]-->
  <ebs:CashProceedsExcessAmountFromDispositionsOfPropertyOrCasualtyEventsSubjectToCertainReinvestmentRight contextRef="c20181015to20181015_CreditFacilityAxis_TermLoanFacilityMember_DebtInstrumentAxis_AmendedCreditAgreementMember_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="U002" decimals="-6">100000000</ebs:CashProceedsExcessAmountFromDispositionsOfPropertyOrCasualtyEventsSubjectToCertainReinvestmentRight>
  <!--Number of Trading Days Before Closing to Determine Business Acquisition Share Price-Adapt Pharma [Member]-Subsequent Event [Member]-->
  <ebs:NumberOfTradingDaysBeforeClosingToDetermineBusinessAcquisitionSharePrice contextRef="c20181015to20181015_BusinessAcquisitionAxis_AdaptPharmaMember_SubsequentEventTypeAxis_SubsequentEventMember">P2D</ebs:NumberOfTradingDaysBeforeClosingToDetermineBusinessAcquisitionSharePrice>
  <!--Number of employees-PaxVax [Member]-Subsequent Event [Member]-->
  <ebs:NumberOfEmployees contextRef="c20181004to20181004_BusinessAcquisitionAxis_PaxVaxMember_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="U008" decimals="INF">250</ebs:NumberOfEmployees>
  <!--Number of employees-Adapt Pharma [Member]-Subsequent Event [Member]-->
  <ebs:NumberOfEmployees contextRef="c20181015to20181015_BusinessAcquisitionAxis_AdaptPharmaMember_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="U008" decimals="INF">50</ebs:NumberOfEmployees>
  <!--Trading Days to Determine Business Acquisition Share Price-Adapt Pharma [Member]-Subsequent Event [Member]-->
  <ebs:TradingDaysToDetermineBusinessAcquisitionSharePrice contextRef="c20181015to20181015_BusinessAcquisitionAxis_AdaptPharmaMember_SubsequentEventTypeAxis_SubsequentEventMember">P10D</ebs:TradingDaysToDetermineBusinessAcquisitionSharePrice>
  <link:footnoteLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:footnote xlink:label="Footnote-Item-1" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">As of December 31, 2017 and September 30, 2018, the balance includes $1,043 of restricted cash.</link:footnote>
    <link:loc xlink:href="#Item-1" xlink:label="Item-1_lbl" xlink:type="locator" />
    <link:footnoteArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Item-1_lbl" xlink:to="Footnote-Item-1" xlink:type="arc" />
    <link:loc xlink:href="#Item-2" xlink:label="Item-2_lbl" xlink:type="locator" />
    <link:footnoteArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Item-2_lbl" xlink:to="Footnote-Item-1" xlink:type="arc" />
    <link:footnote xlink:label="Footnote-Item-2" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">See "Earnings per share" footnote for details on calculation.</link:footnote>
    <link:loc xlink:href="#Item-3" xlink:label="Item-3_lbl" xlink:type="locator" />
    <link:footnoteArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Item-3_lbl" xlink:to="Footnote-Item-2" xlink:type="arc" />
    <link:loc xlink:href="#Item-4" xlink:label="Item-4_lbl" xlink:type="locator" />
    <link:footnoteArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Item-4_lbl" xlink:to="Footnote-Item-2" xlink:type="arc" />
    <link:loc xlink:href="#Item-5" xlink:label="Item-5_lbl" xlink:type="locator" />
    <link:footnoteArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Item-5_lbl" xlink:to="Footnote-Item-2" xlink:type="arc" />
    <link:loc xlink:href="#Item-6" xlink:label="Item-6_lbl" xlink:type="locator" />
    <link:footnoteArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Item-6_lbl" xlink:to="Footnote-Item-2" xlink:type="arc" />
  </link:footnoteLink>
</xbrl>
